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Abstract 
 
Every year, millions of people worldwide undergo stent implantation to widen 
narrowed arteries or to redirect blood away from aneurysms. The rapid post-
operative regrowth of a healthy endothelial layer, a key factor in stented artery repair, 
would reduce complications and improve quality of life for many patients. While this 
has long been a clinical or pharmaceutical issue, this project considers the role of 
local haemodynamics, specifically the effects of stent-modified wall shear stress on 
the endothelium. 
Endothelial cells have a strong mechanobiological response to wall shear stress 
magnitude, direction and time variance. To understand the impact of stent geometry 
on this response through altered fluid dynamics, a novel model vessel was developed 
for the deployment of a wide range of coronary and flow diverter stents in vitro. The 
model allowed the observation of both endothelial cell migration and, via particle 
tracking, disturbed flow within the stents. High-resolution micro-computed 
tomography scanning techniques replicated stent geometry in silico, enabling 
computational fluid dynamics simulations for the assessment of wall shear stress 
distribution. 
Coronary stents greatly influenced fluid flow. The orientation and distribution of 
tracked particle streamlines were transformed proximal to stents struts, which were 
also areas of reduced wall shear stress. These areas correlated with zones of reduced 
cell migration. Flow diverter stents had a lesser impact on observable particle flow; 
yet endothelial cell migration within them was completely arrested. This is likely due 
to their structure directing flow away from the wall and reducing shear stress to an 
even greater extent that coronary stents, over a more substantial area. 
Dissimilar cell migration between coronary and flow diverter stents is a point of 
possible significance as the two are treated alike with respect to post-operative care 
and medication. Continued analysis of various geometries may enable the efficacy of 
individual stent designs to be quantified or predicted. By applying this knowledge in 
the future, careful stent design could reduce their impact, or exert an intentional, 
active influence on endothelial cells, to optimise the healing process. 
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Chapter One 
1 Introduction 
 
The cardiovascular system consists of the heart, blood and blood vessels, and fulfils 
four main functions: the transport of oxygen, heat, and nutrients, and the rapid 
removal of metabolic waste products. Circulating blood is carried away from the 
heart within arteries and delivered throughout the body; including the vital supply to 
the brain via cerebral arteries, and the heart itself via coronary arteries. However, a 
variety of conditions can affect these blood vessels, impeding their ability to function 
and interrupting blood flow. Cardiovascular diseases, which include coronary heart 
disease and cerebral aneurysms, account for over 17 million deaths annually [1]. This 
figure is only expected to rise, as many major risk factors are lifestyle influenced: 
smoking, high fat and high cholesterol diets, obesity and lack of exercise. 
Current, routine treatment of cardiovascular diseases involves the use of stents, bio-
engineered devices which provide mechanical support or alter local mechanical 
conditions. This project considers those devices and the impact their mechanical, 
haemodynamic environment has on cell mechanobiology and, ultimately, on 
successful patient outcome. 
 
1.1 Engineering solutions for coronary arteries 
The coronary arteries are muscular distributing arteries, which supply blood to the 
heart. They ensure adequate oxygenation of the heart muscle (myocardium), 
constricting and dilating to match blood flow with oxygen demand. Given their 
crucial role, the performance of coronary arteries is unique. Blood flow per unit 
weight of the tissue being supplied is ten times greater than the whole body average. 
However, despite this high flow rate, the myocardium remains relatively poorly 
supplied due to its great O2 demand. To compensate, a high proportion of O2 is 
extracted from blood within the coronary vasculature: 65 - 75%, compared to a 
whole body average of 25% [2]. 
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1.1.1 Coronary heart disease 
The vital supply of blood to the myocardium can be affected by a condition known as 
coronary heart disease (CHD), in which deposits build up within the coronary 
arteries. This build up is a process known as atherosclerosis, with the deposits 
referred to as atherosclerotic lesions, or plaques. It can begin in childhood, but 
typically takes decades to progress to a symptomatic level. 
Atherosclerosis is thought to be most likely initiated by endothelial cell (EC) 
dysfunction. These cells, which line the interior surface of blood vessels, are 
described in Section 1.3.1.1. Their dysfunction has been shown to be related to 
mechanical cues, including haemodynamic forces such as shear stress, and plaques 
commonly develop at areas of disturbed blood flow such as artery bifurcations or 
curvature. The mechanobiology of EC, the forces they are exposed to and their 
response, is covered in more detail in Section 1.4. 
Once initiated by EC dysfunction, atherosclerosis progresses through a number of 
stages, listed here and illustrated in Figure 1.1 [3][4]: 
1. The growth of a ‘fatty streak’, made up of lipoproteins (LDL, a form of 
cholesterol) and white blood cells. 
a. LDL particles penetrate the blood vessel wall, accumulate in small 
pools and are chemically modified by EC-produced oxidants.    
b. Modified LDL induce an inflammatory response in EC and vascular 
smooth muscle cells (VSMC), which in turn leads to the expression of 
molecules which promote white blood cell adhesion and migration. 
c. Macrophages, a form of white blood cell that engulfs target cells, 
substances or debris, ingest LDL and develop into fat-laden foam 
cells. 
2. The formation and progression of plaque. 
a. The inner layer of the vessel wall continues to thicken with both 
continuing white blood cell accumulation and VSMC proliferation, 
triggered by growth factors released by foam cells and EC. 
b. VSMC apoptosis, calcification and fibrosis form a hard plaque cap, 
surrounding an LDL-rich core. 
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Figure 1.1 The development of atherosclerotic plaque 
 
In coronary heart disease, atherosclerotic plaque gradually builds up within arteries, reducing 
blood flow. Its development begins with the accumulation of LDL and macrophages in a 
fatty streak (top), and progresses through the formation of a central LDL-rich core and hard, 
fibrous cap (centre). This can then lead to stenosis of the artery due to the ongoing growth of 
a stable, thick-capped plaque, or thrombus due to the rupture of thin-capped plaque (bottom). 
The process may take place over the course of several decades before becoming 
symptomatic. 
(Reproduced with permission [3]). 
Growth driven by 
lipoprotein accumulation. 
Plaque instability and 
rupture. 
Plaque formation: 
growth of core and 
fibrous cap. 
Fatty streak: gradual 
accumulation of LDL 
and macrophages. 
Plaque formation: LDL 
pools form central core. 
Growth driven by VSMC 
proliferation and fibrosis. 
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3. Plaque growth and disruption, which poses two threats: 
a. The first is the risk of the rupture and detachment of plaques, 
particularly those with relatively thin fibrous caps. Rupture exposes 
the core and its contents to flowing blood, and the presence of 
lipoproteins and tissues within the core activates a coagulation 
response: the accumulation of platelets and deposition of fibrin [5]. A 
blood clot, or thrombus, is formed and this thrombus (or pieces of 
detached plaque) can completely block the artery and cause a heart 
attack (myocardial infarction). 
b. The second risk is a less acute, chronic process in which the lumen in 
gradually narrowed by the growth of more stable plaques with 
relatively thick fibrous caps. This reduces the supply of oxygenated 
blood. When myocardial demand can no longer be met, the deficit 
leads to tissue hypoxia, which causes chest pain (angina). 
Poiseuille’s law states that flow rate is proportional to the fourth power of vessel 
radius; therefore any narrowing will have a significant effect on blood supply. 
However, alternate collateral coronary circulation means atherosclerosis within a 
single arterial segment can progress to 75% lumen loss (a 256 fold decrease in flow 
rate) before symptoms appear and treatment is required [6]. Despite the body’s 
ability to compensate for CHD, the disease claims the lives of 7.4 million people per 
year; making it not only the most fatal cardiovascular disease, but the single leading 
cause of death worldwide [1]. 
 
1.1.2 Stent treatment of the coronary arteries 
There is no cure for CHD, although behavioural adjustment to mitigate lifestyle 
associated risk factors, such as stopping smoking, taking up exercise or a healthier 
diet, can help to prevent or slow its development [7]. In some cases, once symptoms 
develop they can be managed or treated through medication: beta-blockers block the 
effects of certain hormones (adrenaline, for example) to reduce the workload on the 
heart and relieve the symptoms of CHD; statins lower cholesterol by reducing its 
formation and increasing its removal in the liver; antiplatelets thin blood to inhibit 
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the formation of clots. However, medication may only delay the need for surgical 
intervention. 
 
CHD has been treated by coronary artery bypass graft (CABG) since 1960. This is 
open-heart surgery, in which a healthy blood vessel segment from the body is 
connected to the affected coronary artery to re-route blood around the blockage. A 
less invasive procedure, percutaneous coronary intervention (PCI) was first 
performed in 1977 [8]. This involved the inflation of a balloon catheter to open 
narrowed arteries by squashing lesions and expanding the surrounding vessel (“plain 
old balloon angioplasty”, or POBA). However, the rates of complications requiring 
re-intervention following POBA were high compared to CABG. Vessel injury and 
over expansion stimulated the growth of neointima, or arterial scar tissue, and post-
treatment lumen diameter could be reduced due to elastic recoil of the wall [9]. 
In 1986 the minimally invasive percutaneous treatment of CHD was augmented with 
the use of small devices known as cardiovascular stents [8]. Stents are expandable 
metal tubes which are transported through the body via catheter and implanted at 
disease sites. In the coronary arteries, stents are deployed during the PCI procedure 
and are pre-loaded onto the same balloons which are used to compress plaque and 
widen narrowed arteries. These coronary stents remain in place when the balloon is 
withdrawn, to maintain the patency of treated vessels by acting as scaffolds and 
preventing the recoil of the vessel wall (Figure 1.2). A ‘gold standard’ stent 
expansion to artery diameter ratio of 1.1:1 to 1.2:1 is used to balance sufficient 
widening against the risk of injury [9]. Early bare metal stents (BMS) halved the 
complication rates seen in POBA [8]. The use of these devices to alleviate symptoms 
is now routine and has increased success rates in the treatment of CHD. In the UK 
today, the use of stents is recommended as good clinical practice, and over 90% of 
PCI procedures involve stent deployment [10]. Globally, over 3 million coronary 
stents are implanted each year [11].  
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Figure 1.2 CHD and coronary stent deployment 
 
A: The lumen of a normal coronary artery (left) is narrowed following the development of 
atherosclerotic plaque (right), reducing the supply of oxygenated blood to the heart (arrow). 
B: The deployment of coronary stents over lesions (left), via the inflation of a balloon 
catheter, compresses the plaque, widens and scaffolds the artery, and restores normal blood 
flow (right).  
C: An example of a typical slotted tube coronary stent, deployed via the inflation of a 
balloon catheter. (Reproduced with permission [12]). 
 
A 
B 
C 
7 
 
1.1.3 Coronary stents 
1.1.3.1 Requirements and design 
A great many coronary stent designs are commercially available and clinicians must 
select the most appropriate based on a number of characteristics. In an effort to aid 
this selection, Hindlet et al (2005) classify stents according to four criteria [13]: 
1. Technical 
2. Mechanical 
3. Clinical 
4. Economic 
Clinical criteria include the rates of complications and major adverse cardiac events 
(MACE) associated with each stent. Economic criteria are important in a public 
health setting, as the efficacy of stents must be weighed against their cost. 
Mechanical criteria describe the ability of the stent to perform its intended task. They 
can include stiffness to prevent elastic recoil and resist wall pressure, flexibility in 
order to conform to vessel curvature and crossing profile (the size of the packed, pre-
deployed stent to be guided through the vasculature). 
Technical criteria describe the physical attributes of the stent: its type, design, 
material and coating, and means of deployment. There are three main types of stent. 
‘Coil’ stents consist of a continuous wound wire and are generally no longer used, as 
they have poor radial strength. ‘Mesh’ stents consist of a dense, symmetrical lattice 
of struts. ‘Slotted tube’ stents typically take the form of struts arranged in a series of 
rings, connected by bridge struts. The majority of modern coronary stents are slotted 
tubes, with the specific design of the rings and bridges varying between model and 
manufacturer (Figure 1.2C). 
The specific design of individual stents can be described by a number of 
parameters [14][15], which include: 
 Number of struts 
 Strut thickness and width 
 Strut contact angle, or its orientation with respect to the direction of flow 
 Cross-sectional strut shape 
 Cell size (here referred to as the inter-strut area, to avoid confusion with 
biological cells) 
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 Metal to artery ratio, or vessel wall coverage 
 Bridge configuration (slotted tube stents only) 
 Crown radius (slotted tube stents only) 
 Peak to valley alignment (slotted tube stents only) 
In improving stent performance, designers must select which of these parameters, 
illustrated in Figure 1.3, to optimise. For slotted tube coronary stents this process can 
be particularly complicated. For example, the number of struts and their contact 
angle affects both scaffolding of the artery wall and radial stiffness. The length of 
struts also affects stiffness, as well as the overall number of strut rings required along 
the stent’s length. The number of rings can also be controlled with bridge length. 
Fewer, longer bridges compromise longitudinal stability, but too many bridges make 
the stent inflexible. The alignment of peaks and valleys further influences the number 
of rings per unit length, in addition to the chance of strut collision when bending, and 
the size of the inter-strut area. These areas may be closed (connected at every 
junction, resulting in smaller areas and reduced flexibility) or open (some junctions 
remain unconnected, resulting in greater flexibility but the risk of tissue prolapse 
within larger areas) [15].  
The above describes the relationship between geometry and mechanical 
performance. Optimisation is made more complex by considering the influence on 
local haemodynamics, which affects the long-term performance of stents and their 
associated complications (discussed further in Section 1.5). 
 
1.1.3.2 Manufacturing 
The majority of slotted tube coronary stents are laser cut from a metal tube (or from a 
metal sheet which is then rolled and welded), enabling the precise and highly 
reproducible fabrication of intricate designs [14]. As this method produces struts of 
square or rectangular cross-section only, electrochemical polishing or tumbling can 
be used to blunt sharp edges and create rounder, more streamlined struts, in addition 
to removing slag [16]. 
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Figure 1.3 Design features of slotted tube coronary stents 
 
Coronary stents consists of a number of variable features and design parameters. 
Circumferential rings of struts (top, between the dashed lines) repeat along the stent’s 
longitudinal axis, are connected in sequence by bridge struts (B) and form enclosed inter-
strut areas known as cells (red shaded region). The typical sinusoidal strut pattern forms 
peaks and valleys (P and V, assuming flow direction from left to right), of specific crown 
radius (C). Individual struts, of square, rectangular or rounded cross-section (bottom), have a 
thickness (T) and a longitudinal width (W). 
 
W 
B 
C 
T 
V 
P 
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Stents are manufactured from a range of materials, the majority of which are metal 
alloys [17]: 
 Stainless steel has long been a commonly used material, due to its mechanical 
properties and resistance to corrosion. 
 Tantalum and platinum-iridium alloys have both shown reductions in post-
stent complications (Section 1.3.2) due to increased biocompatibility, but lack 
radial strength. 
 Titanium is used in a number of biomedical implants as it is highly 
biocompatible. However, its low ductility means stents are rarely made of this 
material alone as they are prone to fracture during expansion. 
 Cobalt-chromium alloys have also been previously applied in other 
biomedical implants. Their use is currently prevalent as, unlike titanium, the 
mechanical properties of these alloys allow extremely thin struts to be 
manufactured. 
 
1.1.3.3 Complications in coronary stenting 
The majority of PCI procedures with stent deployment are successful. Of the small 
number of unsuccessful procedures, approximately 90% fail due to an inability to 
deliver the stent to the lesion site [18]. Failure of correctly implanted stents can occur 
due to recoil or compression (if struts are too thin, or radial strength too weak), strut 
fracture (if too stiff) and longitudinal deformation (if too few bridge struts are 
present) [19]. 
However, successful PCI can still lead to late-stage stent failure weeks or months 
post-stent deployment. This is not due to stent selection or the clinical procedure, but 
rather the biological response of stented arteries, considered in more detail in 
Section 1.3. 
 
1.2 Engineering solutions for cerebral arteries 
The three cerebral arteries (the anterior, middle and posterior) supply oxygen to the 
brain. They arise from the Circle of Willis, a loop of connected arteries which 
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enables blood flow to be shunted to different areas of the brain if any of the 
connecting arteries become blocked. Adequate blood flow to the brain is crucial, and 
as such it is well controlled: a constant, normal flow of approximately 750 ml/min is 
maintained even under extreme conditions [20]. 
 
1.2.1 Intracranial aneurysms 
In comparison to the coronary arteries, the walls of cerebral arteries are relatively 
thin and lack many structural components (described in more detail in 
Section 1.3.1) [21]. As such, local weaknesses and defects in the wall can arise, 
acquired either congenitally or from factors such as smoking or hypertension. Blood 
pressure can then force the vessel to balloon outwards at these points. This forms 
intracranial aneurysms, sacs of blood outside of the artery [22] (Figure 1.4A). 
Aneurysms remain connected to the parent vessel at the neck of the balloon, and 
continuous blood flow into the sac may allow the aneurysm to gradually grow and 
potentially rupture. Burst aneurysms lead to subarachnoid haemorrhage, the leaking 
of blood over the surface of the brain which carries a 60% mortality rate [22], and 
haemorrhagic stroke. Second only to CHD in mortality, strokes claim the lives of 6.7 
million people each year [1]. 
 
1.2.2 Stent treatment of the cerebral arteries 
As for CHD, lifestyle changes can reduce the risk of initial intracranial aneurysm 
development, while medication can decrease their rate of growth and risk of rupture 
by lowering blood pressure and relaxing the blood vessels [22]. Yet, surgical 
intervention may eventually become necessary. Surgical treatment of intracranial 
aneurysms includes neurosurgical clipping, which involves the attachment of a small 
clip at the neck of the aneurysm to isolate it from circulation. This is the most 
invasive option as it requires a craniotomy, an opening in the skull. A less invasive 
percutaneous intervention, endovascular coiling, also exists. This involves the release 
of a coil of thin platinum wire into the aneurysm sac. Packing the aneurysm prevents 
blood flow from entering at the neck and induces the formation of a clot within the 
sac [23]. 
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Figure 1.4 Intracranial aneurysms and flow diverter stent deployment 
 
A: Areas of thin or weak cerebral artery wall (left) can be sites of aneurysm formation, 
which grow over time under the pressure of blood flowing within them (right). 
B: The deployment of flow diverter stents in parent arteries over aneurysm necks (left) can 
redirect blood flow away from the aneurysm sac (right), reducing pressure and therefore 
growth and the risk of rupture. 
C: An example of a typical mesh flow diverter stent, deployed via self-expansion after 
withdrawal of the introducer sheath. (Reproduced with permission [12]). 
A 
B 
C 
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Endovascular coiling was augmented with the use of pre-existing cardiovascular 
stents, which were deployed to hold coils in place and to prevent their migration into 
the parent vessel [23]. More recently, a new type of flow diverting cardiovascular 
stent was developed specifically to treat aneurysms. These devices were based upon 
the principle of endovascular coiling, preventing blood flow from entering the sac, 
but reduced the risk of rupture by removing the need to implant within the aneurysm 
itself. Rather, flow diverter stents are placed within the artery at the neck of the 
aneurysm, where they divert blood flow through the parent vessel and away from the 
sac [24]. Flow diverter stents do not need the widening or scaffolding force of 
coronary stents. As such, they are delivered within an introducer sheath which is 
removed to allow the gentle self-expansion of the stent, which then sits adjacent to 
the vessel wall (Figure 1.4B). 
 
1.2.3 Flow diverter stents 
1.2.3.1 Requirements and design 
The first use of flow diverter stents for the treatment of intracranial aneurysms was 
clinically approved in 2008 [25]. As a relatively modern development, far fewer 
designs are commercially available in comparison to the wide range of coronary 
stents. Flow diverter stents are still classified according to the standards described in 
Section 1.1.3.1 and many of the same mechanical criteria also apply [13]. Additional 
requirements specific to the role of flow diverters include elasticity, to allow the 
compression and subsequent self-expansion of stents. 
All flow diverter stents are ‘mesh’ stents, consisting of a basic lattice of struts 
(Figure 1.4C). As such, in optimising stent performance there are few design 
parameters to consider: the size and number of struts affects the metal to artery ratio, 
the porosity of the mesh and, in turn, the degree of flow diversion and intra-
aneurysmal blood flow [26]–[28]. 
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1.2.3.2 Manufacturing 
The fine mesh of flow diverter stents is formed by braiding separate, thin wires [29]. 
In some cases this is performed by hand, despite the small size of the stent. Braiding 
can, however, lead to the presence of loose struts and untrimmed edges at either end 
of the stent. The use of extruded wires means that flow diverter struts have circular 
cross-section. 
Nitinol (a 55% nickel, 45% titanium alloy) is the material of choice for self-
expanding flow diverter stents due to its shape memory. Nitinol stents can be 
deformed at room temperature and return to their original geometry at body 
temperature. However, the material’s resistance to corrosion is debated [17]. Alloys 
of 25% platinum and 75% cobalt-nickel, or 25% platinum-tungsten and 75% cobalt-
chromium-nickel are also used in the manufacture of flow diverter stents [23][30]. 
 
1.2.3.3 Complications in intracranial stenting 
The placement of flow diverter stents can cause collateral effects on local blood flow 
if, for example, the location of an aneurysm requires the placement of a stent over 
side branches or smaller blood vessels. The reduction in blood flow as it is diverted 
away from these adjoining vessels can, in the worst case, lead to a stroke [24]. 
Incomplete or poor deployment can result in the relocation of stents within the 
vessel, or vessel occlusion due to unexpanded, tapering ends [31][32]. Manipulation 
of the catheter and introducer sheath to encourage full deployment can cause local 
inflammation and vessel perforation [24]. 
The majority of flow diverter deployment procedures are successful and achieve the 
primary goal of aneurysm occlusion. However, as for PCI, post-operative 
complications due to biological responses, detailed in Section 1.3.3, are not 
uncommon [33][34]. 
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1.3 Biological response to stenting 
In addition to immediate or short-term complications due to stent selection or clinical 
deployment, issues can arise in the weeks or months following stent implantation. 
These issues are due to the biological response to the presence of stents as foreign 
bodies and their impact on, and interaction with, local vascular anatomy. 
 
1.3.1 Arterial anatomy 
Arteries consist of distinct layers surrounding a lumen, the interior space through 
which blood flows (Figure 1.5). The endothelium (tunica intima), a flat sheet of 
endothelial cells, is a mechanically weak but vital component (described in more 
detail in the following section). The tunica adventitia is a sheath of connective tissue, 
which holds the vessel in place. The internal and external elastic laminae are the 
borders of the tunica media, the precise make-up of which varies depending on the 
role of specific arteries [35]. Elastic arteries, such as the aorta, contain collagen and 
elastin to allow the vessel to stretch and maintain constant pressure throughout the 
cardiac cycle. Muscular distributing arteries, such as the coronary vasculature, move 
blood from elastic arteries and into smaller arterioles which offer resistance to flow. 
As such, layers of VSMC provide strength and contractive power. Cerebral arteries, 
while still considered muscular arteries, have fewer VSMC layers and elastic fibres, 
lack an external elastic lamina and have a thin adventitia [21]. 
 
1.3.1.1 The endothelium 
The endothelium is a one cell thick sheet of EC which covers the luminal surface of 
blood vessels. EC are flat, elongated cells, approximately 0.2 – 2 µm thick and 1 – 20 
µm across [6]. Initially thought to be an inert layer, EC are actually more dynamic 
than many other cell types, are highly sensitive to extra-cellular stimuli and adapt to 
their environment [36]. This sensitivity and reactivity is demonstrated by their initial 
differentiation from endothelial progenitor cells (EPC) into either arterial or venous 
endothelial cells, depending on the haemodynamic forces they are exposed to as they 
enter the blood stream [37]. 
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Figure 1.5 Layers of the arterial wall 
 
Shown here in cross-section, arteries consist of a number of distinct layers; from the internal 
layer of the endothelium, surrounding the lumen, outward to the adventitia. The total 
thickness of the wall and its precise composition depends upon the role of each specific 
artery: cerebral arteries have thin walls to enhance the exchange of nutrients and water 
across them, while coronary arteries contain more smooth muscle cells to work against flow 
resistance.    
 
Endothelium 
Internal elastic lamina 
Basement membrane 
Smooth muscle 
External elastic lamina 
Adventitia 
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EC act as a physical barrier for the exchange of fluids and particles between the 
lumen and the vessel wall and surrounding tissue. The nature of this barrier varies 
with location. In capillaries, for example, gaps between EC allow transport into the 
surrounding tissue. In the cerebral vasculature tightly packed EC form the blood-
brain barrier. The cerebral endothelium is highly specialised, and tightly regulates the 
exchange of water, nutrients and other solutes between blood and brain tissue [38]. 
In addition to their physical presence, EC have been shown to play a key, active role 
in many aspects of vascular control and health through their biochemical activity [6]. 
Many of these functions are directly related to the conditions described in 
Sections 1.1.1 and 1.2.1: 
 EC inhibit platelet aggregation, via the release of nitric oxide and 
prostacyclin synthesising enzymes. 
 EC inhibit white blood cell adhesion and aggregation, via nitric oxide 
enzymes and surface adhesion molecules. 
 EC regulate the function of VSMC through vasodilators and vasoconstrictors, 
and consequently the resistance to blood flow and blood pressure [36]. 
In general terms, EC provide an antithrombotic environment and exert a measure of 
control over vessel dilation and constriction, regulating blood flow and helping to 
maintain vessel patency [38]. 
 
1.3.2 Biological response to coronary stents 
The endothelium bears the immediate brunt of PCI injury, as both balloon expansion 
and stent deployment can cause denudation of EC [39]. Post-stent complications can 
involve local bleeding, allergic reactions, or infection. However, stent failure is 
generally caused by two major complaints: stent thrombosis and in-stent restenosis 
(ISR) [40]. 
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1.3.2.1 Thrombosis 
Stent thrombosis occurs via a different mechanism than that described in Section 
1.1.1, although the prospective harm remains the same: thrombi can detach, move 
through and potentially block the vasculature, or they can remain in situ and induce 
rapid lumen loss within the stent.  
Stent strut penetration of the vessel wall exposes sub-endothelial, pro-thrombotic and 
pro-coagulant factors to circulating blood. At critical concentrations, these factors 
activate ‘coagulation cascade’ pathways, leading to clot formation [41]. The extent of 
stent thrombosis is therefore largely dependent on the degree of strut penetration 
[42], although, acting as a surface for platelet accumulation, the design of the stent 
also has an impact: stent type, strut thickness, the amount of exposed metal and its 
composition. In addition, the denudation of the endothelium during stent deployment 
means that local protective effects attributed to EC, including the production of anti-
coagulants and suppression of thrombosis, are lost [43].  
Stent thrombosis can develop within the first 24 hours of deployment (acute stent 
thrombosis), or after a year or more (late stent thrombosis), but current coronary stent 
thrombosis rates are <1% [40]. 
 
1.3.2.2 In-stent restenosis 
In-stent restenosis is a less acute, progressive re-narrowing of treated vessels. 
Although it is a gradual process, clinical diagnosis of the condition is explicit: ISR is 
diagnosed to have occurred above a threshold of 50% lumen loss [44]. Restenosis is 
the result of several complex response processes, but is generally considered as the 
progression of four main stages (Figure 1.6): thrombosis and inflammation constitute 
the early phase, over days and weeks, followed by proliferation and remodelling 
[42], [45], [46]. This late phase, and the eventual diagnosis of ISR, can take several 
months [47]. 
In the first week post-stent implantation, thrombus formation peaks and thrombotic 
deposits can build up around struts (the degree to which this occurs can vary, as 
described in Section 1.3.2.1, and may be insignificant in terms of lumen reduction).  
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Figure 1.6 The phases of vascular response to stenting 
 
Following stent deployment ISR can gradually re-narrow treated arteries. This process 
consists of the progression of four main stages:  
In the immediate period post-stent deployment thrombus formation peaks (green), a response 
to vessel injury caused by stent deployment. This is followed by both an inflammatory 
response and the proliferation of exposed vascular smooth muscle cells (blue). After several 
weeks, elastic recoil remodels the vessel wall (red) although the lasting presence of stents, 
acting as scaffolds, minimises its effect. 
(Reproduced with permission [42]). 
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Vessel injury and the presence of the stent as a foreign body then lead to a local 
inflammatory response. This begins a few days post-implantation, and involves the 
further deposition of fibrin, platelets and white blood cells. Inflammation is, as for 
thrombus formation, dependent on the degree of vessel injury and the scale of 
inflammation is in turn linked to the size of neointimal growth [48]. 
Next, VSMC, which are exposed by stent deployment, migrate into the lumen from 
lower layers of the vessel wall. Although contact with flowing blood can provoke 
apoptosis in VSMC [49], vessel injury and inflammation modulates the cells and 
induces both proliferation and an increase in ECM production. In addition, the cells 
synthesise and secrete other substances which exacerbate luminal reduction, 
including vessel contraction and further inflammatory and proliferative activity [50]. 
The final stage, remodelling, involves elastic recoil or vessel contraction. Although 
this stage contributes to restenosis post-POBA, it is virtually eliminated when 
coronary stents are present to act as scaffolds. Despite this advantage, coronary stents 
are particularly at risk of ISR as it is VSMC, exposed by relatively aggressive 
balloon and stent expansion, which have the greatest impact on the process 
(Figure 1.7) [51][52]. ISR develops in approximately 10% of cases, with 5% meeting 
the threshold for clinical diagnosis [40]. 
 
1.3.2.3 Reendothelialisation of stented coronary arteries 
The repair of stented arteries involves the covering of the stent and local vessel 
segment with a renewed endothelial layer. A healthy, functional endothelium can 
exert a degree of control over the local vasculature; reducing complications by 
inducing thrombus suppression and the quiescence of VSMC [43]. 
The precise mechanisms of endothelial renewal are not fully understood. 
Reendothelialisation had been considered to be due solely to the migration of EC 
from adjacent, uninjured sites [41]. Local, damaged EC, as well as VSMC and 
accumulated platelets, release mitogens (chemicals which trigger cell division) [53]. 
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Figure 1.7 In-stent restenosis development 
 
Post-stent deployment, treated vessels can re-narrow due to the development of ISR. 
A: Normal vessel wall, with EC (blue), VSMC (pink) and fibroblasts (purple). 
B: Stent deployment causes initial wall injury and EC denudation local to struts. 
C: Exposed, modulated VSMC (yellow) migrate into the lumen and proliferate. 
D: EC reendothelialise the wall and VSMC differentiate back to a quiescent phenotype. The 
lumen is now occluded local to the stent. 
(Reproduced with permission [46]). 
A 
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These mitogens, which include vascular endothelial growth factors (VEGF), cause 
EC to migrate into damaged and denuded areas and begin proliferating, eventually 
reendothelialising the injury site (the physical process involved in the movement of 
an individual EC across a substrate is covered in more depth in Section 1.4.4).       
In addition to local EC, the presence of EPC have also been noted  [54]. EPC are 
derived from bone marrow and circulate in the blood. Their mobilisation is induced 
by VEGF and circulating EPC adhere to proteins and adhesion molecules on the 
vessel wall. Once captured, progenitor cells can proliferate and differentiate into 
mature arterial EC [55]. 
One further potential mechanism involves the accumulation of endothelial cell 
colony forming unit precursors. These are monocytes and lymphocytes, both types of 
white blood cell, which exhibit the characteristics of mature EC [56]. Colony 
forming unit precursors are thought to arrive and cover injury sites relatively early, 
before secreting more VEGF which further enhances the homing of circulating EPC 
and the proliferation of accumulated EPC [53]. There is, however, still debate as to 
the identity and degree of contribution of the cells involved in the process of 
reendothelialisation. 
 
A 2013 study by Douglas et al investigated the origin of cells within a renewed 
endothelium, by transplanting stented aorta from donor to recipient murine 
models [57]. Vascular repair was found to involve both local aortic donor EC and 
circulating recipient EPC, with the degree of EPC contribution varying between 
animals. Separate studies have contradicted this result, finding that EPC do not 
contribute to reendothelialisation [58][59]. However, it has been noted that the 
methods used in these studies could have influenced both the repair mechanism and 
the ability to properly identify EPC [43]. 
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1.3.3 Biological response to flow diverter stents 
An immediate and serious potential response to flow diverter stent deployment is 
bleeding. Whether caused by vessel perforation or the rupture of treated 
aneurysms [34], any blood loss will lead to subarachnoid haemorrhage [33]. Further 
biological responses to flow diverter stents are similar to those in coronary arteries: 
stent thrombosis and in-stent restenosis (or rather, stenosis, as the vessels are not 
previously occluded). However, the differences in stent deployment method, and 
therefore endothelial injury, greatly alter the rates at which these complications arise. 
 
1.3.3.1 Thrombosis 
Thrombosis is the most common complication following flow diverter stent 
deployment, occurring in 6 – 13% of cases [24][33][34]. Thrombus formation 
develops via the same mechanism described in Section 1.3.2.1, and is thought to be 
worsened by the higher metal content of flow diverter stents. This is demonstrated by 
the fact that rates of flow diverter stent thrombosis incidence are higher in patients 
with larger aneurysms, which require the deployment of longer, or multiple, 
stents [34]. 
 
1.3.3.2 In-stent stenosis 
Until recently, little data on in-flow diverter stent stenosis existed. A small number of 
contemporary studies have found that while incidence of stenosis is seen at a rate 
comparable to coronary stents, it is generally asymptomatic and does not meet the 
50% lumen loss threshold required for clinical diagnosis [32][60][61]. The main 
cause of in-stent stenosis is the proliferation of VSMC, instigated by vessel injury. 
As such the gentle self-expansion of flow diverter stents, in cerebral arteries with 
lower VSMC content than the more muscular coronary arteries [55], carries a lower 
risk of VSMC exposure and proliferation progressing to the point of clinical stenosis. 
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1.3.3.3 Reendothelialisation of stented cerebral arteries 
In addition to aiding in the reduction of the complications described in the previous 
sections, reendothelialisation of flow diverter stents is also a key part of the 
occlusion of the aneurysm being treated. Full endothelialisation of flow diverter 
stents has been observed over 4 – 8 weeks in rabbit models in vivo, with the rate 
dependent on the size of aneurysm necks (endothelialisation is delayed over larger 
necks) and the degree of stent strut apposition (endothelialisation is enhanced where 
stents are in contact with the artery wall) [62]. 
As for coronary stents, discussed in Section 1.3.2.3, the contribution of both local EC 
and circulating EPC in flow diverter endothelialisation has been studied and the 
results have been contradictory. EPC have been found to be a factor in the healing 
process for up to 60 days [29] and identified in both fully endothelialised stent struts 
and aneurysm necks [63]. Conversely, equally complete endothelialisation has been 
observed with the renewed layer consisting solely of local EC from the parent 
vessel [62].    
 
1.3.4 Moderating the biological response to stents 
Stented vessels can be treated with a secondary percutaneous intervention when the 
biological responses described in Sections 1.3.2 and 1.3.3 develop to the point where 
it is required. However, these follow-up procedures themselves show high rates of 
restenosis [64], and a 30% risk of MACE [52]. As such, prevention is considered 
better than cure. Current post-operative care following both coronary and intracranial 
stent deployment includes the use of systemic anti-platelet medication [65][66]. 
 
By modifying or augmenting stents themselves localised treatment, rather than 
systemic, can focus on the vasculature beneath and adjacent to the implanted device. 
As the more established apparatus, coronary stents have seen the most development. 
Current technological trends focus on the targeted release of anti-proliferative agents 
with the use of drug-eluting stents (DES). These stents gradually release a drug into 
the local bloodstream and arterial wall to inhibit the growth of VSMC [67]. DES 
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have reduced ISR incidence to the current 5% rate, compared to 20 – 30% associated 
with BMS [65]. However, one drawback is the relatively short duration of drug 
delivery in comparison to the period of peak neointimal growth [47]. The 
development of polymer stent coatings, within which drugs are embedded, extended 
this duration by reducing the rate of elution [68]. When certain coatings were 
themselves found to cause inflammation, polymer-free strategies, including the use 
of microporous films, were developed [39]. DES are the current benchmark in stent 
efficacy and are used in 75% of procedures [66]. Clinical trials show clear 
improvement between successive generations of DES and, given their success rate, 
drug-eluting balloons have also been developed [8]. These can be used in POBA, or 
in tandem with either BMS or DES.  
Various coatings are also used in non-DES. The use of radioactive particle-emitting 
stents enables a form of internal radiotherapy [69]. Alternatively, coatings such as 
silicon carbide, phosphorylcholine and heparin can passivate stents and reduce their 
interaction with local tissue,  improving their biocompatibility [70].    
A more recent approach is the development of bioabsorbable coronary stents, which 
aim to reduce complications arising from the presence of the stent as a foreign body. 
Bioabsorbable stents are deployed in the standard manner, but dissolve after 
providing initial support to the arterial wall [71]. Several trials have been conducted 
which show positive results in terms of safety, but also ISR rates higher than those 
seen with DES [65]. This is often due to vessel shrinkage, as current bioabsorbable 
materials provide lower radial strength than metallic stents. Thicker, more intrusive 
struts are required to compensate and ISR may still occur in the time required for full 
stent dissolution [68]. In addition, bioabsorbable material such as poly(L-lactide) can 
be too stiff to move with its parent artery [72]. Subsequent fractures which may be 
caused by this lack of flexibility can further reduce radial strength.   
 
Other than bioabsorbable stents, which seek to minimise the impact of stent 
deployment, the strategies described here are designed to exert a more active 
influence on the local artery. The common aim is to reduce inflammation and 
narrowing by targeting VSMC. However, their impact is broader and EC can also be 
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sensitive to their effects, which can delay the regrowth of the endothelium [11], 
impeding vascular repair and increasing the risk of complications. 
The ongoing presence of stents can also be detrimental to the endothelium by 
inducing EC dysfunction. Following the deployment procedure, which can physically 
damage and remove cells, stents do not directly affect EC themselves. Rather, it is 
the impact of stents on local blood flow, and therefore the conditions EC are exposed 
to, which is thought to cause this dysfunction [43]. As mentioned in Section 1.3.1.1, 
EC are sensitive and reactive to their environment. It is therefore necessary to 
consider this environment, its alteration via stent structure and the induced EC 
response. 
 
1.4 Endothelial cell mechanobiology 
1.4.1 The mechanical environment 
As they form a layer on the luminal surface of blood vessels, EC are subjected to 
radial stress caused by blood pressure. In the arteries, mean blood pressure is 
approximately 13 kPa [73]. This pressure also causes the blood vessel to distend: 
diameter increases at systole (the contraction phase of the cardiac cycle), before 
decreasing at diastole (the relaxation phase). EC attached to the vessel wall are 
subjected to a circumferential stress, or hoop stress, as the wall pulses and stretches 
throughout the cardiac cycle. In medium-sized arteries hoop stress is on the order of 
10
5
 Pa [73], and strain is typically 5 – 10% [74][75]. In addition to the cyclic stress 
caused by cardiac rhythm, the coronary arteries are also continuously subjected to 
stretch and compression as they ride on the surface of the heart itself, which is in 
constant motion [55]. 
 
1.4.2 The haemodynamic environment 
EC are exposed to flowing blood which, at its simplest, can be seen as an 
incompressible fluid flowing through straight, cylindrical, rigid tubes [76]. Flow is 
steady and laminar in normal arteries. Although repetitive disturbances can form, 
Reynolds numbers are below transition (~300) and turbulent flow is not present in 
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vivo. The Womersley parameter is also low (~3) [73]. As such, viscous forces 
dominate.  Normal pipe flow can be considered and blood velocity forms a parabolic 
profile [35]. In reality, blood flow is more complex. The magnitude and direction of 
flow varies temporally (through the cardiac cycle) and spatially (with different 
vascular anatomy) [77]. Secondary flow and complex patterns are generated near 
curves and branches [73]. 
Further complicating the picture of simple flow is the fact that blood is not a 
continuous fluid: 55% of blood volume is plasma (water, proteins and ions) and the 
remaining 45% consists of discrete elements (red blood cells, white blood cells and 
platelets). As a particulate suspension, blood is non-Newtonian and viscosity is 
dependent on shear rate [78]. However, when considering the arteries, vessel 
diameter is large (>0.5 mm) compared to the size of the individual elements and 
shear rates are high enough (>100 s
-1
) for viscosity to be independent of them. 
Arterial blood is therefore generally treated as a Newtonian fluid [73][76], and 
viscosity considered to be 3.5 - 4.0 mPa.s [79]–[81]. 
 
The laminar, viscous flow of blood generates a shearing stress on the EC lining 
vessel walls [74][81]. For the simple flow assumptions described above, the Hagen-
Poiseuille equation (         ) provides a reasonable estimate of wall shear 
stress [73]. The specific range of wall shear stress magnitudes found in vivo is 
investigated further in Section 1.7.3, but is orders of magnitude lower than the forces 
described in Section 1.4.1 [73]. However, EC are particularly sensitive to wall shear 
stress; it is essential for EC function, and abnormal levels can cause dysfunction [82]. 
 
1.4.3 Wall shear stress and endothelial cell response 
Despite being several orders of magnitude weaker than either radial or hoop stress, 
above a threshold of 0.08 Pa wall shear stress is the dominant force affecting EC 
behaviour [83]. Under basal levels of shear stress, EC function normally and 
contribute to good vascular health [81]. Deviation from these levels can cause 
dysfunction within the vessel. This arises not from direct injury (wall shear stress of 
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50 Pa is required to damage EC [84]) but from the effects of EC biochemistry 
influenced by shear stress.  
Initial exposure to flow generated wall shear stress induces differentiation between 
progenitor cells and functional EC [37]. In addition, dissimilar levels of shear stress 
between vessels influence differentiation between venous and arterial EC. Ongoing 
sensitivity and reactivity to shear stress enables the endothelium to help arteries 
adapt to changes in blood flow, via the expression of vasodilators and 
vasoconstrictors. If shear stress levels become too high, vasodilators are expressed to 
widen vessels. Too low, and vasoconstrictors narrow vessels to return shear stress to 
baseline levels [73][85]. This behaviour aids in the maintenance of normal blood 
pressure and allows the supply of oxygenated blood to meet demand. 
 
The influence of wall shear stress on vascular health can be illustrated by the fact 
that, although the entire cardiovascular system is exposed to the systemic risk factors 
of CHD, atherosclerotic lesion formation is focal. This discrepancy has been 
attributed to local haemodynamics for over a century [86]. After some debate over 
what specific aspect of blood flow causes this outcome, it was suggested that low and 
oscillatory shear stress was responsible [87]–[89]. It is observed that lesions 
preferentially progress around bifurcations and at the inner wall of curved arteries, 
which are areas of low or even reverse flow [85][90]. This conclusion is supported 
by a number of studies which combine patient data with shear stress estimates from 
computational simulations, and find lesions progress in regions of low shear 
stress [91][92]. 
This theory is widely accepted, but not universally. Peiffer et al (2013) performed a 
systematic review of 27 papers, several of which did not find the expected 
correlation between low shear and atherosclerosis [86]. Those that did interpreted 
disease progression and haemodynamic factors in different ways. In addition, there 
was little consistency between the magnitudes of shear stress defined as the low/high 
thresholds (this point is considered further in Section 1.7.3). 
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Poor vascular health can be related to the endothelium by examining EC behaviour 
under low wall shear stress. Chien et al (1998) [93], Chatzizsis et al (2007) [87] and 
Van der Heiden et al (2013) [43] detail the changes in EC biochemical functions 
which may occur under low or oscillatory shear stress, examples of which are shown 
in Table 1.1. It is clear that vasodysfunctional effects are induced, particularly those 
related to vessel narrowing, and plaque and thrombus formation (and therefore 
atherosclerosis, and the post-stent complications described in Section 1.3). 
In comparison, contrasting behaviour under high shear stress confers a protective 
effect [43]. High shear stress also enhances EC migration, a fact which is of special 
relevance to post-treatment vascular repair and the endothelialisation of 
stents [94][95]. However, while the response of EC to shear stress can be observed, 
the exact mechanisms and structures through which they sense it are not yet fully 
understood [77]. 
 
1.4.4 Wall shear stress and endothelial cell mechanotransduction 
EC modify their local environment via mechanotransduction, the conversion of 
mechanical stimuli into chemical activity. Mechanotransduction may be local (the 
activation of a single mechanoreceptor on the cell) or decentralised (forces are 
transmitted throughout the cell, activating many mechanoreceptors) [81]. 
The specific sensors which enable EC to detect wall shear stress magnitude or 
direction are not known, but candidate mechanoreceptors have been 
identified [43][96]. These include the action of wall shear force upon the following 
structures: 
 The glycocalyx, a protein which covers the luminal surface of EC [97]. 
 Primary cilia, small organelles which project from the EC into the 
bloodstream [98]. 
 The cytoskeleton, the network of protein filaments and microtubules that give 
cells their shape. The cytoskeleton can resist deformation, but also induces it 
to enable cell migration [99].  
 Integrins, proteins that attach cells to the underlying extracellular matrix. 
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Function Effect of low shear stress 
Vascular tone: release of vasodilators ↓ 
Vascular tone: release of vasoconstrictors ↑ 
VSMC: release of growth promoters ↑ 
VSMC: release of growth inhibitors ↓ 
Release of oxidants ↑ 
Release of antioxidants ↓ 
Cholesterol accumulation ↑ 
Reduction of inflammation  ↓ 
Extracellular matrix synthesis and degradation ↓   ↑ 
Plaque calcification ↑ 
EC apoptosis ↑ 
 
Table 1.1 Specialised functions of EC related to vessel patency and their up or 
down regulation under low shear stress conditions 
 
Low wall shear stress can induce endothelial dysfunction, which in turn leads to a number of 
vasodysfunctional effects (particularly related to vessel narrowing) due to the influence EC 
have on their local vasculature. 
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 Ion channels, proteins which form pores in the cell membrane and allow ions 
to pass through. 
 A combination of cell adhesion and signalling proteins, known as the 
VEGFR2/VE-cadherin/Pecam-1 complex [100]. 
 
As has been previously mentioned, EC are not only sensitive to wall shear stress, but 
also reactive. Once the force has been detected, this reaction is due to the presence of 
DNA sequences known as shear stress response elements (SSRE) which activate the 
expression of certain genes. For example, Nagel et al (1994) studied the expression 
of three intercellular adhesion molecules (ICAM) at wall shear stress levels between 
0.25 and 4.6 Pa [101]. The only molecule to be affected by the change in mechanical 
conditions was ICAM-1, which was up-regulated with increased shear stress. The 
ICAM-1 promoter gene was also the only molecule which contained an SSRE. 
 
One explanation for the observed effects of shear stress on EC migration is the 
influence of flow on cell polarity. Polarity is essential for cell migration via 
cytoskeleton rearrangement: it defines a leading edge for protrusion and adhesion of 
the cell body, and a rear for retraction. This combined, repeated action propels cells 
over their substrate [102]. High, uniform shear stress can enhance polarity, whereas 
low or oscillatory shear stress can prevent it. 
This was demonstrated, and a proposed mechanism suggested, by a series of 
experiments by Hsiao et al (2016) [103]. EC within an empty channel were observed 
to migrate in the direction of flow, while EC within a ridged channel (replicating 
stent geometry) accumulated immediately downstream of the first obstacle (Figure 
1.8A and B). This area was identified, via particle tracking and computer simulation, 
as a site of bidirectional flow. 
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Figure 1.8 Endothelial cell migration under disturbed flow 
 
HUVEC within a parallel plate chamber were exposed to unidirectional flow and the leading 
edge of the migrating cell monolayer (white line) was monitored over 24 hours. 
A: HUVEC in an empty chamber rapidly migrated through the field of view. 
B: HUVEC in a ridged chamber, representing stent struts. A low number of cells crossed the 
ridge, where their migration was inhibited within a region of disturbed, bidirectional flow. 
C: HUVEC in a ridged chamber, with a ROCK inhibitor to silence bidirectional mechanical 
cues. A greater number of cells crossed the ridge, and continued to migrate beyond the 
region of disturbed flow. 
D: Migration paths of individual HUVEC (red dots) over time. Yellow lines represent a 15% 
deviation from the direction of flow.  Bidirectional flow reduced HUVEC persistence 
(centre), hindering overall downstream migration compared to cells within an empty 
chamber (left) or in the presence of a ROCK inhibitor (right). 
Flow from left to right. 
Scale bar: 100 µm (A-C), 500 µm (D). 
(Reproduced with permission [103]). 
0 h 6 h 12 h 24 h 
Unidirectional Bidirectional 
A 
B 
C 
D 
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It was proposed that bidirectional flow increases MLC activity (myosin light chain, a 
motor protein involved in cell motility [104]), which in turn induces multiple 
protrusions around the cell. This reduces polarity and thus inhibits migration. The 
above experiment was then repeated with the addition of a Rho-associated protein 
kinase (ROCK) inhibitor. ROCK up-regulates MLC activity, therefore ROCK 
inhibition was expected to reduce MLC activity, increasing cell polarity and EC 
migration [105]. Indeed, EC in the presence of ROCK inhibitors were observed to 
migrate beyond areas of disturbed flow, their sensitivity to bidirectional mechanical 
cues having been essentially suppressed (Figure 1.8C). 
Tracking individual EC at multiple time-points revealed that cell migration distances 
were not always reduced in bidirectional flow due to arrested movement, but rather 
by a decrease in the directional persistence of that movement. EC were in continuous 
motion but, in the presence of disturbed flow induced by replica stent geometry, the 
direction of this motion was not consistent (Figure 1.8D). 
 
1.5 Stent geometry and endothelial cell behaviour 
The effect of stent geometry on EC behaviour has been investigated both directly and 
indirectly. Clinical studies tend to be indirect: particular stent designs have 
associated rates of ISR and thrombosis, from which the presence or absence of a 
healthy, functional endothelium may be inferred [106]. The relationship between 
stent design and endothelial function can also be assessed via in vitro and in silico 
methods [107]. Once again, this is often indirect: the effect of stent structure on 
haemodynamics is studied in in silico models and cell-free in vitro models, and 
conclusions are drawn by relating those results to separate studies of EC under 
similar conditions [108]. In other cases, EC seeded within in vitro models can reveal 
links between their behaviour and stent-induced flow directly [103]. In considering 
the impact of stent geometry in this section, all of these approaches are taken into 
account.  
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1.5.1 Stent length 
Many studies believe stent length to be the most important factor related to stent 
design, based on the link between length and rates of ISR (only initial lumen 
diameter is considered to be a greater predictor) [9][109][110]. This would appear to 
be a logical conclusion. Increased stent length means more struts, a greater amount of 
exposed metal and, it may be assumed in the case of coronary stents, a wider extent 
of plaque within the vessel necessitating the stent to begin with. This means greater 
initial injury to EC, and requires reendothelialisation over a larger vessel area under 
disrupted blood flow. 
However, other than diameter, length is perhaps the only aspect of stent design that 
cannot be altered. Although it is minimised where possible, surgeons must select 
stents based on the size of the plaque, narrowed arterial segment, or aneurysm neck 
in each individual case [109]. 
 
1.5.2 Stent structure 
As shown in Section 1.1.3.1, ‘stent design’ is a broad term which includes many 
different parameters. In silico study is therefore particularly useful, providing the 
ability to consider variation in individual components while keeping all other factors 
equal [111]. LaDisa et al (2004) found that the area of vessel wall exposed to low 
shear stress increases with the number of struts, their longitudinal width and 
thickness, and stent to vessel expansion ratio  (Figure 1.9A) [112]. Hsiao et al (2012) 
agree that wall shear stress is particularly sensitive to strut thickness (Figure 1.9B), 
but they did not find the same for longitudinal width. In addition, they suggest that 
crown radius and the overall design pattern have little effect on wall shear stress 
distribution [113]. Pant et al (2010) altered the shape of bridges connecting strut 
rings, and found that different designs had an influence on blood flow and wall shear 
stress even in stents of otherwise similar strut dimensions and spacing (Figure 
1.9C) [111]. 
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Figure 1.9 Parametric studies of stent design and local wall shear stress 
 
Computational models of stented vessels have been widely used for the parametric study of 
stent design features, investigating their effect on haemodynamics and shear stress. 
A: Increasing the overall number of stent struts reduces wall shear stress [112]. 
B: Increasing the thickness of stent struts reduces wall shear stress [113]. 
C: Wall shear stress distribution is altered with different connecting bridge designs [111]. 
Flow from left to right. 
(All images reproduced with permission; image B by permission of the Institution of 
Engineering & Technology). 
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In their review, Sangiorgi et al (2007) touch upon the substantial differences in wall 
shear stress and haemodynamics between different stent designs, and particularly 
between stent types (slotted tube, mesh, etc.). However, they also state that this does 
not necessarily translate into different vascular response in vivo: they propose that, 
unlike stent type or strut diameter, the geometry of stents (the various designs used in 
commercial models) does not seem to influence clinical outcome [70]. Despite this 
conclusion, they concede that ‘hydrodynamic compatibility’ should be recognised as 
an important feature of stent design, classification and selection. 
 
Peacock et al (1995) demonstrated flow disturbances arising from the shedding of 
vortices from stent struts in vitro [84]. These instabilities decayed relatively rapidly 
(within 5 cm) but the influence of stents could still extend beyond their own length. 
Coil stents were found to create larger instabilities than slotted tube stents (although 
the latter model also had thinner struts). Benard et al (2003) also found areas of 
recirculation downstream of struts which were oriented perpendicular to flow [94]. 
These locations were areas of lowest shear stress, whereas regions of highest shear 
stress were located adjacent to struts which were parallel to flow. This study also 
examined slightly different stent designs, with differences in fluid dynamics only 
becoming apparent at very low flow rates. 
Simon et al (2000) studied the migration of seeded EC around objects of various 
sizes while under flow [114]. Cell coverage and migration was reduced when the 
thickness of these objects passed 75 µm, and was non-existent around 250 µm thick 
samples. Cell free areas were smallest where edges were parallel to flow, and largest 
downstream of perpendicular edges, correlating with areas of high and low shear 
stress in Benard’s model. Hamuro et al (2001) investigated stent edge angle, the 
angle of the strut face exposed to oncoming flow [115]. Cell migration was greatest 
at 35° (leaning away from oncoming flow) and lowest at 90° (upright). Intermediate 
migration was seen at both 70° and 135° (leaning into oncoming flow), with little 
difference between the two. 
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It should be noted that the preceding concerns dimensions and designs related to 
coronary stents only. As a more recent development, flow diverter stents have not 
been as extensively studied. However, recent work by Marosfoi et al (2016) offers 
initial evidence that flow diverter design (strut size and orientation) also influences 
endothelialisation [29]. 
 
1.5.3 Modifying stent impact 
The current clinical methods to reduce post-stent complications described in 
Section 1.3.4 tackle the issue with a pharmacological approach, via drugs or material 
coatings, or with the eventual break-up of the stent. All of these techniques carry 
associated risk factors and the use of medicines in particular can worsen vascular 
health through their effect on the endothelium. The impact of stent structure on local 
blood flow discussed in the previous section, and its subsequent effect on EC, allows 
vascular repair to be addressed from a new angle: stent design and the altered 
haemodynamic environment. 
The most common approach is to lessen the impact of the stent on local 
haemodynamics while using existing designs. The application of stronger materials 
in stent manufacturing enables the use of ‘ultra-thin’ struts (>70 µm), reducing flow 
disturbance [116]. Other techniques encourage reendothelialisation through 
micropatterning of the stent surface. EC migration has been shown to increase in 
stents containing evenly spaced parallel microgrooves 14 – 15 µm across and 2 µm 
deep [117]. A more extreme method is the use of a microporous elastomer film to 
completely cover the stent (and the entire circumference of the vessel wall), leaving a 
flat, unbroken luminal surface [39]. 
While these techniques aim to reduce areas of stent-induced low shear stress, others 
take a more active approach and aim to increase EC migration by augmenting local 
shear stress. In recent years, stents have been designed to induce helical or spiral 
blood flow through the artery. This secondary motion is often seen in natural blood 
flow, and can prevent the formation of stagnation points and flow 
separation [53][118]. The use of secondary devices has also been trialled. In 2003 the 
Anti-Restenotic Diffuser (ARED) flow divider was developed, to be deployed 
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following coronary stent implantation [119]. This is a solid cylinder of 1 mm 
diameter and 10 – 15 mm length which sits at the centre of the lumen within the 
stented arterial segment, anchored to the stent via a series of self-expanding legs. The 
device essentially reduces the local fluid volume, doubling the wall shear stress 
magnitude found in unaltered control stents. The ARED was studied in vivo in 
animal models, but has not been implanted in humans [53]. 
  
1.6 Experimental techniques 
1.6.1 In vivo models 
Following stent implantation, angiography can monitor subsequent vessel occlusion. 
This data can identify the presence of ISR or thrombi but, save for histology samples 
in the unfortunate case of patient death, the detailed progression of disease or 
reendothelialisation cannot be studied [40]. More specific data is available in the 
form of animal models, typically larger mammals such as rabbit or porcine models, 
which are histologically similar to humans [51]. The progression and regrowth of 
cells can be examined at a specific time point by dissection of the stented vessel, en 
face staining and microscopy. 
However, in vivo models have several drawbacks. Animals are typically too young, 
or in good health, to see the formation of initial cardiovascular disease, which must 
therefore be induced. Atherogenesis can be stimulated by cuffing vessels [120], or by 
maintaining animals on high-fat diets over a period of several months [121][122]. 
Aneurysms can be created by treating vessels with elastase, to weaken the wall via 
the destruction of elastin fibres, or by genetically modifying animals to be 
predisposed to the condition [55][63][123]. Although plaques or aneurysms are not 
necessarily required to study the biological response to the presence of stent 
structure, the deployment of even oversized stents does not sufficiently denude 
healthy vessels in order for reendothelialisation to be monitored [51]. Finally, where 
endothelialisation and arterial healing is seen, it typically progresses at a much more 
rapid rate within animal models than in human patients [41][47]. This is of particular 
importance when in vivo data is used to inform the duration of post-operative 
medication or DES release.      
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1.6.2 In vitro model design and fabrication 
In vitro models provide the ability to monitor biological responses in much greater 
detail than in vivo models, over multiple time points and in repeated experiments. 
They also allow experimental parameters to be adjusted, to enable the study of 
cellular response to particular conditions. A thorough review of the in vitro 
techniques used for the mechanical stimulation of EC over the last 40 years is 
provided by Davis et al (2015) [124]. The majority apply shear stress to cells via 
cone and plate devices, or orbital shakers. Initial in vitro models of continuous flow, 
such as those created by Levesque and Nerem (1985) [125] and Tsuboi et 
al (1995) [126], used parallel plate flow chambers. Early studies of stents within 
these models used small metal coupons to replicate their structure [127]. Although 
simple approximations, these methods are often sufficient to test 
hypotheses [94][95][114], and are still used to evaluate the use of different materials 
and surface treatments [117]. Yet, parallel plate studies are ultimately limited as 
representations of blood vessels and channels of circular cross-section and 
appropriate diameter provide a more realistic model. These have been created by dip 
coating glass rods in an elastomer [128], continuously applying small amounts of the 
same material to a rotating mandrel [74], or pouring into a mould between a mandrel 
and outer shell [129]. Bifurcations, aneurysms, and stenosis have also be modelled 
through simple additions to these methods [130]. 
The replication of accurate stent geometry began by creating models around casts of 
ex vivo histological coronary artery samples [84]. Following this, the actual 
deployment of clinical-grade stents in vitro was performed by Cardinal et 
al (2006) [131]. A tissue-engineered blood vessel mimic was created, into which a 
coronary stent was inserted. A simpler model, again fabricated via dip coating, was 
created by Punchard et al in 2007 [132], and used two years later for the deployment 
and testing of a commercially available coronary stent [107]. 
 
The choice of material for these in vitro models is limited as several criteria must be 
fulfilled, primarily cell biocompatibility and transparency for microscopy if real-time 
imaging is required. To recreate realistic vessel geometry and stent deployment, the 
ability to shape the material is also necessary; glass [95], PMMA [94], and 
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PTFE [133] are therefore unsuitable. Polydimethylsiloxane (PDMS), a silicone 
elastomer, meets these requirements and is credited for the rapid growth in 
microfluidics and biological labs-on-a-chip [134]. PDMS consists of a pre-polymer 
(base) and cross-linker (curing agent), which are mixed and cured [135]. PDMS is 
ideal for rapid prototyping, compatible with a variety of fabrication techniques and 
cheap enough to use in relatively large quantities [136]. 
Although it is heavily used in the literature [124], PDMS has its disadvantages and 
opinion is split. It is generally considered well suited to cell culture as it is 
transparent, gas permeable, and biocompatible [137]. However, PDMS can be 
hydrophobic, and leach potentially toxic cross-linked oligomers. It also has a 
tendency to absorb small molecules, which can change solution concentrations and 
effect results [136][137]. In their review of the material, Sackmann et al (2014) 
suggest that these points may make the description of PDMS as ‘biocompatible’ 
somewhat misleading [134]. 
Nonetheless, PDMS has been shown to support cell attachment. Lee et al (2004) 
analysed the effect of various mixing ratios and recommend the standard 10:1 base to 
curing agent ratio, as cell growth is similar to that seen on standard tissue culture 
apparatus [138]. Curing temperature and time (which influence the final stiffness of 
the material) had no effect on attachment or proliferation. Brown et al (2005) also 
recommend a 10:1 ratio, which both they and Khanafer et al (2009) [139] consider to 
have a physiologically relevant elastic modulus (described in Section 1.7.1). Pre-
soaking  PDMS in culture media to prevent absorption was found by Mata et 
al (2005) to have little effect on surface chemistry, although the deposition of a 
variety of media ingredients was suggested [140]. 
 
A biocompatible model is essential as a complete understanding of the influence of 
stents on EC is not possible without the inclusion of cells in research. The EC most 
commonly used within in vitro models are human umbilical vein endothelial cells 
(HUVEC) [132][141], as umbilical cords provide a readily available source. Venous 
cells, as opposed to arterial, are used due to the comparative size of the umbilical 
vessels and the ease of isolation. The culture of EC was first described in 1973 by 
Jaffe et al [142], who maintained populations of HUVEC for up to 5 months. Despite 
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being isolated from umbilical veins, HUVEC are deemed suitable for in vitro studies 
of coronary arteries as the differences between specific in vivo environments are 
small in comparison to the differences between in vivo and in vitro culture [143]. In 
addition, local mechanical conditions can induce EC to demonstrate arterial-like 
characteristics [37][144]. 
When used in combination with PDMS, HUVEC attachment requires surfaces to be 
pre-coated in fibronectin [145], with concentrations ranging from 5 to 
100 µg/ml [138][146]. HUVEC are seeded at approximately 2x10
6
 cells/ml, resulting 
in coverage of around 75% [75][141]. In some model vessels cells are attached 
around the full circumference of the channel, by slow rotation over 12 hours [132], 
or by simply turning the model upside down after just 10 minutes [141]. 
 
1.6.3 Applied conditions 
The application of fluid flow is an obvious necessity in the study of model arteries. 
In simple parallel plate models this has been achieved using gravity driven 
flow [127]. Specific conditions (flow rate, wall shear stress, etc.) are met by altering 
the dimensions of the channel. Full size models require higher flow rates to generate 
physiologically relevant conditions. These are typically supplied by syringe 
drivers [141], peristaltic pumps [147], or pressure pumps [103], all of which can 
supply a range of flow rates. A small number of studies have combined the 
application of realistic pulsatile flow with thin, compliant vessel walls to expose EC 
to the combined action of the multiple forces described in Section 
1.4 [75][128][148][149]. However, the majority simply consider wall shear stress 
alone, applying whatever flow conditions are necessary to generate the desired 
magnitude. Figure 1.10 illustrates the levels of wall shear stress applied in in vitro 
and in silico models. Interest in the link between regions of low shear stress and EC 
dysfunction can be seen as most studies applied no more than 1.5 Pa. 
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Figure 1.10 Wall shear stress magnitude applied in vitro and in silico 
 
The magnitude of wall shear stress applied in a number of in vitro models and computer 
simulations is shown, with colours corresponding to the descriptions used by the authors. 
Red: Low shear stress. 
Blue: Intermediate or average shear stress.  
Green: High shear stress. 
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In a number of models, dextran (a polysaccharide) is used to increase the viscosity of 
cell culture media so that its rheological behaviour approximates plasma or whole 
blood [37][74][101][146][147][155]. This reduces demand on the pump when 
applying specific levels of shear stress, and can bring the flow rate and Reynolds 
number into physiologically relevant ranges. However, relatively high concentrations 
are required (>15% w/v, depending on molecular weight) [156]. van den Broek et 
al (2008) suggest that this addition leads to adverse side effects, such as the increase 
of osmolality (a measure of salt or electrolyte concentration) [157]. They, and others, 
recommend a different polysaccharide known as xanthan gum (XG) which is 
required in much smaller amounts (0.7 gl
-1
 is stated as the required concentration to 
reach blood viscosity),  keeping osmolality within a safe range [158]. 
 
1.6.4 In vitro model experimentation 
Examples of in vitro experiments studying the effects of wall shear stress on EC 
under flow are detailed in Table 1.2. Experiments must balance the duration of cell 
viability against the time required to observe noticeable effects. A 24 hour time 
frame is most often chosen, as EC regrowth has been seen to occur in vivo within the 
first day post-neointimal injury [107]. Most studies use a control: cells kept in static 
conditions, uninjured cells, or cells not subjected to stent deployment. The majority 
of analysis is performed at a single time point once the experiment is complete and 
any mid-experiment analysis, where it exists, is limited to easily observable 
parameters such as cell size and migration distance. 
Studies not listed in Table 1.2 include those by Liu et al (2014), in which a stent was 
placed onto static EC culture [159]. Cell-free models were created by Peacock et al 
(1995) and Bernard et al (2003) to study stent-induced flow disturbance, using static 
probes and laser particle image velocimetry (PIV) [84][94]. 
 
 
 
44 
 
T
im
e 
p
o
in
t 
P
er
i 
P
er
i 
&
 p
o
st
 
P
o
st
 
P
er
i 
P
o
st
 
P
o
st
 
P
o
st
 
P
o
st
 
P
o
st
 
P
o
st
 
M
o
d
el
 
P
ar
al
le
l 
p
la
te
 
F
E
P
 t
u
b
e 
w
it
h
 h
y
d
ro
g
el
 
li
n
in
g
, 
cl
in
ic
al
 s
te
n
t 
T
is
su
e 
en
g
in
ee
re
d
 v
es
se
l,
 
cl
in
ic
al
 s
te
n
t 
P
ar
al
le
l 
p
la
te
, 
m
o
ck
 s
te
n
t 
 
S
il
ic
o
n
e 
tu
b
e 
S
il
ic
o
n
e 
tu
b
e,
 c
li
n
ic
al
 s
te
n
t 
P
ar
al
le
l 
p
la
te
, 
m
o
ck
 s
te
n
t 
P
ar
al
le
l 
p
la
te
, 
m
o
ck
 s
te
n
t 
P
ar
al
le
l 
p
la
te
, 
m
o
ck
 s
te
n
t 
S
il
ic
o
n
e 
tu
b
e 
M
et
h
o
d
 o
f 
a
ss
es
sm
en
t 
C
el
l 
p
ro
li
fe
ra
ti
o
n
, 
sp
re
ad
, 
m
ig
ra
ti
o
n
 r
at
e 
an
d
 d
is
ta
n
ce
. 
A
re
a 
o
f 
w
o
u
n
d
 c
lo
su
re
. 
R
at
e 
o
f 
w
o
u
n
d
 c
lo
su
re
. 
 
 
A
re
a 
o
f 
co
v
er
ag
e,
 m
o
rp
h
o
lo
g
y
. 
C
el
l 
m
ig
ra
ti
o
n
 d
is
ta
n
ce
, 
p
er
si
st
en
ce
 a
n
d
 o
ri
en
ta
ti
o
n
. 
A
re
a 
o
f 
co
v
er
ag
e.
 
C
el
l 
o
ri
en
ta
ti
o
n
 a
n
d
 e
lo
n
g
at
io
n
. 
C
el
l 
p
ro
li
fe
ra
ti
o
n
, 
o
ri
en
ta
ti
o
n
, 
m
o
rp
h
o
lo
g
y
, 
g
en
e 
ex
p
re
ss
io
n
 a
n
d
 m
et
ab
o
li
c 
ac
ti
v
it
y
. 
C
el
l 
m
ig
ra
ti
o
n
 d
is
ta
n
ce
. 
A
re
as
 o
f 
co
v
er
ag
e 
an
d
 e
x
p
o
se
d
 
w
al
l.
 
C
el
l 
p
ro
li
fe
ra
ti
o
n
, 
m
ig
ra
ti
o
n
 d
is
ta
n
ce
, 
ap
o
p
to
si
s 
ra
te
 a
n
d
 
N
it
ri
c 
o
x
id
e 
p
ro
d
u
ct
io
n
. 
C
el
l 
p
ro
li
fe
ra
ti
o
n
, 
m
ig
ra
ti
o
n
 d
is
ta
n
ce
, 
ap
o
p
to
si
s 
ra
te
 a
n
d
 
N
it
ri
c 
o
x
id
e 
p
ro
d
u
ct
io
n
. 
C
el
l 
o
ri
en
ta
ti
o
n
 a
n
d
 e
lo
n
g
at
io
n
, 
g
en
e 
ex
p
re
ss
io
n
 a
n
d
 
p
ro
te
in
 c
o
n
ce
n
tr
at
io
n
. 
D
u
ra
ti
o
n
 
2
4
 h
o
u
rs
 
4
 d
ay
s*
 
1
4
 d
ay
s 
9
6
 h
o
u
rs
 
2
4
 h
o
u
rs
 
2
4
 h
o
u
rs
 
2
4
 h
o
u
rs
 
7
 d
ay
s 
7
 d
ay
s 
2
4
 h
o
u
rs
 
S
tu
d
y
 
A
lb
u
q
u
er
q
u
e,
 2
0
0
0
. 
[9
5
] 
A
n
to
in
e,
 2
0
1
6
. 
[1
6
0
] 
C
ar
d
in
al
, 
2
0
0
9
. 
[1
6
1
] 
H
si
ao
, 
2
0
1
6
. 
[1
0
3
] 
M
o
o
re
, 
1
9
9
4
. 
[7
4
] 
P
u
n
ch
ar
d
, 
2
0
0
9
. 
[1
0
7
] 
S
im
o
n
, 
2
0
0
0
. 
[1
1
4
] 
S
p
ra
g
u
e,
 1
9
9
7
. 
[1
2
7
] 
S
p
ra
g
u
e,
 2
0
1
2
. 
[1
1
7
] 
Z
ie
g
le
r,
 1
9
9
8
. 
[1
4
6
] 
 
Table 1.2 In vitro experiments assessing HUVEC under laminar flow 
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To the author’s knowledge, commercially available clinical stents have only been 
deployed in in vitro models with seeded EC, and exposed to laminar flow, in three 
previous studies (Table 1.2): a tissue engineered blood vessel mimic (Cardinal et al, 
2009 [161]), a dip-coated silicone tube (Punchard et al, 2009 [107]), and an FEP tube 
with a hydrogel lining (Antoine et al, 2016 [160]). A complete cell monolayer was 
present in each model and, as such, the only assessment of EC migration, in the work 
of Antoine et al, was limited to wound closure. 
 
1.6.5 In silico modelling 
As mentioned in the previous section, studies have employed PIV and particle 
tracking velocimetry (PTV), optical methods of visualising and analysing flow 
patterns and extracting velocity data. These techniques are advantageous in their 
ability to offer rapid or instantaneous data, their non-destructive nature, and their 
ability to be performed on cell migration models in situ. However, disadvantages 
include the accuracy and resolution of resultant velocity (and therefore shear stress) 
data. 
As such, a substantial amount of the literature employs in silico model vessels and 
computational fluid dynamics (CFD) simulations to study local haemodynamics. 
CFD is a useful tool, allowing the extraction of detailed information on flow patterns, 
areas of recirculation, velocity profiles, wall shear stress magnitudes and various 
shear indices [92][111]. The ability to run multiple simulations in silico allows 
models to be quickly assessed under a range of applied conditions and enables 
parametric study. 
The flow of blood is generally simulated, in some cases even when modelling in 
vitro experiments which use cell culture medium [130]. Based on the assumptions 
described in Section 1.4.2, the majority of these simulations consider blood as a 
Newtonian fluid. Blood density is always taken as 1050 - 1060 kg/m
3
 and viscosity 
as 3 - 4 mPa.s [88][111][133][162][163]. Studies which do not rely on this 
assumption use the Carreau method to describe non-Newtonian flow with 
generalised Newtonian fluids (viscosity is dependent on shear rate, but not on shear 
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rate history. This is not true non-Newtonian flow, but is a good approximation) 
[113][164]–[166].  
Stent models can be created with various complexity and accuracy with computer-
aided design (CAD) software, ranging from basic geometric shapes to idealised 
commercial designs [113][167]. Models have been employed for parametric analysis 
of specific features such as strut thickness, using CAD generated mesh patterns by 
LaDisa et al (2004) [112], and rigid rings by Barakat and Cheng (2000) [168]. This 
latter example also compared simple 2D geometries with more complex 3D models. 
The importance of model accuracy and realism is illustrated by the fact that 2D 
simulations overestimated flow disturbance in comparison to 3D (this is assumed to 
be due to 3D models allowing secondary flow to develop, which inhibits radial 
velocity and the size of flow separation zones). 
Unlike the above examples, which simulated steady-state flow around stents in 
straight vessels, Balossino et al (2008) applied pulsatile flow and a deformed artery 
wall [167]. The total area exposed to <0.5 Pa of wall shears stress (the value they 
assume to be the critical threshold for ISR development) was seen to decrease in 
stents with thicker struts, contrary to the findings of the above simulations and those 
described in Section 1.5.2. These results were presumed to be due to the combination 
of pulsatile flow and modified wall geometry, and could further demonstrate the 
value of increased model realism. 
 
In addition to measuring wall shear stress across surface area, or at specific points, 
various wall shear metrics have been proposed for the assessment of stent designs. 
Time averaged wall shear stress (TAWSS) considers the force on the wall over the 
entire cardiac cycle [165]. The oscillatory shear index (OSI) quantifies flow 
reversal [86], while the haemodynamic low and reverse flow index (HLRFI)  
quantifies the effect of both flow reversal and areas of low flow [111]. Transverse 
wall shear stress (transWSS) is the time-average of wall shear components 
perpendicular to flow direction [169]. Each of these metrics returns different results. 
It is up to the user to decide, depending on the research question, which wall shear 
qualities they deem to be the most important. In terms of identifying or predicting 
locations of EC dysfunction, it has been suggested that the low shear index (LSI) is 
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superior to the above. Rather than simply labelling a specific wall shear magnitude as 
‘low’ and applying this threshold globally, LSI defines low shear in relation to the 
normal or intermediate conditions in each individual environment [170]. 
 
1.6.6 Replicating accurate stent geometry in silico 
More accurate in silico data can be obtained by basing computational models on 
realistic stent deployment. Clinical scans of patients’ vessels have been used, 
however the available resolution is only high enough to reproduce arterial segments, 
not the stents themselves [88][163]. Their structure can be replicated by creating 
finite element (FE) models of crimped stents and simulating their deployment within 
the vessel [167][171], but there is no guarantee that the final geometry is faithful to 
that in vivo. 
 
In order to properly compare in vitro EC behaviour to precise local wall shear stress, 
the specific geometry of the model vessel must be replicated. CAD is sufficient for 
simple representations of stents, e.g. ridged channels [103], but to capture entire, 
complex clinical stents some form of scanning is most often employed.   
Optical coherence tomography is widely used in vivo and the technique can also be 
applied within in vitro models [172][173]. A catheter is pulled through the vessel and 
uses reflected near-infrared light to build an image of the surrounding structure. The 
use of relatively long wavelengths means light can penetrate 1 – 2 mm below the 
surface, enabling a 3D picture of stent strut penetration to be created. However, the 
resultant images can be low resolution (~20 µm), and any vessel curvature is lost as 
readings are taken perpendicular to the catheter. 
Micro-computed tomography (µCT) scanning is more commonly used to obtain the 
geometry of stented models, and can resolve features of just 0.5 µm. However, 
simultaneous imaging of stents and vessel walls, whether tissue or in vitro model, is 
problematic due to their different radiopacity. One solution to this problem involves 
capturing the stent only and recreating the wall in silico using FE software. The stent 
is then modelled as a rigid body and the wall collapsed around it as far as applied 
material properties will allow, essentially shrink-wrapping the stent [162]. As per the 
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previously described model of stent expansion, this method is half faithful 
reproduction of geometry, half virtual model. 
A second solution to the visualisation issues inherent to µCT is to better define the 
wall/lumen boundary, and allow simultaneous imaging, by increasing the visibility of 
the otherwise empty lumen. This has been carried out by corrosion casting, in which 
the lumen is filled with a radiopaque material and the surrounding vessel is 
destroyed [174], and with the use of contrast agents. Contrast agents have the 
advantage of leaving the model intact, and have been shown to produce good results 
in both ex vivo and in vitro examples [133]. Figure 1.11 illustrates the level of detail 
that can be obtained and shows that even in simple, straight vessels stent deployment 
can result in non-symmetrical expansion and strut misalignment that would not be 
replicated in idealised models, proving the advantage of capturing realistic 
geometries. 
 
1.7 Physiological data 
Relevant literature was reviewed for information on which to base the structure and 
size of in vitro models, and the conditions applied within both them and 
accompanying in silico models. Conforming, where possible, to anatomical values of 
the properties described in the following sections ensured that in vitro and in silico 
models were physiologically relevant, and increased the translational potential of 
resultant data. Sources were restricted to studies of arterial segments unaffected by 
disease, to omit extreme or abnormal results and to provide an idea of a ‘normal’ 
artery. In addition, the properties described below are, where possible, those of the 
coronary arteries only. 
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Figure 1.11 3D model of a stented tube reconstructed from µCT data 
 
A flow diverter stent deployed within a PTFE tube was scanned using high-resolution µCT. 
Both the wall and stent were reconstructed via the use of a contrast agent to better define the 
wall-lumen boundary. In this 3D reconstruction of the scan data, the level of detail attainable 
enables strut prolapse (single arrow) and misalignment (double arrows) to be captured. 
(Reproduced with permission [133]). 
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1.7.1 Mechanical properties of the arterial wall 
A number of studies consider the mechanical properties of diseased coronary arteries 
only, and often the plaque itself, in order to investigate its structure and stability 
(similarly, research focuses on the properties of aneurysmal sacs with the aim of 
predicting rupture and the need for intervention) [121]. Data on the stiffness of 
healthy arterial segments typically varies over several orders of magnitude. This 
wide range highlights the great impact of both age and lifestyle on vessel stiffness, 
but is also due to the variety of material being tested: from macrostructure (whole 
vessels and tissue) to microstructure (tissue components such as collagen and 
elastin) [175]. 
A general idea of arterial wall stiffness is required to ensure that stent deployment 
can be modelled accurately, in terms of the degree of strut penetration and local wall 
distention. The elastic modulus of macrostructure bulk tissue has been found to vary 
between 0.1 – 100 MPa, whereas individual microstructural components are a stiffer 
1 – 1000 MPa [175]. One example of a specific arterial segment, the stiffness of a 
carotid artery, was found to be at the lower end of this first range, at 0.9 MPa [176]. 
 
1.7.2 Coronary artery diameter 
The size of coronary arteries varies greatly and has been found to differ with age, 
sex, race, and body surface area. Specific values of coronary artery diameter for 
healthy adult populations were found in 14 studies. 132 averaged measurements were 
taken from a total of 1001 samples, which represented a range of arterial 
segments [177]–[190]. 
From this data, the minimum coronary artery diameter was 1.29 mm, in a branch of 
the left anterior descending artery. The maximum was 4.89 mm, in a segment of the 
left main artery. The mean coronary artery diameter was found to be 2.90 mm, 
±0.90 mm SD. 
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1.7.3 Wall shear stress 
In investigating the response of EC to wall shear stress, a sound understanding of the 
magnitude of the force reached in coronary arterial flow is crucial. This not only aids 
in the application of appropriate conditions in in vitro and in silico models, but also 
in defining the bounds of what is considered to be low, high, etc., for conclusions to 
be drawn. Further to the applied values in Section 1.6.3, Figure 1.12 illustrates 
quantitative data for physiological wall shear stress, with accompanying qualitative 
categories. The coronary arteries are generally exposed to wall shear stress ≤3 Pa, 
although in three cases the maximum stated value was found to be 7 Pa [82][85][87]. 
Mean, or intermediate, wall shear stress levels range from approximately 1 to 2.5 Pa, 
and the majority of the sources reviewed here considered 1 Pa to be the threshold 
below which shear stress may be described as low. Beyond this, there is little 
consistency. There is no single threshold above which shear stress is described as 
high. Many studies’ low and high ranges are considered by others to lie within the 
mean, and in some cases the two opposed definitions actually overlap. For example, 
Stone et al define low shear stress as <1.2 Pa [89], a value within the range Chiu et al 
describe as increased/higher [82]. Such examples are of note, given that conclusions 
are often drawn based upon these definitions. 
 
1.7.4 Velocity and flow rates 
Reaching the desired magnitude of wall shear stress within in vitro models requires 
the application of a specific flow velocity or volumetric rate. These values may or 
may not be physiologically relevant, depending on the size of the model and the 
viscosity of the fluid being used. An impression of the flow found in vivo can be used 
to assess just how disparate the necessary in vitro values are, and can provide further 
information on local wall shear stress levels.  
 
 
 
 
52 
 
                                [12] 
                                [36] 
                                [53] 
                                [82] 
                                [85] 
                                [87] 
                                [89] 
                                [90] 
                                [91] 
                                [108] 
                                [141] 
                                [167] 
                                [191] 
                                [192] 
                                [193] 
                                [194] 
                                 
0    0.5    1.0    1.5    2.0    2.5    3.0   
      Wall shear stress (Pa)         
Figure 1.12 Physiological magnitude of coronary artery wall shear stress 
 
The magnitude of coronary artery wall shear stress measurements from a number of sources 
is shown, with colours corresponding to the descriptions used by the authors. 
Red: Low shear stress. 
Blue: Intermediate or average shear stress.  
Green: High shear stress. 
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5 studies stated volumetric flow rates for individual arterial segments 
[180][186][190][194][195]. The minimum rate was 18 ml/min and the maximum 
161 ml/min, both measured by Hundley et al [190]. The mean was found to be 
80 ml/min. Data regarding coronary artery flow velocity was limited to 5 
measurements in 2 studies [195][196]. Blood flow was measured and time averaged, 
to provide mean velocities for the whole cardiac cycle. The minimum velocity was 
0.06 m/s, the maximum 0.149 m/s and the mean 0.08 m/s. 
To equate this data to that in Section 1.7.3, corresponding levels of wall shear stress 
can be calculated. Assuming coronary arteries of 2.9 mm diameter (the average 
found in Section 1.7.2), the minimum, maximum and mean volumetric flow rates 
induce shear stress of 0.44, 3.92 and 1.95 Pa respectively. Minimum, maximum and 
mean velocities induce shear stress of 0.62, 1.54 and 0.83 Pa. These values lie within 
the range seen in the previous section. 
 
1.8 Study rationale 
The regrowth of a healthy endothelial layer, whether by local EC migration or 
circulating EPC capture, is a key component of vascular repair and vital to the 
reduction of post-procedural complications. It is known that this process is hindered 
by EC dysfunction, caused by the presence of cardiovascular stents and their effect 
on local haemodynamics; specifically modified wall shear stress. Considered design 
could improve vascular health by minimising the impact of stents, or enable them to 
exert an active, beneficial influence on their environment. 
Optimising stented artery repair requires knowledge of precisely how particular stent 
design features influence wall shear stress and EC behaviour. Previous studies have 
considered these two factors separately, with simple representative geometry and 
idealised computational models. Only with the use of a physiologically relevant 
system, realistic complex stent geometry and accurate computer simulation can a full 
understanding of stent-induced biomechanics be achieved. 
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1.9 Aims 
This work aimed to create an experimental platform through which the 
biomechanical conditions of stented vessels could be studied, by developing a unique 
combination of in vitro and in silico techniques:   
 A novel, physiologically relevant, biocompatible in vitro model vessel for the 
deployment of clinical cardiovascular stents. 
 An experimental protocol for the real-time study of endothelial cell migration 
local to stent geometry within the in vitro model. 
 An experimental protocol for the study of stent-induced fluid dynamics 
within the in vitro model, enabling the rapid acquisition of flow data in situ, 
via non-destructive means. 
 A protocol for the precise reproduction of in vitro vessel and stent geometry 
in silico, to permit the study of stent-induced fluid dynamics via computer 
simulation, enabling the acquisition of flow data of higher accuracy and 
resolution. 
Ensuring the above techniques were effective, accurate, repeatable and time-
efficient would allow their application to a wide range of coronary and flow 
diverter stents. This would enable the assessment of the effect of diverse stent 
geometry on wall shear stress modification and its subsequent impact on 
endothelial cell behaviour. 
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Chapter Two 
2 Materials and Methods 
 
2.1 In vitro model 
2.1.1 Fluid properties 
To aid in model design and ensure that appropriate conditions were applied during 
experiments, the density and dynamic viscosity of fluids was required. This was 
obtained from reference data where possible. However, for cell culture medium, 
values for the specific mixtures used here (listed in Section 2.2.2) were unavailable 
and were therefore measured. 
Density was measured by transferring 1 ml of medium, warmed to 37°C, to a digital 
scale (ABS-N/ABJ-NM, Kern & Sohn) to obtain the mass to volume ratio. Medium 
viscosity approached the lower limit of available viscometers, particularly at cell 
incubation temperature. Therefore, two different techniques were used and the 
findings compared to the literature: 
 
2.1.1.1 Reflectance viscometry 
Reflectance viscometry was performed in collaboration with Michele Schirru (The 
Leonardo Centre for Tribology, University of Sheffield). 0.5 ml of cell culture 
medium was placed onto a sensor plate. This was connected to a waveform function 
generator (TG5011, TTi) and a transmitting transducer, to produce an ultrasonic 
wave. The reflection of ultrasonic shear waves from the solid-liquid interface was 
detected by a receiving transducer and recorded on an oscilloscope (LT342, LeCroy). 
Algorithms developed by Schirru were then applied to correlate the reflection 
coefficient to viscosity [197]. 
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2.1.1.2 Vibrational viscometry 
2 ml of cell culture medium warmed to 37°C was transferred into a vial and placed in 
a vibrational viscometer (SV-1A Vibro Viscometer, A&D Company). Three sensor 
plates were lowered into the fluid: one temperature sensor and two vibrating 
viscosity sensors. The viscometer measured the electric current required to maintain 
this vibration at 30 Hz and these measurements were then converted to viscosity. 
Viscosity was recorded as the fluid cooled over time. Results were calibrated against, 
and compared to, equivalent data obtained from a 2 ml reference sample of water. 
  
2.1.2 Material properties 
In vitro model vessels were fabricated using PDMS (Sylgard 184, Dow Corning 
Corp.). Samples with various cross-linking densities were created for mechanical 
testing to compare the material to arterial tissue and to assess suitability for stent 
deployment. PDMS base and curing agent components were combined at 5:1, 10:1, 
15:1, 20:1, 30:1, 40:1, 50:1 and 60:1 ratios by weight and mixed for 10 minutes. 34 g 
of each mixture was poured into a 90 mm diameter Petri dish, to form a layer 5.5 mm 
deep. To account for small, unavoidable variations in this process, three separate 
batches of each mixing ratio were prepared. 
As curing temperature is known to affect the mechanical properties of PDMS, test 
samples were prepared under the same conditions as the final model (Section 2.1.4). 
Specifically, PDMS was cured at room temperature for 24 hours, followed by 15 
minutes in a 100°C oven. To eliminate bubbles, which could act as defects and 
distort results, samples were kept in a vacuum desiccator (5311-0250, Nalgene) for 
the duration of the room temperature curing period. Cured PDMS was cut into test 
pieces of 30 mm length, 10 mm width and 5.5 mm depth and the three most uniform 
pieces from each batch were selected for testing. 
Test pieces were inserted into a dynamic mechanical analysis instrument 
(EnduraTEC ELF 3200, BOSE) for tensile testing. Grips were attached over 10 mm 
at either end of the sample, leaving a pre-extension initial length of 10 mm in the 
centre. Each PDMS sample underwent a maximum 5 mm of extension, at a speed of 
0.1 mm/s. The applied load and extension were recorded, stress and strain calculated 
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and plotted, and the gradient of the linear elastic region identified to then obtain the 
elastic modulus. 
 
2.1.3 Mould design and preparation 
Moulds were designed to create channels of 1.5, 2 and 2.5 mm internal diameter 
which were exposed to an average wall shear stress of 1 Pa (the use of these specific 
values, which take into account both physiological relevance and practical 
limitations, is discussed in Sections 3.1.1 and 3.1.3). The volumetric flow rate 
required to attain this level of shear stress was calculated using the Hagen-Poiseuille 
equation: 
      
   
   
 
Q is the volumetric flow rate, τmean the mean wall shear stress, r the vessel radius and 
μ the dynamic viscosity of the fluid. Mean velocity, V, was calculated by dividing 
flow rate by cross-sectional area: 
  
 
   
 
The Reynolds number (Re) could then be calculated, using vessel diameter D and 
fluid density ρ: 
   
   
 
 
Finally, the Reynolds number was used to calculate the entrance length (L) required 
for laminar flow with a parabolic velocity profile to fully develop within the vessel: 
      
EL is the entrance length number, which is dependent on the flow regime. Assuming 
a transition between laminar and turbulent flow at Re = 2300: 
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The above was calculated for 1.5, 2 and 2.5 mm diameter channels using viscosity 
and density data for the full range of fluids used. This allowed the correct flow rate to 
be applied in each experiment and ensured that models were long enough for flow to 
fully develop before reaching the leading edge of deployed stents. 
Based on this data, 8 ml polystyrene cuvettes (Sarstedt) were used to create moulds 
(Figure 2.1). To create channels, 1.5, 2 and 2.5 mm diameter aluminium rods were 
cut to 100 mm length and inserted into the cuvettes. Holes were punched in rubber 
caps, which were then placed in the bottom and top of each cuvette to centre the 
rods. Additional holes were punched around the circumference of the top cap to 
allow air to escape during degassing. 
 
2.1.4 Model fabrication 
PDMS for in vitro models was prepared by mixing the base and curing agent 
components at a 10:1 ratio by weight for 10 minutes and degassing in a vacuum 
desiccator for 20 minutes. A minimum of 9 g of PDMS was prepared per mould, to 
ensure a usable model length of at least 80 mm.  
PDMS was poured into the cuvette with the bottom cap and aluminium rod already 
inserted and the top cap was then applied. To ensure the model was properly filled, 
and to remove any remaining bubbles, the PDMS within the cuvette was degassed 
for a further 20 minutes, then centrifuged for 10 minutes at 626 g (Centrifuge 5702, 
Eppendorf). The PDMS was then left to cure at room temperature for 24 hours. 
Once hardened, the PDMS was released by breaking the cuvette apart. The rod and 
end caps were removed, and cleaned for re-use. The ends of the PDMS were 
trimmed, leaving an 80 mm x 10 mm x 10 mm PDMS block, with a 1.5, 2 or 2.5 mm 
diameter channel in the centre, referred to herein as the model vessel (Figure 2.2A). 
This was placed into an oven at 100°C for 15 minutes, to fully complete the curing 
process and eliminate any potentially cytotoxic unlinked monomers. 
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Figure 2.1 In vitro model mould 
 
Plastic cuvettes were used a moulds to create model vessels in PDMS, with metal rods of 
various diameters in place to create circular channels within them. 
Left: Individual components used in the mould (cuvette, rod and rubber caps) and their 
dimensions. 
Right: An assembled mould. PDMS would be poured into the mould up to the level of the 
upper rubber cap. 
Ø 1.5/2/2.5 mm 
1
0
0
 m
m
 
8
4
.8
 m
m
 
9 mm 
10.5 mm 
Ø 13 mm 
Ø 12 mm 
Ø
 1
.5
/2
/2
.5
 m
m
 
Ø
 1
.5
/2
/2
.5
 m
m
 
60 
 
 
 
 
 
 
Figure 2.2 In vitro model fabrication and stent deployment 
 
A: To create model vessels, PDMS was poured into a mould (left). Once cured, the mould 
(consisting of a cuvette, rod and rubber caps) was removed, leaving the resultant PDMS 
model vessel (right). 
B: Coronary stents were deployed in the model via the inflation of balloon catheters. 
C: Flow diverter stents were deployed in the model via the retraction of introducer sheaths. 
 
A 
B 
C 
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For experiments with seeded HUVEC, PDMS vessels were sterilised via autoclave at 
121°C for 30 minutes and coated with 10 µg/ml fibronectin, prepared by adding 1 
mg/ml fibronectin (fibronectin from bovine plasma, Sigma-Aldrich) to phosphate 
buffered saline (PBS, Sigma-Aldrich). The solution was injected into the vessel (140, 
250 and 390 µl to completely fill each 1.5, 2 and 2.5 mm diameter model 
respectively) and left for 1 hour at room temperature. The fibronectin solution was 
then removed and the vessel flushed with 1 ml of PBS. 
Model vessels were used for stent deployment and experimentation within 48 hours 
of PDMS curing and 24 hours of fibronectin coating. 
 
2.1.5 Stent deployment 
Coronary and flow diverter stents were deployed following clinical guidelines and 
manufacturers’ instructions where possible. For experiments with HUVEC, stents 
were deployed after cell seeding and attachment (detailed in Section 2.2.4) in aseptic 
conditions. 
Stent deployment was assessed by visual inspection under a light microscope 
(AE2000, Motic). Struts were checked for expansion and for some degree of pushing 
against, or penetrating into, the PDMS wall. If required, a balloon catheter could be 
reinserted and inflated to complete deployment. Any stents which were not correctly 
or completely deployed could shift under fluid flow and were not used in 
experiments. 
 
2.1.5.1 Coronary stent deployment 
Balloon catheters with pre-mounted coronary stents were connected to a dilation 
syringe with pressure gauge. Any protective sheaths or coverings were removed and 
the catheter was inserted into the model vessel. The catheter was held in place with 
the mounted stent positioned centrally (Figure 2.2B). The syringe’s threaded plunger 
was rotated to gradually increase the pressure within the balloon to that 
recommended by the manufacturer. A 1.2:1 balloon to vessel ratio was used, as per 
clinical guidelines (e.g. coronary stents within 2.5 mm diameter vessels were dilated 
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to 3 mm), typically requiring a pressure between 6 and 11 atm. The balloon was held 
at the required pressure for 30 seconds, before the plunger was released and negative 
pressure applied to contract the balloon, which was then carefully removed. 
 
2.1.5.2 Flow diverter stent deployment 
Self-expanding flow diverter stents were inserted into the model on a guide catheter, 
whilst covered by a protective introducer sheath. Stents were again positioned 
midway along the vessel length, and held in place as the sheath was gradually pulled 
back (Figure 2.2C). Flow diverter stents generally started to expand once struts were 
freed from the sheath; however a slow back-and-forth motion was often required to 
encourage full expansion along the entire length of the stent. 
 
2.1.6 Assessing stent geometry 
The length and nominal diameter of stents was provided by the manufacturer with 
each sample. However, the size of struts was often only provided in one dimension, 
given as a range, or simply not stated. Therefore, in an effort to obtain accurate 
values, struts were measured with a digital calliper (Absolute AOS Digimatic, 
Mitutoyo) and photographed under magnification, with the image scale calibrated 
against a haemocytometer grid. 
The metal-to-artery ratio of stents was calculated by measuring the lateral surface 
area of one fully expanded repeating unit of stent geometry (the metal surface area, 
or MSA), and dividing this by the area of the vessel wall bounded by the repeating 
unit (Figure 2.3B). 
The orientation of struts relative to the direction of flow was measured using the 
Directionality function in the Fiji ImageJ plug-in (National Institutes of Health), with 
the software returning a table of structure directionality (angle relative to 0°, the 
direction of flow) and the length of structure at that orientation (as a percentage of 
the total). For each stent design the analysis was performed on an image of one 
repeating unit of geometry (Figure 2.3C), as well as the full stent length at two 
different orientations, and an average of these results was taken. 
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Figure 2.3 Assessing stent geometry 
 
The geometry of deployed stents was assessed by measuring strut dimensions, and 
calculating the metal-to-artery ratio and strut orientation. 
A: Representative image of a deployed coronary stent as they appeared under magnification, 
along its longitudinal axis. 
B: The metal-to-artery ratio of stents was calculated by dividing the lateral surface area of 
one repeating unit of stent geometry (the MSA, in black) by the area bounded by that unit 
(within the red box). 
C: Strut orientation was calculated by measuring the angle of struts relative to flow (left, 
green lines) and the length of struts at each orientation as a percentage of the total (right). 
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2.2 Cell migration studies 
HUVEC were seeded within model vessels to assess their migration under flow. The 
protocol detailed in this section was carried out for a variety of coronary and flow 
diverter stents, as well as empty non-stented vessels as controls. Unless stated 
otherwise, work was conducted under aseptic conditions in a laminar flow hood and 
all cell culture media warmed to 37°C. 
 
2.2.1 Isolation of HUVEC 
HUVEC were isolated from umbilical cords collected from the Jessop Wing 
maternity unit, Sheffield, after informed consent and without patient identifiers. A 
frequent supply of isolated cells was provided by colleagues from the Department of 
Infection, Immunity and Cardiovascular Disease, University of Sheffield, using the 
collagenase digestion method described here in brief [142]. 
Each umbilical cord was wiped clean, having been stored in serum-free media 
(M199, Sigma-Aldrich) at 4°C for a maximum of 2 days. The umbilical vein was 
cannulated and media flushed through to remove blood clots. The vein was then 
filled with a further 20 ml of serum-free media containing 1 mg/ml of collagenase 
(collagenase from Clostridium histolyticum, Sigma-Aldrich) and left at room 
temperature for 15 minutes. The cord was gently manipulated to encourage the 
complete detachment of the endothelium. The collagenase solution and detached 
HUVEC were then drained into a tube and media flushed through the vein once more 
to remove as many cells as possible. 
The cell suspension was centrifuged at 157 g for 5 minutes and the resultant cell 
pellet resuspended in EC growth medium (Section 2.2.2.1), seeded into T75 flasks 
and incubated. If required, the endothelial nature of the cells and the purity of the cell 
yield could be confirmed by staining for von Willebrand Factor and Pecam-1 [99]. 
After 24 hours, HUVEC were washed with PBS and fresh media was added. Cells 
were passaged once they reached 80 – 90% confluence (this method is detailed in 
Section 2.2.3) and were collected at passage 2 (P2). 
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2.2.2 Preparation of cell culture medium 
2.2.2.1 EC growth medium 
A mixture referred to herein as EC growth medium was used for HUVEC culture and 
experimentation. The concentration of individual components, listed below, is given 
in relation to a 500 ml mixture: 
 Basal media (PromoCell) 
 SupplementMix (PromoCell), containing: 
o Foetal calf serum (FCS)    2% v/v 
o Endothelial cell growth supplement   0.4% v/v  
o Epidermal growth factor (recombinant human) 0.1 ng/ml 
o Basic fibroblast growth factor (recombinant human) 1 ng/ml 
o Heparin      90 µg/ml 
o Hydrocortisone     1 µg/ml 
 FCS (Labtech International)     20%  v/v 
 Penicillin (Sigma-Aldrich)     100 units/ml 
 Streptomycin (Sigma-Aldrich)    100 µg/ml 
 L-glutamine (Sigma-Aldrich)     2 mM 
 
2.2.2.2 Thickened medium 
Two thickening agents were used to assess higher viscosity flow. The first, 100,000 
Mr dextran powder (dextran from Leuconostoc, Sigma-Aldrich), was added to PBS to 
create a stock solution at 25% w/v. This was sterilised via autoclave at 121°C for 30 
minutes and added to EC growth medium in varying amounts to create 50 ml 
samples of thickened medium at five different concentrations: 
 1% w/v - 2 ml stock solution, 48 ml medium 
 2% w/v – 4 ml stock solution, 46 ml medium 
 3% w/v – 6 ml stock solution, 44 ml medium 
 4% w/v – 8 ml stock solution, 42 ml medium 
 5% w/v – 10 ml stock solution, 40 ml medium 
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The second thickening agent, XG powder (xanthan gum from Xanthomonas 
campestris, Sigma-Aldrich), was sterilised by exposure to ultraviolet light for 2 
hours. This was then added directly to EC growth medium, again creating 50 ml 
samples of thickened medium at 5 different concentrations: 
 0.2 g/l – 0.01 g XG powder, 50 ml medium 
 0.4 g/l – 0.02 g XG powder, 50 ml medium 
 0.6 g/l – 0.03 g XG powder, 50 ml medium 
 0.8 g/l – 0.04 g XG powder, 50 ml medium 
 1.0 g/l – 0.05 g XG powder, 50 ml medium 
The impact of thickening agents on cell viability was assessed by seeding HUVEC in 
well plates following the protocol detailed in Section 2.2.3 and, after 24 hours, 
replacing the standard EC growth medium with the above thickened samples. Cells 
were detached and counted after a further 72 hours, with the medium refreshed at the 
midway point. Wells containing standard EC growth medium were maintained as a 
control and additional control wells contained 80% EC growth medium and 20% 
PBS to account for the diluting effect of dextran stock solution. The effect of 
thickening agents on medium viscosity was measured as per Section 2.1.1. 
 
2.2.2.3 ROCK inhibitor 
In collaboration with Svenja Dannewitz Prosseda (Department of Infection, 
Immunity and Cardiovascular Disease, University of Sheffield) additional cell 
migration studies were performed using HUVEC in standard EC growth medium 
supplemented with 2 µM Y27632 (Calbiochem). This biochemical tool is a ROCK 
inhibitor, which enhances cell polarity and migration by silencing bidirectional 
mechanical cues (Section 1.4.4). 
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2.2.3 Cell culture 
HUVEC were maintained in 0.1% gelatin-coated T75 flasks with 12 ml of EC 
growth medium, within an incubator at 37°C and 5% CO2. The medium was changed 
every 3 – 4 days until cells reached approximately 90% confluency. At this point, the 
growth medium was discarded and the cells rinsed with 10 ml of PBS. 2.5 ml of 
trypsin-EDTA solution (Sigma-Aldrich) was added and the flask incubated for 
5 minutes as the HUVEC detached, after which 10 ml of growth medium was added 
to deactivate the trypsin-EDTA. The contents of the flask were then decanted into a 
50 ml tube, which was centrifuged for 5 minutes at 157 g to form a cell pellet. The 
supernatant was removed and the pellet resuspended in 1 ml of EC growth medium. 
To sustain the HUVEC culture, 100 µl of cell suspension was placed into a new 
gelatin-coated T75 flask with 12 ml of fresh EC growth medium. This was returned 
to the incubator to attach and proliferate. HUVEC were maintained up to P5. 
 
2.2.4 Seeding endothelial cells within in vitro models 
HUVEC were used for migration studies at P3 – 5, at approximately 90% 
confluence. 24 hours prior to seeding, the flask of cells to be used was removed from 
the incubator and the medium replaced with 10 ml of fresh EC growth medium and 
1 µl of fluorescent dye solution (1 mg of CellTracker Green CMFDA, Fisher 
Scientific, with 10 µl of dimethyl sulfoxide, Sigma-Aldrich, resulting in a dimethyl 
sulfoxide concentration of 0.01% within the flask). The cells were re-incubated and 
the following day detached, formed into a pellet and resuspended as described in 
Section 2.2.3. 20 µl of the cell suspension was then removed and mixed with 20 µl of 
0.4% trypan blue solution (Fisher Scientific). This mixture was injected onto a 
haemocytometer and the live, unstained cells were counted. 
HUVEC were seeded into the in vitro models at a density of approximately 1000 
cells/mm
2 
to attach to the lower half of the vessel only, due to practical requirements 
which are discussed in more detail in Section 3.6. The 1 ml suspension from a 90% 
confluent T75 flask would typically contain approximately 3 million cells, which 
was diluted with additional media to obtain the correct concentration. A final cell 
suspension of 1.3 million cells/ml was required for vessels of 1.5 mm diameter, 
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1 million cells/ml for vessels of 2 mm diameter and 800,000 cells/ml for vessels of 
2.5 mm diameter. 
Cell suspensions were slowly injected into model vessels until the filling front 
approached the half-way point, leaving the remaining half empty (Figure 2.4A). The 
vessels were placed in the incubator and left for the HUVEC to settle onto the lower 
surface and attach over the course of 12 – 18 hours. Successful attachment was 
indicated by a change in HUVEC morphology and confirmed by flushing the vessel 
with PBS. The use of PBS rather than media ensured that only well attached HUVEC 
remained, and vessels were flushed from the cell-free end so that no cells were 
pushed downstream of the seeding point. Continued attachment was again verified 
under a light microscope (AE2000, Motic), and the vessel was filled along its entire 
length with EC growth medium. 
For redundancy, multiple model vessels were seeded per stent sample. The best 
examples, in terms of attached cell confluency and a well-defined border between the 
cell monolayer and bare wall, were selected for stenting. The leading edge of 
attached HUVEC was marked and a stent inserted from the cell-free end and 
deployed as per Section 2.1.5. Coronary stents were deployed with their upstream 
edge as close to this mark as possible (Figure 2.4B), whereas flow diverter stents 
were deployed with their upstream edge approximately 2 mm over the cell layer 
(Figure 2.4C). The reasoning behind this change in protocol, due to variability in 
flow diverter stent geometry, is discussed in Section 5.5. The vessel was then 
checked under the microscope once more, to assess the condition of HUVEC post-
deployment. 
 
2.2.5 Tracking endothelial cell migration 
Following HUVEC attachment and stent deployment, model vessels were linked to 
one of two flow systems as described below. The system used in each instance was 
dependent on the maximum flow rate the equipment could supply and the rate 
required in each model. 
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Figure 2.4 Cell seeding and stent deployment 
 
A: Cross-section (left) and longitudinal view (right) of HUVEC seeded partway along the 
model vessel, on its lower half only. 
B: Coronary stents were deployed downstream of attached HUVEC, with their upstream 
edge as close to the cells as possible. The red line represents the plane of focus used in 
microscope imaging, the lower edge of the wall and adjacent stent struts. 
C: Flow diverter stents were deployed with their upstream edge overlapping attached 
HUVEC by approximately 2 mm. 
D: Stented vessels were connected to a pump and fluid reservoir, via tubing of equal internal 
diameter. Flow was applied from the cell-covered end of the model. 
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2.2.5.1 Peristaltic pump 
Models of 2 and 2.5 mm diameter were connected to silicone tubing and, as a 
reservoir, a borosilicate bottle filled with 50 ml of EC growth medium (Figure 2.4D). 
The tubing was then inserted into a cassette for connection to a peristaltic pump 
(FH100M Multi-channel Peristaltic Pump, Fisher Scientific) and the vessel and 
reservoir placed in a 37°C egg incubator (Kingsuro Max. 20, Rcom). The pump was 
turned on, set to 25% of the flow rate required to generate an average of 1 Pa wall 
shear stress within the vessel and gradually increased to the required rate over an 
hour. 
 
2.2.5.2 Air pressure pump 
Models of 1.5 mm diameter were connected to an ibidi Pump System (ibidi GmbH), 
consisting of an air pressure pump, fluidic unit with reservoirs and PumpControl 
software. The vessel and entire fluidic unit were able to fit within a 37°C CO2 
incubator. The pump was programmed to supply constant unidirectional flow, once 
again gradually increasing the rate up to that required to generate 1 Pa of wall shear 
stress. Experiments using the ibidi Pump System were performed in collaboration 
with Svenja Dannewitz Prosseda (Department of Infection, Immunity and 
Cardiovascular Disease, University of Sheffield). 
 
Once maximum flow rates were reached experiments were considered to be at time 
point 0 (t = 0) and an image was captured. The model was then left under flow for as 
long as possible and, without pausing the pump, periodically removed from the 
incubator to be imaged over the course of the experiment. 2 and 2.5 mm models were 
photographed using a digital camera (EOS 1200D, Canon) attached to an inverted 
microscope (AE2000, Motic), under brightfield illumination or fluorescent light 
provided by a Stereo Microscope Fluorescence Adapter with a Royal Blue 
wavelength set (NIGHTSEA). 1.5 mm models connected to the ibidi system were 
imaged on an Eclipse Ti inverted microscope (Nikon) within a cage incubator 
(Okolab), linked to MetaMorph microscopy automation and image analysis software 
(Molecular Devices). This provided the option of leaving the model on the 
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microscope stage for the duration of the experiment and concurrently programming 
the software to capture images at specific time points and locations. In each case, the 
plane of focus was positioned on the lower edge of the wall and adjacent stent struts 
(illustrated in Figure 2.4).  
 
2.2.6 Data analysis 
All images were scaled against a haemocytometer grid. The seeded cell boundary 
was marked in images from t = 0. In images from later time points the leading edge 
of the monolayer was located and, if it had moved, marked again. Any discrete cells 
which may have moved downstream ahead of the monolayer were also located. As 
individual HUVEC were not identified between time points, their specific migration 
rates and persistence could not be found. In lieu, maximum distance from the seeded 
boundary was measured at each time point, from which a general migration rate was 
calculated. Total cell numbers and location in relation to stent struts were also 
recorded. 
 
2.3 Particle tracking 
Flow patterns and particle accumulation were visualised by tracking the motion of 
suspended particles through the model. As per the cell migration studies, the protocol 
detailed in this section was carried out for a variety of coronary and flow diverter 
stents, as well as empty non-stented vessels as controls. However, 1.5 mm diameter 
models were not included in this study. 
 
2.3.1 Set up 
Vessels were connected to a fluid reservoir and peristaltic pump, as described in 
Section 2.2.5.1. Any models previously used with HUVEC were first cleaned of 
debris. Reservoirs were filled with 12 ml of room temperature 70% industrial 
methylated spirit (IMS). A suspension of 10 µm polystyrene particles (FluoSpheres, 
Fisher Scientific) with 3.6 x 10
6
 particles/ml was agitated via vortex mixer (Lab 
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Dancer S42, IKA). 40 µl of the suspension was then transferred to the reservoir at a 
250:1 fluid to particle volume ratio. The pump was briefly set to maximum power, to 
circulate the fluid and distribute the particles around the system. The flow rate was 
then reduced to 6.5 ml/min for 2 mm diameter vessels, and 12.8 ml/min for 2.5 mm 
diameter vessels. At these rates, the Reynolds number was 43 and 68 respectively, 
matching that in blood flow of 1 Pa wall shear stress within the same model. 
 
2.3.2 Image acquisition 
Model vessels were placed onto the stage of an inverted microscope (AE2000, 
Motic), with a connected camera (Moticam 2300, Motic). A 4x objective lens was 
used to ensure the full diameter of the vessel was in view and a live image was 
displayed via Images Plus software (Motic). The vessel was oriented so that the 
leading edge of the stent was within the image, with flow moving horizontally from 
left to right. The bottommost stent struts were brought into focus (the same plane of 
focus used in cell migration studies, as illustrated in Figure 2.4), before light 
intensity, aperture diaphragm opening and camera exposure were adjusted until 
moving particles could be seen. 
The camera software was used to record a 2 minute video. The vessel was then 
repositioned so that the field of view was moved downstream, with a small amount 
of overlap with the previous field. Another 2 minute video was recorded and the 
vessel repositioned again. This process was repeated until the downstream end of the 
stent was captured in a final field of view (Figure 2.5A). 
Once the procedure was complete, particle accumulation was recorded (see 
Section 2.3.5). Following this, the model was flushed, removed from the system and 
rinsed with acetone to dissolve and remove any remaining particles. The model was 
rotated by 90° to expose different stent geometry and reconnected to the pump with a 
fresh reservoir. The above process was then repeated. 
 
 
73 
 
2.3.3 Image processing 
Video recordings were split into image sequences using Video to JPG Converter 
software (DVDVideoSoft). These images were, if required, reoriented to ensure that 
the direction of flow was exactly horizontal and that adjacent fields of view could be 
aligned. The software returned images at a frame rate of 20 frames per second (fps), 
and every second frame was selected. For each field of view two sets of 300 images, 
each representing roughly 30 seconds of flow, were selected for tracking 
(Figure 2.5B). One frame from each image sequence was used to isolate the struts by 
removing the PDMS wall, along with any attached particles or debris, providing a 
clear image of stent geometry onto which tracks could be overlaid (Figure 2.5C). 
 
2.3.4 Tracking and analysis 
Image sequences were opened as stacks in ImageJ. Each particle was individually 
tracked by marking its centre point in consecutive images in the sequence, and 
creating a line connecting these points. Multiple particles following the same track 
were counted. Particles which were out of focus or could not be reliably identified 
between images were not tracked. This excluded faster moving particles deeper 
within the vessel and those following wall curvature at the upper and lower edges of 
the images. Furthermore, any particles that were already within the field of view at 
the beginning of sequences, or remained within it at the end, were also omitted. This 
ensured that for later analysis all tracks represented the complete path of particles 
and that any points at which they appeared to be cut short could be identified as 
locations of arrested motion. 
Once complete, tracks from each sequence were isolated from the background image 
and exported (Figure 2.5C). To visualise the impact of local stent geometry, tracks 
were overlaid on the previously isolated strut images (Figure 2.5D). The orientation 
of tracks was quantified with ImageJ as described in Section 2.1.6. Distribution was 
quantified by noting the position of tracks, and the number of particles moving along 
them, in relation to a 100 µm grid of 1.5 mm height x 2.5 mm length in each field of 
view. This information was used to create heat maps, to visualise distribution and 
areas of particle dispersal or collection (Figure 2.5E). 
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Figure 2.5 Particle tracking protocol 
 
A: Video recordings were taken at overlapping fields of view along the total length of stents. 
B: Two image stacks, each representing 30 seconds of flow, were separated from individual 
recordings at each field of view. 
C: Flowing particles were tracked in each stack, and local stent geometry was isolated. 
D: Particle tracks and stent geometry were combined, to visualise local flow patterns. 
E: Heat maps of particle distribution were created by counting tracks, and the number of 
particles moving along them, in relation to a 2.5 mm x 1.5 mm grid of 100 µm squares. 
A 
B 
C 
E 
D 
75 
 
2.3.5 Particle accumulation 
Following particle tracking, the accumulation of any particles during the experiment 
was recorded by imaging the entire model under 1x magnification on a stereo 
microscope (SMZ-171 BLED, Motic). Brightfield images, capturing model and stent 
geometry, were overlaid by fluorescent light images to highlight particles at this 
relatively low magnification. All particles within the stents, and 2 mm up and 
downstream of the leading and trailing edges, were counted. 
To compare accumulation between shorter stents, where particle tracking was 
complete within 3 or 4 fields of view (6 – 8 minutes of flow), and longer stents (8 or 
9 fields of view, or 16 – 18 minutes), each 2.5 mm diameter model was left under 
flow for a total of 20 minutes. With a 50% lower flow rate, 2 mm diameter models 
were imaged after 20 minutes (to compare accumulation after the same time under 
flow as 2.5 mm models) and again after 40 minutes (to compare accumulation after 
the same total flow volume of particle suspension). 
 
2.4 Micro-computed tomography 
µCT scanning was performed to reconstruct in vitro model geometry in silico, for 
analysis with CFD software. Three techniques were trialled: scanning model vessels 
alone, scanning model vessels with a contrast agent and scanning casts of model 
vessels (these methods were also assessed as a means of reproducing ex vivo stented 
artery samples for similar in silico modelling and analysis). 
 
2.4.1 Sample preparation 
In vitro models which had been used with HUVEC or fluorescent particle tracking 
were cleaned of debris with acetone and 70% IMS. To minimise sample size, the 
wall around the stent was thinned and empty sections at either end were cut away, 
with care taken to ensure stents were not distorted. Scans of model vessels alone 
were taken (Figure 2.6A). Alternatively, to assess the use of a contrast agent, a 
60% w/v barium sulphate suspension was injected into the lumen (Figure 2.6B). 
 
76 
 
 
 
 
 
 
Figure 2.6 µCT sample preparation 
 
µCT scanning of model vessels was used to recreate in vitro geometry in silico, for CFD 
analysis. Three techniques of pre-scan sample preparation were trialled, to optimise the 
faithful reproduction of in vitro vessel and stent geometry.   
A: Excess PDMS was trimmed from models before stented vessels were scanned. 
B: Excess PDMS was trimmed and the lumen filled with a contrast agent before scanning. 
C: The model was silanised and covered in additional PDMS. The original wall PDMS and 
stent were removed from the resultant cast of the lumen, which was then scanned. 
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To create casts, model vessels were left in a desiccator with 3 – 4 drops of 
trichloro(1H, 1H, 2H, 2H-perfluorooctyl)silane (Sigma-Aldrich) for 20 minutes, to 
silanise by evaporation deposition. Each vessel was then placed in the bottom of a 
cuvette and 5 g of PDMS (prepared as per Section 2.1.4) was immediately poured in 
to cover the model. Mixing ratios of 5:1, 10:1 and 15:1 were trialled for casting. The 
cuvette was centrifuged at 626 g for 10 minutes to force the fluid PDMS into the 
model vessel and to remove air. The PDMS was left to cure at room temperature, for 
a minimum of 72 hours. 
 
Once cured, the solid block was removed from the cuvette. Without surface 
treatment, the additional PDMS would have seamlessly and irreversibly bonded with 
the existing PDMS wall. This was prevented by the presence of the <100 nm thick 
silane film and, as such, the model vessel was easily removed from the surrounding 
PDMS. A scalpel was used to create a shallow slit in the wall of the model, which 
was then gently prised apart. This left only the PDMS which had filled the lumen. 
Rather than come away with the wall, stents remained attached to this final section 
and were carefully removed. This process left a cast of the lumen, capturing the 
geometry of both the wall and stent (Figure 2.6C). Casts were again cleaned with 
acetone and IMS, and stored in a clean vial prior to scanning. 
 
2.4.2 µCT scanning 
µCT scans were performed with a SkyScan 1172 high-resolution desktop µCT 
scanner (Bruker). Stented vessels (with or without contrast agent) and casts were 
secured to an 8 mm diameter rotating stage within the machine with double-sided 
tape, oriented vertically (Figure 2.7A). The x-ray source was turned on and control 
software was opened to provide a live image via an 11 megapixel x-ray camera, as 
well as the means to alter scan parameters: voltage, current, resolution, the use of 
aluminium filters, etc. 
 
 
78 
 
 
 
Figure 2.7 µCT scanning and modelling protocol 
 
µCT scanning of model vessels was used to recreate in vitro geometry in silico. 
A: Samples were placed onto the stage within the CT scanner. 
B: As the stage rotated, scans produced images of 2D x-ray shadows at each rotation step. 
C: Raw projection images were converted into cross-section slices of the sample. 
D: Slices were cleaned of noise and interference. 
E: Slices were converted into 3D in silico models to be used for CFD analysis. 
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The vertical position of the stage, the camera pixel size (large, 1000 x 500; medium, 
2000 x 1000; small, 4000 x 2000) and the proximity of the camera to the sample 
were set to maximise resolution while ensuring that the region of interest (i.e. the full 
length of the stent or cast) remained within the field of view. When the sample 
extended beyond the widest field of view (typically models containing stents longer 
than 13 mm) multiple oversize scans were performed. The stage, being metallic, was 
always kept outside of the field of view to reduce interference. 
 
The stage was set to rotate 180°, in 0.7° steps. Additional settings were varied, to 
optimise parameters for the type of sample being scanned (Table 2.1). Voltage 
determined the intensity of the x-ray beam, its penetration, and the contrast of the 
resultant image. Current determined the number of emitted x-ray photons and the 
brightness of the resultant image. Filters blocked low intensity x-rays when required, 
improving contrast and reducing noise. 
The scan was started and as the stage rotated the camera captured an x-ray 
tomography projection image of the sample at each rotation step (Figure 2.7B). Scan 
time was dependent on the settings used and ranged from 10 minutes to several 
hours. 
  
2.4.3 Reconstruction 
µCT image datasets were opened in reconstruction software (NRecon user interface 
and NReconServer reconstruction engine, Bruker), to convert the projection images 
of the sample into a series of cross-sectional slices (Figure 2.7C). The upper and 
lower boundaries of the reconstruction range were selected, as well as a single point 
located between the two. This point was reconstructed alone, acting as a preview 
slice to fine tune parameters (beam-hardening correction, ring artefacts correction 
level and smoothing level) and the dynamic image range (DIR), before the 
reconstruction process was applied to the entire model. As such, the preview point in 
heterogeneous samples was selected at locations where the full range of materials 
was present. 
 
80 
 
 
 
 
 
Sample 
Source voltage      
(kV) 
Source current     
(µA) 
Aluminium filter 
Model vessel 50 180 0.5 mm 
Model vessel – low 
power test 
35 180 0.5 mm 
Model vessel and 
contrast agent 
50 180 0.5 mm 
Ex vivo vessel and 
contrast agent 
50 180 0.5 mm 
PDMS cast 50 150 None 
PDMS cast – low 
power test 
40 150 None 
PDMS cast – high 
power test 
60 150 None 
 
Table 2.1 µCT parameters for in vitro and ex vivo vessels, and PDMS casts 
 
As samples can consist of a number of different materials, with differing radiopacity, x-ray 
source voltage and current, and the use of filters, can all be varied to optimise the images 
captured during µCT scanning. 
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DIR (the difference between the maximum and minimum pixel brightness) was used 
to discriminate between materials via differences in x-ray attenuation. This was 
presented as a histogram, in Hounsfield units (HU), and calibrated by selecting a 
region of empty space and setting a value of -1000 HU. The applied DIR and 
reconstruction parameters depended on the requirements of individual scans and are 
discussed further in Chapter 3. 
 
Following reconstruction, DataViewer software (Bruker) was used to visualise the 
stacked reconstructed slices as a complete model. This allowed the quality of the 
reconstruction to be assessed and the dataset to be reoriented. To simplify the process 
of preparing the in silico model for CFD analysis, the dataset was rotated to be as 
straight as possible and resaved as a series of cross-sectional slices in the transaxial 
x-y plane (viewing the model down the length of the vessel). 
 
2.5 Computational fluid dynamics 
2.5.1 Model preparation 
Reconstructed image datasets were opened as stacks in ImageJ and converted from 
greyscale to binary. The lumen, as the fluid volume to be meshed, was highlighted 
against a black background in each instance. For reconstructed casts, this was already 
the case. Contrast agent reconstructions required stent struts and the wall to be 
subtracted from the image, leaving the agent within the lumen, whereas in 
reconstructions of unaltered models, struts and wall were simply inverted. 
Images could then be edited, to remove interference from bubbles or wall damage, 
and CT artefacts such as noise and beam hardening (Figure 2.7D). Simple cleaning 
could be rapidly carried out on the entire stack within ScanIP software (Synopsys 
Inc.) with the island removal and cavity fill functions removing extraneous voxels. 
Larger defects, if present, required manual editing on an image by image basis. The 
amount of editing which was necessary varied greatly depending on scan and 
reconstruction parameters, and the type of sample scanned, and is discussed further 
in Chapter 3. 
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2.5.2 Meshing 
Completed models were imported into ScanIP software and the fluid domain selected 
via thresholding to form a mask (Figure 2.7E). As the images were already in binary 
format, only white voxels were selected and therefore the exact threshold range was 
unimportant. 
Masks were converted to volume meshes consisting of tetrahedral elements via the 
ScanIP +FE Module, in FLUENT CFD Output format, using the +FE Free mesh 
algorithm. Element size and internal volume change rate were altered on a 100-point 
scale, where element edge length was dependent on voxel size, a product of the 
original µCT scan resolution (Table 2.2). 
Once complete, the Mesh Quality Inspection Tool was checked for errors or 
warnings, before mesh files were exported. 
 
2.5.3 Simulation 
Mesh files were imported into ANSYS FLUENT software (ANSYS, Inc.), a finite 
volume based solver, to simulate the steady-state laminar flow of incompressible 
Newtonian fluids via the solution of the governing equations. 
The first is the continuity equation, representing conservation of mass, where v is the 
velocity vector: 
      
The second is the Navier-Stokes equation, representing conservation of momentum, 
where ρ is fluid density, p pressure and µ fluid dynamic viscosity: 
                 
Cell culture media was modelled with a dynamic viscosity of 0.0008 Pa.s and density 
of 1005 kg/m
3
. Thickened media/blood was modelled with a dynamic viscosity of 
0.0035 Pa.s and density of 1060 kg/m
3
. 
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Mesh density 
Coarsest (-50) Default (0) Finest (+50) 
Min. edge length 4V V/2 V/3 
Max. edge length 10V V V/1.5 
Target max. error V/10 V/10 V/20 
 
Table 2.2 Mesh element size as a factor of voxel size 
 
The ScanIP +FE Module was used to create volume meshes from 3D reconstructions of 
model vessels. Element size could be altered on a 100-point scale, where element edge 
length was dependent on voxel size (V), equal to µCT scan resolution. 
 
 
 
 
 
 
 
 
 
84 
 
Boundary conditions were set as follows: non-slip conditions were applied at the 
wall, zero pressure at the outlet and velocity at the inlet. As the in vitro models were 
shortened prior to scanning, an insufficient entrance length for flow development 
was present. Rather than extend the model, and increase computational expense, a 
fully developed 3D parabolic flow was applied at the inlet boundary via a user 
defined function (UDF). Separate UDFs were created for each model, to account for 
differences in radius and required velocity, and were interpreted by ANSYS Fluent 
and hooked at the inlet. 
 
As an incompressible flow, calculations were performed using the coupled pressure 
based solver, in which the continuity and momentum equations are solved 
simultaneously. The SIMPLE algorithm, suitable for steady-state flow, was selected 
as the solution method. Default spatial discretization schemes were used:  gradients 
of solution variables were determined via the least-squares cell-based method, 
pressure was interpolated via the second-order scheme and momentum via the 
second-order upwind scheme. A convergence criterion of 10
-6
 was used for 
continuity and x-, y- and z-velocity. 
 
2.5.4 Post-processing 
Simulation results were assessed using ANSYS CFD-Post (ANSYS, Inc.). Velocity 
field volume renders and vector plots were displayed to verify that the UDF was 
correctly applied and to visualise flow around stent struts. Contour plots of wall 
shear stress on the vessel wall and stent struts were displayed, and the data extracted 
to find minimum, maximum and average values for vessels. Reference lines along 
the wall were selected and used to plot changing wall shear stress magnitude through 
the length of stents. Where possible, this data was compared to cell behaviour at 
corresponding locations within in vitro models. 
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2.6 Statistical analysis 
Statistical analysis was not carried out where, due to the developmental nature of the 
work and the limited number of available stent samples, a sufficient number of 
experiments could not be performed (n=1 - 2). 
However, wherever possible, experiments were performed a minimum of three times 
(n≥3) and in these cases data is presented as the mean ± standard deviation. 
Statistical significance was determined via two-way ANOVA with Sidak post-hoc 
test (Prism, GraphPad Software Inc.) where applicable. Statistical significance was 
defined as a probability value of p<0.05. 
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Chapter Three 
3 Platform Development 
 
This chapter encompasses the development of the fabrication, experimental and 
modelling methods detailed in Chapter 2. It describes the steps taken to arrive at 
these protocols, validate their use and assess their efficacy and efficiency. While 
some stented vessels are presented as examples, full results for coronary and flow 
diverter stents can be found in Chapters 4 and 5 respectively. 
 
3.1 In vitro model 
3.1.1 Fluid properties   
1 ml of EC growth medium was determined to weigh 1.005 g; the density of the fluid 
was 1005 kg/m
3
. Viscosity data could only be collected from a maximum of 34°C as 
the temperature of the medium could not be maintained during set-up. Measurements 
were therefore taken at multiple points as the medium cooled. The viscosity of EC 
growth medium was compared to that of water over the measured temperature range, 
and this relationship extrapolated to obtain viscosity at 37°C. Despite some variation 
between instruments, potentially due to measurements being made at their lower 
limits, EC growth medium containing 20% FCS was on average 15% more viscous 
than water (Figure 3.1). EC growth medium viscosity at 37°C was therefore taken to 
be 0.8 mPa.s, based on a reference value of 0.69 mPa.s for water [198]. 
For cell migration studies, 1 Pa was selected as the average wall shear stress 
magnitude to be applied in the model based on the range of applied and physiological 
parameters from relevant literature (Sections 1.6.3 and 1.7.3), the power of available 
pump systems and previous work in-group [103]. Wall shear rate was 1250 s
-1
 in 
each model. Table 3.1 details how the resultant flow properties varied with vessel 
diameter. 
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Figure 3.1 Viscosity of EC growth medium 
 
The viscosity of EC growth medium was measured as the fluid cooled and compared to that 
of water over the same temperature range. The medium, containing 20% FCS, was on 
average 15% more viscous than water. 
Mean with SD (n=4). 
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Model diameter 
(mm) 
Flow rate 
(ml/min) 
Average velocity 
(m/s) 
Reynolds 
number 
1.5 25 0.23 442 
2 59 0.31 785 
2.5 115 0.39 1227 
 
 
Table 3.1 Applied flow properties 
 
In cell migration studies an average wall shear stress of 1 Pa was applied in each model by 
the flow of EC growth medium. The flow rate was therefore adjusted to maintain this level 
of wall shear stress across the various model diameters used. 
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3.1.2 Material properties 
Samples of a variety of PDMS base and curing agent ratios were created for 
mechanical testing. 60:1 samples would not cure and remained fluid, whereas 50:1 
and 40:1 samples were gelatinous. 30:1 and 20:1 samples were solid, yet remained 
tacky due to an abundance of unlinked monomers and were therefore unsuitable for 
use. 15:1, 10:1 and 5:1 samples were fully cured at room temperature and were 
tested. 
3 batches of each ratio were created and 3 samples from each batch underwent 
tensile testing. The average elastic modulus was found to be 0.342 MPa (15:1), 
0.697 MPa (10:1), and 1.000 MPa (5:1), shown in Figure 3.2. 
 
3.1.3 Model dimensions 
Vessel diameter was informed by physiological data from literature (Section 1.7.2). 
As atherosclerotic lesions were not modelled, and stents were not required to 
compress material while expanding, data regarding healthy coronary arteries only 
was sought out. Coronary stents were tested under the assumption that PCI had been 
successful (i.e. normal lumen diameter and associated blood flow had been restored). 
Diameters of 1.5, 2 and 2.5 mm, within the physiological range, were selected based 
on the power of available pump systems and the nominal diameters of available 
stents. 1.5 mm vessels were the largest within which the ibidi system, with a 
maximum flow rate of 35 ml/min, could generate 1 Pa of wall shear stress. Flow 
diverter stents were only available with 2 mm nominal diameter, for deployment in 
vessels of equal size. The majority of available coronary stents had a 3 mm nominal 
diameter, for deployment at a 1.1:1 to 1.2:1 stent to vessel ratio. 2.5 mm was the 
smallest vessel diameter within this deployment range and was used to minimise the 
required pump power. 
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Figure 3.2 Elastic modulus of PDMS 
 
The elastic modulus of PDMS was calculated following tensile testing. Elastic modulus 
varied greatly between the three curing agent mixing ratios trialled, but was always within 
the wider physiological range of arterial tissues (0.1 – 100 MPa [175]) and, at lower ratios, 
comparable to that of a carotid artery segment (red region [176]). All samples were cured at 
room temperature for 24 hours, followed by 15 minutes in a 100°C oven. 
Mean with SD (n=9). 
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The entrance lengths required for fully developed flow based on the conditions 
detailed in Table 3.1 were calculated using the equations outlined in Section 2.1.3 
and found to be 40 mm (1.5 mm diameter vessels), 95 mm (2 mm diameter), and 185 
mm (2.5 mm diameter). The combined length of the model and attached silicone 
tubing of equal diameter ensured that the distance between the pump head and 
stented/seeded area was sufficient for flow to fully develop upstream of regions of 
interest. 
The cuvette mould resulted in a wall thickness of 4.5 mm, well within microscope 
focal length. Flat surfaces provided the stability required for cell seeding and 
imaging. The mould prevented the need to cut the PDMS to the required size and as 
such each side remained transparent. 
 
3.1.4 PDMS enabled the rapid fabrication of biocompatible model vessels 
PDMS models were cured at room temperature, eliminating shrinkage to ensure that 
models were of the expected size when applying specific flow conditions. This also 
prevented the expansion of any small bubbles which may have remained despite 
centrifuging, which could hamper visibility or distort the vessel wall geometry. After 
24 hours the PDMS was solid and cytotoxic unlinked monomers could be eliminated 
by a brief spell at higher temperature without affecting the dimensions of the model. 
Despite this, a fibronectin coating was still required to achieve and maintain 
successful cell attachment under flow (Figure 3.3). 
 
3.2 Stent deployment 
3.2.1 Clinical stents could be fully deployed within model vessels 
Coronary and flow diverter stents were successfully deployed within model vessels 
and were stable under flow. Flow diverter stent struts lay adjacent to the vessel wall, 
where self-expansion was arrested. In contrast, the high-pressure balloon expansion 
of coronary stents widened the vessel, stretching the wall between struts. Typical 
deployments are shown in Figure 3.4, and are comparable to equivalent ex vivo 
histology samples. 
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Figure 3.3 Cell attachment within PDMS vessels 
 
HUVEC were seeded within bare PDMS vessels (left), vessels coated with gelatin (centre) 
and vessels coated with fibronectin (right), and left for 12 hours to attach. HUVEC would 
not attach onto bare PMDS, and those attached on a gelatin coat were removed under flow. 
Only 10 µg/ml fibronectin was able to maintain attachment under both static and flow 
conditions. 
Scale bar: 0.5 mm. 
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Figure 3.4 Deployed stent strut location in vitro and in vivo 
 
Following stent deployment in model vessels, images of cross-section slices were taken to 
compare the final position of struts to those in ex vivo histology. In each example, additional 
PDMS cured within the lumen prevented struts from being moved or distorted when cut. 
A: Coronary stent deployment via balloon inflation pushes struts (blue) against the wall (red 
line), widening the vessel beyond its initial diameter (green line). 
B: Self-expanding flow diverter stent deployment maintains the original vessel shape and 
diameter. Struts lay adjacent to the wall. 
C: Photomicrograph of a coronary stent stretching and widening the artery wall, as per in 
vitro deployment [45]. Struts penetrate neointima, but not the wall itself (yellow box). 
D: Photomicrograph of a flow diverter stent and unmodified vessel wall, as per in vitro 
deployment [199]. Struts lay adjacent to the wall and aneurysm (at the top of the image). 
Scale bar: 0.2 mm. 
(All images reproduced with permission). 
B A 
D C 
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An accurate, quantitative measure of penetration or stretch was not possible, as 
stented models could not be cut by microtome to produce thin, high-quality images 
as per the histological examples. Samples were cut by scalpel, and were therefore 
relatively thick and outside of focal length. Despite additional cured PDMS present 
within the lumen to provide support, the examples shown in Figure 3.4 are rare cases 
of this method not distorting the struts to some degree. 
 
3.2.2 Definitive measurement of deployed stent geometry was unattainable 
Strut size, orientation and metal-to-artery ratio was measured for each available stent 
design. Accurate dimensions could not be attained as attempts to manipulate struts 
could result in distortion, as mentioned in Section 3.2.1. As such, dimensions were 
taken to the nearest 5 µm. Measurement using µCT data was also problematic, 
detailed in Section 3.5.2. 
The metal-to-artery ratio of stents could be calculated from images without specific 
strut dimensions, by comparing the number of pixels filled by the stent (the MSA) to 
the total number of pixels in the bounded area. For stents with circular cross-section, 
width varied across the strut and the metal-to-artery ratio depended on the degree of 
contact with the vessel wall. The MSA was measured at the strut’s widest point; 
therefore the maximum metal-to-artery ratios are stated here. For stents with square 
or rectangular cross-sections, strut width and MSA was constant and the metal-to-
artery ratio did not vary with wall contact. 
Strut orientation varied between deployments of the same stent design. Increased 
expansion rotated struts away from the direction of flow, taken to be 0°, and vice 
versa. While averages of each of the above properties accounted for variability and 
reduced errors, definitive measurement of stents in vitro was difficult. 
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3.3 Cell migration study set-up 
3.3.1 Cell migration assays began from specific initial HUVEC location 
Cell suspensions were injected halfway into model vessels (Figure 2.4). In larger, 2.5 
mm diameter vessels, careful handling of the model during attachment was necessary 
to hold the filling front stationary. In 1.5 mm diameter vessels, care was needed to 
ensure capillary action did not draw the suspension further through the model. With 
practice, medium/air boundaries could be maintained at the required points. 
Following cell attachment, this resulted in monolayers with straight, well-defined 
leading edges against which stents could be positioned (Figure 3.5). 
Attached HUVEC were relatively resilient and able to survive repeated flushing as 
tubing and reservoirs were connected (cells could also survive stent deployment 
directly over the monolayer, as shown in Figure 3.6). Minor damage to the 
monolayer could be caused by guide wires, balloons and sheaths during stent 
deployment, but wound closure was observed during experiments. 
   
3.3.2 HUVEC migration could be tracked under flow 
HUVEC seeded within empty control tubes showed clear migration under flow of 1 
Pa average wall shear stress. This consisted of movement of the monolayer leading 
edge in the direction of flow, often led by the more rapid migration of individual 
leader cells (Figure 3.7). 
Migration distances and rates were obtained for cells within empty control tubes of 
1.5 and 2.5 mm diameter, after 24 hours under flow (Figure 3.8). This showed a 
maximum monolayer migration equivalent to 50 – 60% vessel diameter over that 
time period with leader cells, where present, covering twice that distance. 
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Figure 3.5 Attached HUVEC/empty vessel boundary 
 
HUVEC could be seeded up to specific points within model vessels to attain straight, clearly 
defined boundaries (red line) between cell covered (left) and cell free areas (right). This 
technique aided in accurate stent deployment and provided a clear initial position from which 
cell migration could be measured. 
Scale bar: 0.5 mm. 
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Figure 3.6 Stent deployment over attached HUVEC 
 
HUVEC were seeded along the full length of model vessels and, once attached, stents were 
deployed over the monolayers. Although some areas of damage were seen, HUVEC 
remained well attached, even following coronary stent balloon expansion. This prevented the 
identification of initial positions required to monitor cell migration. 
A: Coroflex Blue coronary stent deployed via balloon expansion. 
B: Self-expanding Silk flow diverter stent.   
Scale bar: 0.5 mm. 
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Figure 3.7 Cell migration in 2.5 mm diameter empty control vessels 
 
The migration of HUVEC monolayers (green line) and leader cells (green dots) beyond an 
initial seeding point (red line) was observed in the direction of flow within empty 2.5 mm 
diameter vessels over 24 hours. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
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Figure 3.8 Cell migration distance and rate in control vessels 
 
The rate of HUVEC migration over 24 hours within empty vessels was measured. Rate 
increased with vessel diameter. No leader cells were observed in 1.5 mm diameter models. 
Flow of 1 Pa average wall shear stress. 
Mean with SD (n=3). 
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Cells seeded within 1.5 mm tubes and connected to the ibidi system could be 
monitored over a longer duration (Figure 3.9). Figure 3.10 shows a maximum 
monolayer migration approximately equal to vessel diameter over 48 hours, but 
reveals a nearly 50% reduction in migration rate after the first time point at 12 hours, 
beyond which rates remain steady. Figure 3.10 also shows that, in empty vessels with 
constant unidirectional flow, HUVEC in medium supplemented with a ROCK 
inhibitor covered two-thirds the distance of cells in untreated medium. 
All model vessels seeded with cells but not selected for use in flow experiments were 
left as static controls. The majority showed zero migration, or low numbers of cells 
moving ≤50 µm over 24 hours (Figure 3.11A, B, C). However, in one single case, 
the monolayer within a 2 mm diameter static control was observed to move 800 µm 
(Figure 3.11D), discussed further in Section 3.6. 
 
3.3.3 Cell migration assays were hampered by practical limitations 
Fewer than 1 in 5 of the models with sufficient cell attachment for connection to 
pump systems saw HUVEC survive long enough under flow for a successful cell 
migration assay (considered to be t ≥24 h). The maximum duration reached by 
individual experiments was 72 hours (in a model connected to the peristaltic pump) 
and 90 hours (in a model connected to the ibidi system). 
The visibility of cells could hinder accurate measurement of cell migration, 
particularly around dense stent struts, or as debris began to build up. HUVEC stained 
with CellTracker dye could be observed under fluorescent light supplied by the 
NIGHTSEA system. However, individual cells were not bright enough to be imaged 
and only clusters which were already visible under brightfield could be captured 
(Figure 3.12). 
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Figure 3.9 Cell migration in 1.5 mm diameter empty control vessels 
 
The migration of HUVEC monolayers (green line) beyond an initial seeding point (red line) 
was observed in the direction of flow within empty 1.5 mm diameter vessels over 48 hours. 
Left: Migration with standard EC medium, as a control. 
Right: Migration with EC medium supplemented with + 2µM Y27632 ROCK inhibitor. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
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Figure 3.10 Cell migration distance and rate in 1.5 mm diameter control vessels 
 
The distance and rate of HUVEC migration within empty 1.5 mm diameter vessels was 
measured. Migration rate decreased over 24 hours and, in comparison to standard EC growth 
medium, was reduced in the presence of a ROCK inhibitor. 
Flow of 1 Pa average wall shear stress. 
Mean with SD (n=3). 
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Figure 3.11 Cells in empty control tubes under static conditions 
 
HUVEC were seeded in model vessels and not attached to flow systems, to act as static 
controls. No migration of HUVEC monolayers (green line) beyond an initial seeding point 
(red line) was observed after 24 hours under static conditions (representative examples 
shown in A, B and C), with the exception of one sample (D). 
Scale bar: 0.5 mm. 
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Figure 3.12 Locating HUVEC using the NIGHTSEA fluorescence system 
 
Fluorescent staining was used in an attempt to better image HUVEC within model vessels. 
However, in both empty and stented vessels only areas of high cell density were visible 
under fluorescence, rendering the system unsuitable for tracking individual cells. 
Top: HUVEC monolayer within an empty vessel, under brightfield (left) and fluorescence 
(right). 
Bottom: HUVEC monolayer seeded up to a point (red line) within a flow diverter stent, 
under brightfield (left) and fluorescence (right). 
Scale bar: 0.5mm. 
The addition of both XG and dextran increased the viscosity of EC growth medium, 
enabling 1 Pa wall shear stress to be generated under more physiologically relevant 
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flow velocities. Higher concentrations of XG and dextran doubled and trebled 
viscosity respectively (Figures 3.13 and 3.14). Even so, while a plasma-equivalent 
viscosity of 1.5 mPa.s could be achieved, the thickest medium would still be less 
than half of the blood-equivalent 3.5 mPa.s at 37°C. The use of both thickening 
agents, in any concentration, also saw a decline in the number of live, attached cells 
after 72 hours of culture (Figure 3.15). 
 
3.4 Particle tracking set-up 
3.4.1 Flow patterns were revealed at blood-equivalent Reynolds number 
10 µm FluoSphere particles were suspended in room temperature 70% IMS and 
tracked through model vessels. Fluid density was 790 kg/m
3
 and dynamic viscosity 
0.00126 Pa.s at room temperature. Thus, the application of 6.5 ml/min (2 mm 
diameter vessel) and 12.8 ml/min flow (2.5 mm diameter vessel) gave Reynolds 
numbers of 43 and 68 respectively. This was equivalent to the Reynolds number of 
blood flow with 1 Pa wall shear stress within the same diameter. 
Under these conditions, particles could be clearly identified and tracked local to the 
vessel wall and stent struts where velocity was reduced. Fluorescence was not 
required to locate particles and could skew data by highlighting those deeper within 
the vessel, which would otherwise be out of focus. 
Figure 3.16 provides an example of the data obtained from particle tracking studies. 
As expected for empty control tubes, streamlines are parallel to flow. Tracks are 
evenly distributed across the vessel, as is the frequency of particles moving along 
them. 
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Figure 3.13 Viscosity of EC growth medium with dextran thickening agent 
 
The viscosity of EC growth medium containing dextran at various concentrations (w/v) was 
measured as the fluid cooled. The presence of dextran increased viscosity beyond that of 
standard EC growth medium. 
(n=1). 
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Figure 3.14 Viscosity of EC growth medium with XG thickening agent 
 
The viscosity of EC growth medium containing XG at various concentrations was measured 
as the fluid cooled. The presence of XG increased viscosity beyond that of standard EC 
growth medium. 
(n=1). 
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Figure 3.15 Live cell numbers in thickened EC growth medium 
 
HUVEC were cultured for 72 hours in well plates containing growth medium supplemented 
with various concentrations of dextran and XG. The addition of thickening agents at 
increasing concentrations reduced the numbers of live, viable cells in comparison to standard 
EC growth medium. 
Mean with SD (n=3). 
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Figure 3.16 Representative particle tracking data 
 
A particle suspension was pumped through an empty 2.5 mm diameter model vessel. A 
video recording was taken, from which individual particle motion was tracked.    
Top: Tracking revealed particles following streamlines (red: 1 particle per streamline, 
green: 2, blue: 3). 
Bottom: Heat map of particle density, illustrating the location of streamlines and the 
frequency of particles moving along them over a superimposed 100 µm grid. 
Flow from left to right, 12.8 ml/min. 
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3.4.2 Velocity and wall shear stress was not extracted from tracking data 
Particle tracking was used to visualise flow patterns only. Beyond the location of 
tracks, and the number of particles moving along them, no quantitative data was 
obtained due to a high probability of error. 
While image stacks were returned by the software at 20 fps, the frame rate of the 
original recordings varied and could not be manually controlled. Data was lost when 
converting from higher rates and frames were duplicated when converting from rates 
below 20 fps. Selecting every other frame for tracking mitigated this second issue but 
specific, regular time intervals with which to confidently calculate velocity could not 
be attained. The possibility of human error in manual tracking was also a factor 
(Figure 3.17A). This was further complicated by the fact that the manual tracking 
function in ImageJ would not return position data while simultaneously displaying 
previous tracks. This made the reliable tracking of hundreds of particles per field of 
view impossible. 
The ability to distinguish between changes in velocity magnitude and direction in 3D 
space is particularly important when tracking particles moving over and around stent 
struts. Therefore the use of 2D imaging was an additional problem, illustrated in 
Figure 3.17B, again preventing accurate velocimetry.  
 
3.4.3 Low particle accumulation was measured in empty models 
Following particle tracking, models were left for a total of 20 minutes under flow. 
The pump was then stopped and the models imaged to assess the accumulation of 
fluorescent particles to provide an empty vessel control for comparison to stented 
models. Briefly flushing the vessel with IMS beforehand removed any loose particles 
and ensured that this was not simply a measure of where particles lay once flow was 
arrested. 
Given the time under flow and the 150,000 particles present in the solution, the 
number of accumulated particles in empty control models was relatively low 
(Figure 3.18), suggesting migration to the centre of the vessel and regions of high 
velocity under Poiseuille flow. 
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Figure 3.17 Errors inherent in manual particle tracking 
 
A: Apparent particle velocity between points (bottom) varies with inconsistent selection of 
the particle’s location at each point along its path (top). 
B: Apparent velocity varies as 2D images do not account for out of plane movement. A 
particle moving over a stent strut and viewed from the side (upper path) has a constant 
velocity (blue line). However, when viewing the same particle from below (lower path), as 
per the particle tracking method used here, the out of plane motion causes apparent velocity 
to change (red line). 
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Figure 3.18 Particle accumulation in empty tubes 
 
Top: After 20 minutes, the flow of a particle suspension through a 2.5 mm diameter tube 
was arrested and the tube imaged under fluorescent light. From this image, the tube was 
divided into 1 mm sections and the number of accumulated fluorescent particles within each 
section was counted. 
Bottom: Particle count for an empty 2.5 mm tube after 20 minutes under flow (blue), an 
empty 2 mm tube after an equal amount of time (red), and the same 2 mm tube after an equal 
total volume of particle suspension (green). 
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3.5 In silico modelling 
µCT scanning was used as a means of reproducing in vitro vessels in silico for 
modelling and analysis. Three types of sample were assessed – model vessels, model 
vessels containing a contrast agent and PDMS casts of model vessels. Various 
scanning and reconstruction parameters were applied in each case in an effort to find 
and optimise the best method of accurately capturing model geometry. Scan 
resolution as high as 3 µm/pixel was used to obtain high quality data for final 
models, and as low as 17 µm/pixel in rapid trials. 
 
3.5.1 µCT scanning of model vessels does not capture both stent and wall 
Stents are radiopaque due to the high x-ray attenuation of their metallic struts. 
Therefore, they could clearly be seen during µCT scanning and were easily isolated 
during reconstruction. However, optimising reconstruction parameters for stents 
rendered the wall invisible. PDMS is relatively radiotransparent and lower power 
was required to visualise the vessel. This increased sensitivity and the widened DIR 
required to reconstruct both materials resulted in noise and large image artefacts. In 
effect, the x-ray bright stents were ‘overexposed’ and obliterated the wall 
(Figure 3.19). 
A high-resolution µCT scan of a coronary stent was performed and a dataset of 
images was reconstructed, optimised to obtain stent geometry only. This was 
provided to collaborators, Amanda Inzoli and Silvia Bonardelli (Politecnico di 
Milano, Italy), for the application of the FE wall method described in Section 1.6.6. 
A model was successfully created and used to perform CFD analysis and assess wall 
shear stress along the vessel. However, key information was lost with the omission of 
the PDMS wall. In this particular example the in vitro stent was slightly under 
expanded. The FE wall was therefore able to constrict further before being arrested 
by stent structure and the diameter of the resultant in silico model was too low. 
Applying the same flow conditions as those used in vitro returned an average wall 
shear stress approximately 50% higher than that expected (Figure 3.20). 
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Figure 3.19 Preview cross-sections of µCT reconstruction 
 
Following µCT scans of stents, cross-section previews allowed reconstruction parameters to 
be changed. Adjusting the DIR both altered the apparent geometry of structures and 
introduced interference. (Negative images are presented for clarity). 
A: Image optimised for stent, producing thin struts (52539.6 – 76750.3 HU). 
B: Image optimised for stent, producing thick struts (-138.2 – 32643.9 HU). 
C: Altering the DIR so that PDMS becomes visible renders the vessel wall indefinable due 
to increased interference (-7275.0 – 11239.0 HU). 
C 
A B 
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Figure 3.20 Wall shear stress distribution from CFD analysis using an FE wall 
 
µCT data from a Coroflex Blue coronary stent was reconstructed to create a 3D model. The 
vessel wall was recreated in silico, by collapsing a model wall around the stent. The over-
contraction of the model wall resulted in a higher average wall shear stress than that applied 
in vitro (1 Pa). Wall shear stress magnitude and distribution was also altered as apparent strut 
size (S) increased in models created from reconstructions with altered DIR. 
Image courtesy of Amanda Inzoli and Sylvia Bonardelli (Politecnico di Milano, Italy). 
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3.5.2 Stent struts could not be accurately reconstructed from µCT data 
An additional complication to that in described in Section 3.5.1 was the variation of 
strut dimensions with applied µCT and reconstruction parameters. For example, 
when altering the DIR for reconstruction, the apparent strut size changed (visible in 
Figure 3.19). Struts would appear thicker as the DIR was widened, with their true 
diameter at an unknown point in the range (a similar problem was encountered again 
when thresholding the images for conversion to binary format). In extreme examples, 
particularly seen in flow diverter stents, thinner struts disappeared entirely. Any 
attempt to capture them during the µCT reconstruction process resulted in the same 
interference that obscured the PDMS wall.  
The effect of this issue is shown in Figure 3.20. Each case represents the same source 
µCT data, with various reconstruction ranges applied to produce three different 
apparent strut sizes. A clear effect on wall shear stress magnitude and distribution 
can be seen (in this example the effect is pronounced further by thicker struts altering 
the collapse of the FE wall around the stent). 
A small strut section was scanned at high resolution and measured as precisely as 
possible in an attempt to calibrate the DIR and reduce this error. Difficulties in 
accurately measuring stent struts have already been described in Section 3.2.2. 
Figure 3.20 shows that a change of only 6 µm represents a 10% increase in strut size. 
Furthermore, identical reconstruction parameters affected different stents to varying 
degrees. Table 3.2 shows the impact of DIR on the total strut volume of four stents. 
Compared to reconstruction at mid-range DIR, volume increase at high range varied 
between 0.5% and 13%, whereas volume loss at low range varied between 62% and 
90%. These differences may arise from dissimilar materials’ x-ray attenuation, or 
from the different amounts of metal present in each stent design, necessitating 
calibration on a stent-by-stent basis. 
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Stent material 
Stent length 
(mm) 
Stent volume (mm
3
) 
Narrow range Mid-range Wide range 
F562 cobalt 
chromium 
10 
0.73 
(-66%) 
2.14 
2.42 
(+13%) 
L605 cobalt 
chromium 
8 
0.47 
(-62%) 
1.24 
1.40 
(+13%) 
MP35N cobalt 
chromium 
9 
0.36 
(-74%) 
1.41 
1.51 
(+7%) 
316L stainless 
steel 
8 
0.20 
(-90%) 
1.94 
1.95 
(+0.5%) 
 
Table 3.2 Apparent stent volume varying with DIR 
 
During µCT reconstruction apparent strut diameter, and therefore the volume of the final 
model stent, varied with DIR parameters. Narrowing the DIR decreased apparent volume in 
comparison to a mid-range, whereas widening the DIR gained volume. Applying the same 
DIR parameters to coronary stents of different length and material resulted in large 
differences in apparent volume variation between them. Thus, DIR could not be standardised 
to ensure the faithful reconstruction of accurate stent geometry in every case. 
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3.5.3 A contrast agent did not sufficiently define the wall 
Model vessels were scanned with a 60% barium sulphate suspension within the 
lumen. This suspension was used to act as a contrast agent, as it had higher x-ray 
attenuation than PDMS and was relatively radiopaque. It was hoped that, unlike 
PDMS, this agent would remain visible while µCT power was increased and DIR 
was narrowed to optimise for stents. This would provide a clear definition between 
stent struts (in white, at the upper end of the image range), PDMS (in black, outside 
of the image range), and the contrast agent (at a greyscale intensity within the range). 
This would allow struts to be isolated and subtracted from the image, resulting in the 
contrast agent alone describing the shape of the fluid volume.  
However, the 60% barium sulphate suspension was highly viscous and therefore it 
was difficult to ensure that every part of the lumen was filled, particularly around 
intricate stent geometry, and gaps were only revealed once the model had been 
scanned. The contrast agent was more visible under x-ray than PDMS, but was still 
too radiotransparent relative to metallic stents and the required sensitivity again 
resulted in noise and artefacts. Although this interference was less pronounced in 
comparison to scans taken without a contrast agent, and large segments of wall could 
be defined, image stacks still required extensive manual editing to remove 
interference and repair sections. 
Figure 3.21 illustrates the process required to obtain a final in silico model from µCT 
data using a contrast agent. While some image slices were relatively intact, others 
required 25% of the wall replacing. In the final model, 6% of the total vessel wall 
was manually recreated, all local to stent struts where accurate geometry was most 
essential. In addition, this process was aided by reconstructing and overlaying the 
stent alone, which raised the same issue regarding true strut dimensions described in 
Section 3.5.2. 
 
 
 
 
 
120 
 
 
 
Figure 3.21 Model reconstruction process from µCT data using a contrast agent 
 
A µCT scan of an XTRM-Track coronary stent was performed with a contrast agent within 
the lumen and image reconstruction performed on cross-section slices (left) to create a 3D in 
silico model (right). 
A: Post-reconstruction, the contrast agent provided a visible, but poorly defined wall/lumen 
boundary. 
B: Attempting to visualise this boundary resulted in interference and distorted geometry. 
C: Overlaying separately reconstructed stent geometry (red) onto the wall (blue) highlighted 
areas of interference, which could be removed. 
D: Areas of missing wall were replaced (yellow) using information from neighbouring 
image slices. 
 
A 
B 
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3.5.4 PDMS casting reproduced stented vessel geometry in vitro 
Casts were created by silanising model vessels and filling the lumen with additional 
PDMS. As the model no longer needed to be biocompatible at this point, the PDMS 
could be left for as long as required to fully cure at room temperature, preventing any 
shrinkage. Casts could be cleanly separated from the model. For coronary stents, the 
tip of a needle was used to pry a single strut away from the cast. Severing this with a 
scalpel allowed adjoining struts to be carefully pulled away and the entire stent was 
removed in this manner. 5:1 and 10:1 PDMS mixing ratios were trialled, with 5:1 
providing more favourable results (Figure 3.22). It is likely that the lower viscosity 
of 5:1 PDMS when fluid, and higher stiffness when cured, helped to fill and capture 
fine geometry. 
Any coronary stent struts which were prolapsed into the lumen had to be pulled 
through the cast. The PDMS around these struts returned to its original position once 
they were removed, and cast geometry was preserved. However, as all flow diverter 
stent struts lay adjacent to the wall, the same technique could not be applied 
(Figure 3.23). For these models the cast and stent were cut at each end and struts 
pulled out longitudinally through the lumen. 
 
3.5.5 PDMS cast geometry was accurately reproduced in silico 
The use of homogenous PDMS casts ensured that µCT scan and reconstruction 
parameters could be optimised for a single material, eliminating the issues found in 
Sections 3.5.1. The effect on apparent size was also greatly reduced, confirmed by 
creating and scanning PDMS samples of known size. Settings could therefore be 
applied to provide a steep, well defined boundary in greyscale intensity for 
reconstruction and thresholding, with no effect on the dimensions of the model.   
Fine structural details were visible, including intact voids representing prolapsed 
struts. This simple process resulted in accurate reproductions of cast geometry and a 
vast reduction in effort required to prepare the in silico models for meshing 
(Figure 3.24). Rigid body registration of in silico models of stents and their resultant 
casts was performed in Amira (FEI), resulting in good alignment of the two (Figure 
3.25). 
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Figure 3.22 PDMS casts of coronary stents 
 
PDMS was cured within the lumen of model vessels containing coronary stents, which were 
then removed to create casts for µCT scanning. The use of different PDMS mixing ratios 
was assessed to ensure the accuracy of casts. Casting with a 10:1 ratio resulted in poorly 
defined struts and damage within complex geometry (red boxes). Stiffer, more damage 
resistant PDMS with a 5:1 ratio resulted in a much cleaner, well-defined cast. 
A: Cast of a Pro Kinetic Energy coronary stent, 10:1 ratio. 
B: Cast of a Pro Kinetic Energy coronary stent, 5:1 ratio. 
C: Cast of a Velocity coronary stent, 10:1 ratio. 
D: Cast of a Velocity coronary stent, 5:1 ratio. 
Scale bar: 0.5 mm. 
A B 
C D 
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Figure 3.23 PDMS casts of flow diverter stents 
 
PDMS was cured within the lumen of 2 mm diameter model vessels containing Silk flow 
diverter stents, which were then removed to create casts for µCT scanning. In flow diverter 
stents PDMS was able to fill gaps between the wall and the struts which lay adjacent to it, 
hindering the removal of a clean cast. 
A: Pulling struts away from the cast through the wall destroyed the surface. 
B: Pulling struts out of the lumen from either end of the stent protected the wall from 
damage and preserved fine details.  
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Figure 3.24 Reconstructed µCT data of a stent cast in PDMS 
 
The use of PDMS casts of model vessels provided µCT scan data of accurately sized 
geometry and captured fine stent strut detail, including prolapsed struts (red arrow). 
A: Optimising µCT scan and reconstruction parameters for homogeneous PDMS casts 
produced an image of the lumen with a clearly defined wall boundary. 
B: Cutaway of a section of wall boundary reconstructed from a 9.92 µm resolution scan of a 
Coroflex Blue coronary stent cast. 
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Figure 3.25 Image registration of a stent and associated cast 
 
Rigid body registration was performed on models of a Coroflex Blue coronary stent and its 
associated cast, reconstructed from data from separate µCT scans. The two were aligned in 
an effort to measure the ability of casts to recreate the geometry of stents.  
A: Reconstructed Coroflex Blue stent model. 
B: Reconstructed Coroflex Blue cast model. 
C: Rigid body registration between stent and cast models. 
Inset: Although good alignment was found between stents and casts, this was a measure of 
orientation and did not take apparent strut size into account. The struts of varying thickness 
illustrated here (grey) would all be considered to be equally well aligned with the same cast 
(yellow). 
A B 
C 
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3.5.6 Computational fluid dynamics models were created from µCT data 
All models were successfully meshed in ScanIP and the simplicity of the software 
offset a relative lack of user control in comparison to ANSYS packages. No 
smoothing was applied at any stage as this process had too great an impact on 
smaller struts. The lack of smoothing rendered data from particularly low resolution 
µCT scans unusable as large voxels formed a stepwise geometry. 
Meshing and FLUENT set-up variables were informed by residual analysis and grid 
independence studies performed by Amanda Inzoli and Silvia Bonardelli (Politecnico 
di Milano, Italy), on CFD models as mentioned in Section 3.5.1. Computational cost 
was balanced against the accuracy of results and the ability to confidently compare 
data from separate models. Stability in their model was achieved with convergence 
criterion of 10
-6
 and a mesh of ≥2 million elements, and these factors were applied 
here. 
 
3.6 Discussion 
Chapter 2 presented a method for the fabrication of an in vitro model vessel, and 
protocols for stent deployment, cell migration studies, particle tracking, and in silico 
geometry reconstruction and analysis. This chapter considered the choice of those 
techniques and the necessary materials, equipment and means of image and data 
analysis. In order to directly compare coronary and flow diverter stents the same 
model and conditions were applied in both. Therefore, the properties discussed in 
Section 1.7 and replicated in the sections which followed were those of the coronary 
arteries only. This decision was made based upon the number of available stents of 
each type, the information available in the literature and the conditions applied in 
comparable work in-group. 
 
In order to fabricate an in vitro model vessel, a reliable value for EC growth medium 
viscosity was vital. Firstly, this improved the accuracy of the model as using the EC 
growth medium described in Section 2.2.2.1 while applying pre-existing viscosity 
data from the literature, for example 0.7 mPa.s or 1.0 mPa.s [141][154], would result 
in wall shear stress being under and over estimated by 12% and 25% respectively. 
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Secondly, because wall shear stress is inversely proportional to the cube of the vessel 
radius, flow rates required to generate specific magnitudes of the force increased 
rapidly with vessel size. Therefore, understanding EC growth medium fluid 
properties was particularly important as, in larger models, Reynolds number can 
increase above 2000 and flow begins to transition from laminar to turbulent. Indeed, 
testing wider coronary stents, or modelling larger artery diameters or higher shear 
stress levels [125][154], would induce fully turbulent flow. Overestimating viscosity, 
and therefore underestimating Reynolds number, could result in flow entering an 
entirely different regime than that assumed, thereby invalidating the model. 
The viscosity data therefore put an upper limit on vessel size and applied wall shear 
stress, and is one of the reasons why the use of medium thickening agents was 
considered [156]. Thickening agents would also tackle one of the drawbacks of the 
majority of in vitro models: the fact that fluid properties cannot be completely 
matched to those in vivo. Studying wall shear stress with media rather than blood, for 
example, means that fluid velocity and Reynolds number are much higher than 
measured physiological levels (Section 1.7). Subsequently, any effort to understand 
the impact of varying those variables would, in turn, lead to altered wall shear stress. 
The use of a full-scale model vessel already reduced the disparity between in vitro 
and in vivo conditions compared to microfluidic parallel plate experiments 
[147][153][154], and the addition of thickening agents would allow all physiological 
flow properties to be met. However, the use of dextran and XG were not further 
evaluated due to their detrimental effect on HUVEC. This was unexpected as 
previous studies have successfully used similar concentrations in flow 
experiments [147]. Other options were available, including the use of higher 
molecular weight dextran which could be utilised in smaller quantities [200]. 
However, thickening agents would render any data from cell experiments 
incomparable to the bulk of work done with standard EC growth medium and would 
introduce additional variables, due to the potential effects of osmolality and glucose 
concentration on cell metabolism and behaviour [157]. 
The comparison between vessels of different size also presented a challenge. 
Changing diameter not only resulted in different fluid flow variables, but also 
required the use of different pump systems. Peristaltic pumps, by their nature, 
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produce a pulse which could potentially induce not only unsteady flow but also the 
mechanical forces described in Section 1.4.1. This pulse, and its effects, would 
change with pump power (and is not present at all in the ibidi pressure pump 
system). To reduce any disparity in pulse frequency, tubing size was carefully 
selected so that the power required by 2 mm and 2.5 mm models was as similar as 
possible. 2 mm diameter models were connected to tubing of 3.1 mm inner 
diameter (ID) and required 53% pump power to generate 1 Pa average wall shear 
stress. 2.5 mm models were connected to 4.8 mm ID tubing and required 57% pump 
power. Factoring in maximum power rpm and the number of rollers in the pump 
head, this resulted in 636 and 684 pulses per minute (or 10.6 and 11.4 Hz 
respectively). To then minimise the amplitude of these pulses, soft silicone tubing 
and the air pocket within the reservoir acted as dampeners. This is estimated to 
reduce pulsation by up to 90% [201]. Indeed, by observing the flow of particles or 
debris, no pulsation could be seen under any flow conditions. 
 
PDMS was chosen to be used to create in vitro vessel walls due to its ease of use, 
transparency, relative biocompatibility and compliancy, in spite of its many 
disadvantages (discussed in Section 1.6.2). While alternative materials such as PTFE 
and PMMA are too stiff, PDMS was well suited to stent deployment [130][133]. The 
values of elastic modulus seen with different mixing ratios were within the 
physiological ranges found in the literature (Section 1.7.1). A ratio of 10:1 was 
selected for use in the model due to its similarity to arterial tissue and the increased 
biocompatibility of that ratio [138]. 
When making comparisons to arterial tissue, the elastic modulus of PDMS was 
measured as it was observed that, rather than penetrating or indenting the vessel, 
stents pushed against it and caused widening (Figure 3.4), leading to hoop stress and 
radial compression in the wall. An example of stent deployment was inspected by Dr. 
Ana Paula Narata (INSERM U930, France) and was considered to be acceptable. 
This important check confirmed that experiments were not performed on models 
which were not representative of in vivo deployment, for example causing stents to 
be excessively embedded into the wall, or too far prolapsed into the lumen. 
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While human coronary artery endothelial cells (HCAEC) are commercially available, 
and the coronary arteries were being modelled here, HUVEC were selected for use in 
cell migration studies due to their frequent supply from the Jessop Wing maternity 
unit, Sheffield. The demonstration of arterial-like characteristics by EC, described in 
Section 1.6.2, has been found in literature to require 24 hours’ exposure to arterial 
mechanical conditions [144]. As this was the typical duration of experiments in this 
work, it cannot be assumed that such a change took place in the cells under 
observation here. Nonetheless, the use of HUVEC was deemed satisfactory given the 
other arguments made in Section 1.6.2. One disadvantage to PDMS was the 
requirement of a fibronectin coating for successful HUVEC attachment, as this 
necessary step prevented repeat experiments being performed on the same models. 
Applying fibronectin prior to stent deployment ensured that cell migration data was 
reliable. However, this would not hold true once a second coating was applied prior 
to a follow-up experiment as stent struts would also be coated and would therefore 
present a more favourable surface for HUVEC. 
Rotating the vessel during attachment, to enable HUVEC to attach around the full 
circumference of the wall [107], was considered but ultimately not attempted to 
avoid further complicating the protocol. It was thought that seeding onto the lower 
surface of the vessel only would allow HUVEC migration to be influenced not only 
by stent geometry, but also by empty space around the cells that would not normally 
be available to them. This proved not to be the case: monolayer leading edges 
remained relatively uniform while the area occupied by individual leader cells tended 
to narrow as migration distance increased. This result was unexpected and not 
previously mentioned in literature (the experiments discussed in Section 1.6.4 and 
Table 1.2 were not designed to study cell migration in vessels of circular cross-
section). However, this finding could be due to one or more limitations of the model: 
the use of relatively low cell numbers, a lack of cell proliferation over the duration of 
the experiment, or simply the migration of cells outside of the limited surface area 
within the microscope focal plane. 
To accurately measure cell migration an initial position had to be identified. Cells 
were therefore seeded partway along the model to create a clear boundary between 
attached HUVEC and empty vessel wall. This was necessary as HUVEC attached too 
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well to be damaged by stent deployment (Figure 3.6). Even after the high-pressure 
balloon expansion of coronary stents, or the scraping of flow diverter sheaths, too 
many cells remained within the stent to consider the vessel de-endothelialised and to 
enable migration to be monitored. Previous in vivo studies have also reported this 
problem, discussed in Section 1.6.1 and further in Chapter 6 [103][122]. The 
straightest, most well-defined boundaries of cell attachment were used where 
possible, as this enabled the most accurate placement of stents. This reduced the time 
taken for cells to migrate to stents’ leading edges (the region of interest) during 
experiments. 
 
Clear cell migration under flow was seen in empty control models (Figure 3.7). 
Migration rates were higher than the 0.01 – 0.02 mm/h under similar conditions 
found in literature [95][127]. However, those studies were examples of microfluidic 
systems and, accordingly, migration rate reduced with model diameter here 
(Figure 3.8). Cell migration studies were also performed with the use of a ROCK 
inhibitor (Section 2.2.2.3) to highlight the impact of disturbed flow on HUVEC. 
Reduced migration was seen with the use of a ROCK inhibitor in comparison to 
standard un-supplemented medium. Although ROCK inhibitors have been shown to 
enhance HUVEC migration and accumulation within stents by allowing cells to 
migrate within areas of complex bi-directional flow (Section 1.4.4) [103], this 
advantage is redundant under the steady, unidirectional flow conditions applied here. 
The complete inhibition of ROCK can prevent cell migration [104][202], but due to 
the variability between individual experiments it cannot be stated that any reduction 
in migration seen here is due to the presence of the inhibitor. 
A number of unused models provided a large sample of static controls. None showed 
migration, or no more than that seen in standard static culture as cells spread, except 
one. This lone example of migration under static conditions, clearly identified against 
marks on the PDMS (Figure 3.11D), is puzzling. Although some small degree of cell 
migration under static conditions has been seen in previous studies (50 – 
70 µm [95]), the 800 µm found in Figure 3.11D is comparable to that in some 
experiments under flow (Figure 3.8). While it is possible that the model was 
disturbed during attachment, the initial image at t = 0 was taken after the vessel was 
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flushed. Images of the other side of the monolayer were not taken as per the 
experimental protocol. If extra images had been taken, apparent migration may have 
been seen in that direction also, in which case this single example could have been 
due to a particularly fast growing (and spreading) culture. 
A maximum experiment duration of 72 hours was possible with the peristaltic pump, 
however the majority of experiments did not last this long. Experiments were 
typically stopped between 24 hours (the minimum duration to define an experiment 
as successful, comparable to those in the literature listed in Table 1.2) and 48 hours 
due to excessive wear on the tubing caused by the action of the pump rollers. With 
no moving mechanical parts, the ibidi system could run for longer periods. Although 
its reservoirs were relatively small, unlike the peristaltic pump system they could 
easily be replenished with fresh medium. 
 
Although particle tracking in in vitro models is typically performed for 
velocimetry [203][204], it was conducted here as a simple means of visualising flow. 
This became more pertinent as it became clear that the most viable methods of 
successfully recreating model geometry in silico for more powerful CFD analysis 
(casting), would be destructive. Therefore, flow data would otherwise only be 
available at the model’s end of life and dependent on successful in silico modelling. 
Particle tracking also allowed the accumulation of bodies with similar size to EPC to 
be studied. 
IMS was used as the particle suspension’s fluid phase because, compared to water, it 
greatly reduced the frequency at which bubbles formed and attached to struts. IMS 
therefore minimised their impact on particle motion. As particles were only visible at 
very low flow rates, similitude was applied to enable the use of a less viscous fluid 
while maintaining a physiologically relevant parameter in the Reynolds number. 
Equating Reynolds number to that of blood allowed a sufficient reduction in velocity, 
yet meant that particle tracking and accumulation data could not be directly 
compared to cell migration or CFD data, as those specific conditions were not 
simulated. However, tracking data from different stents could still be compared and 
contrasted, allowing any influence of differing geometry to be investigated. 
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µCT scanning was found to be a good method of converting in vitro geometry into in 
silico models, though the processes involved in this conversion had some 
disadvantages. For example, scanned samples interfered with each other and required 
scanning individually. Orienting models vertically ensured constant x-ray absorption 
throughout their rotation but meant that the models were often outside of the field of 
view and therefore required multiple scans. These factors presented the greatest 
drawback of µCT scanning: high time and resource cost, especially when scanning at 
higher, usable resolutions. 
If time and expense were not a factor, more comprehensive parametric studies could 
have been carried out to properly assess the impact of scan parameters on the final 
model. In particular, investigating resolution would have been of interest. 
Specifically, if there was a maximum useful resolution beyond which any 
improvement (and associated costs) conferred no advantage to the accuracy of the 
final model and CFD simulation. 
 
Post-scan, the FE wall recreation method removed the need to extract low-intensity 
materials and parameters could be optimised for individual stents. The problems 
inherent in this method have already been discussed in Section 3.5.1. As the main 
aim was to faithfully replicate in vitro model geometry, the use of a technique in 
which the entire wall is created virtually was not appropriate [162]. However, an 
argument can be made that no other method is a truly faithful model, when 
considering the compounded impact of scanning (power and resolution), 
reconstruction (DIR), modelling (binary thresholding, smoothing), CFD analysis 
(meshing) and, in this case, casting. 
The use of a contrast agent as a means of better identifying the vessel wall during 
µCT reconstruction was not continued. The original description of the method in the 
literature stated that some image editing was required, however the level of effort 
required to obtain a model of relatively low quality was under-estimated [133]. 
It was found that µCT scanning and reconstruction most accurately reproduced the 
geometry of PDMS casts and this method was therefore pursued. The important next 
step was to ascertain how accurately casts reproduced the geometry of stented 
vessels. Empty vessels and their resultant casts could be compared with ease. The 
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presence of a silane film did not have a measurable impact given the <75 nm 
thickness of the deposition layer [205], nor was it detectable at the µCT resolutions 
used. Physically measuring intricate stent geometry and the associated sections on 
casts was problematic, therefore reconstructed in silico models were aligned via rigid 
body registration. Visually, this method returned a good result (Figure 3.25) and the 
software could provide a measure of alignment, however it was not known where 
this value lay on a scale from bad to perfect alignment. In addition, alignment was a 
measure of position and direction and did not necessarily signify a tight fit 
(Figure 3.25, inset). A more precise, quantifiable measure of fit could be made 
possible by comparing the stent to a model of the voids the stent struts left in the 
cast, with the software then able to minimise the difference between the two. This 
would require accurate strut dimensions to size the model stent and to identify the 
full volume of voids residing on the exterior of the cast. The problem is therefore 
circular: casts had to be used as stent geometry could not be accurately reproduced; 
yet the precision of such casts could not be definitively proven without the use of 
accurate stent geometry. 
 
The methods and protocols outlined in Chapter 2, and discussed in this chapter, 
describe the development of a novel model vessel and combined in vitro and in silico 
evaluation, suitable for the study of the impact of stent geometry on local wall shear 
stress and endothelial cell migration. The following chapters consider the application 
of this experimental platform in the assessment of a range of commercially available, 
clinical-grade coronary and flow diverter stents. 
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Chapter Four 
4 In Vitro and In Silico Study of Coronary Stent 
Haemodynamics and Cell Migration 
 
The regrowth of a healthy endothelial layer is hindered by EC dysfunction caused, at 
least in part, by the presence of cardiovascular stents and their effect on local wall 
shear stress (Sections 1.4 and 1.5). Chapters 2 and 3 considered the creation of an 
experimental platform through which the biomechanical conditions of stented vessels 
could be studied. This chapter concerns the application of that platform to a range of 
clinical-grade coronary stents, enabling the assessment of the effect of diverse stent 
geometry on wall shear stress modification, and its subsequent impact on endothelial 
cell behaviour. 
 
4.1 Coronary stent deployment 
4.1.1 Coronary stent geometry showed great variability 
Ten different coronary stent designs were made available by Prof. Julian Gunn 
(Department of Infection, Immunity and Cardiovascular Disease, University of 
Sheffield). These were deployed within in vitro model vessels of 1.5 and 2.5 mm 
diameter, as discussed in Chapter 3. All were of the ‘slotted tube’ type, meaning that 
they were laser cut and therefore had square cross-section and 90° edge angle. 
Coronary stents were manufactured from a variety of materials and, in general, 
showed a wide range of distinct strut sizes, MSA and strut orientation (Table 4.1 and 
Figure 4.1, based on analysis detailed in Figure 2.3). Exceptions were: 
 The Orsiro, a drug-eluting version of the Pro Kinetic Energy with identical 
geometry. 
 The Penchant, with identical geometry to the BiodivYsio OC (the difference 
in trademark being related to the stent delivery system). 
 The Coroflex Blue Neo, an updated version of the Coroflex Blue, with 
reduced strut thickness. 
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Table 4.1 Properties of coronary stents 
 
Only coronary stents of 3 mm nominal diameter were deployed within 2.5 mm model 
vessels, although the length of those stents varied. 
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Table 4.1 (cont.) Properties of coronary stents 
 
Only coronary stents of 3 mm nominal diameter were deployed within 2.5 mm model 
vessels, although the length of those stents varied. 
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Figure 4.1 Coronary stent strut orientation 
 
The orientation of coronary stent struts was measured in relation to the direction of applied 
flow (0°), as illustrated in Figure 2.3. The length of struts at each angle (to the nearest 10°) is 
shown here as a percentage of the total strut length. Each chart represents an average 
measurement taken from two faces of each stent (rotating the stent 90° between the two) and 
one repeating unit of stent geometry. 
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Figure 4.1 (cont.) Coronary stent strut orientation 
 
The orientation of coronary stent struts was measured in relation to the direction of applied 
flow (0°), as illustrated in Figure 2.3. The length of struts at each angle (to the nearest 10°) is 
shown here as a percentage of the total strut length. Each chart represents an average 
measurement taken from two faces of each stent (rotating the stent 90° between the two) and 
one repeating unit of stent geometry. 
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4.1.2 Deployment showed slight variation between coronary stents 
As mentioned in Section 3.2.2, there was slight variation in the geometry of stent 
structure even after deployment of examples of the same design. This variability 
could arise from the orientation of the folded stent during delivery, the application of 
pressure to the balloon, or perhaps small differences in the PDMS wall. These 
variations included strut prolapse and under-expansion (Figure 4.2), all of which 
could influence flow patterns to some degree. The extent of this variability was 
somewhat limited by following correct deployment procedures and by using stents of 
appropriate nominal diameter. 
 
4.2 Coronary stent geometry influenced flow patterns 
4.2.1 Coronary stent geometry influenced streamline orientation 
Particle tracking revealed the impact of the presence of coronary stents on local flow 
patterns and the disparity in this impact between stent designs. Streamlines through 
coronary stents are shown in Figures 4.3 – 4.7 (for clarity, representative areas are 
presented here and streamlines through the full stents are provided in the Appendix). 
Over the full length of stents there was good agreement between the two sequences 
taken in each field of view and clear streamline patterns followed from one field of 
view to the next. Observing more closely, in sections of complex geometry and 
immediately up and downstream of struts, areas of reversed flow, recirculation and 
stagnation were identified (Figure 4.8). 
Stents were seen to have a large effect on track orientation, as particles would 
typically follow struts for some distance before crossing them and returning to a 
longitudinal path. The impact of stent design on flow direction, and therefore on the 
direction of mechanical cues, was quantified by calculating the percentage of tracks 
that deviated from a path within ±5° of the direction of applied flow (Figure 4.9). 
This threshold was applied to ensure that stent-induced flow deviation was captured 
while minor deviations, due to equipment disturbance or manual tracking errors, 
were omitted.  
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Figure 4.2 Under expanded coronary stent geometry 
 
Each individual stent deployment produced variations in geometry, even between stents of 
identical design. Segments could under or over expand during balloon inflation, leading to 
small changes in strut position and orientation. In this example, an under expanded Coroflex 
Blue bridge strut remained in contact with a main ring strut, creating a small enclosed region. 
Scale bar: 100 µm. 
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Figure 4.3 Tracked particle streamlines in BiodivYsio OC and Chroma 
coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. Tracking was performed for two 30-second long sequences (red and blue tracks) on 
two stent faces, with the stent rotated by 90° between the two faces. 
Top: BiodivYsio OC stent. 
Bottom: Chroma stent. 
Flow from left to right, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
Representative images are mid-stent length and the plane of focus on the bottom of the 
vessel. 
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Figure 4.4 Tracked particle streamlines in Coroflex Blue and Coroflex Blue Neo 
coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. Tracking was performed for two 30-second long sequences (red and blue tracks) on 
two stent faces, with the stent rotated by 90° between the two faces. 
Top: Coroflex Blue stent. 
Bottom: Coroflex Blue Neo stent. 
Flow from left to right, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
Representative images are mid-stent length and the plane of focus on the bottom of the 
vessel. 
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Figure 4.5 Tracked particle streamlines in Matrix and Orsiro coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. Tracking was performed for two 30-second long sequences (red and blue tracks) on 
two stent faces, with the stent rotated by 90° between the two faces. 
Top: Matrix stent. 
Bottom: Orsiro stent. 
Flow from left to right, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
Representative images are mid-stent length and the plane of focus on the bottom of the 
vessel. 
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Figure 4.6 Tracked particle streamlines in Penchant and Pro Kinetic Energy 
coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. Tracking was performed for two 30-second long sequences (red and blue tracks) on 
two stent faces, with the stent rotated by 90° between the two faces. 
Top: Penchant stent. 
Bottom: Pro Kinetic Energy stent. 
Flow from left to right, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
Representative images are mid-stent length and the plane of focus on the bottom of the 
vessel. 
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Figure 4.7 Tracked particle streamlines in Velocity and XTRM-Track coronary 
stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. Tracking was performed for two 30-second long sequences (red and blue tracks) on 
two stent faces, with the stent rotated by 90° between the two faces. 
Top: Velocity stent. 
Bottom: XTRM-Track stent. 
Flow from left to right, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
Representative images are mid-stent length and the plane of focus on the bottom of the 
vessel. 
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Figure 4.8 Complex flow within coronary stent geometry 
 
Particle tracking revealed areas of complex flow patterns local to struts within coronary stent 
geometry. 
A: Recirculation seen within a valley structure of a Coroflex Blue stent. 
B: Flow reversal seen between Coroflex Blue main ring and bridge struts. 
C: Flow reversal and recirculation seen within a bridge strut of a BiodivYsio OC stent. 
Flow from left to right, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
Scale bar: 100 µm. 
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Figure 4.9 Particle track orientation in coronary stents 
 
The orientation of tracked particle streamlines moving through coronary stents deployed 
within 2.5 mm diameter vessels was measured to quantify the impact of stent design on the 
direction of flow and, therefore, the direction of mechanical cues cells would be exposed to. 
The length of tracks at an angle greater than ±5° of the direction of flow (0°) is shown as a 
percentage of the total length of tracks within each stent. This threshold was applied to 
ensure that stent-induced flow deviation was captured while minor deviations, due to 
equipment disturbance or manual tracking errors, were omitted. As there is variation in stent 
geometry and strut orientation, so too is there variation in particle track orientation between 
the various commercially available stents. 
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Figure 4.10 shows the percentage of tracks deviating from ±5° flow direction varying 
with the angle of stent struts, and strut thickness. There is no clear relationship 
between either. For example, the greatest deviation was seen in the Velocity, 
Coroflex Blue Neo, and XTRM-Track stents, with over 50% of tracked particles 
deviating from ±5° flow direction in each. However, these three stents represent the 
full range of mode strut angles (40, 30 and 10° respectively). In addition, the 
Velocity had the thickest struts (130 µm), whereas the Coroflex Blue Neo had the 
thinnest (60 µm). After investigating averaged orientation, the percentage of tracks 
deviating from ±5° of flow for separate faces of each stent was assessed (Figure 
4.11), with the stents rotated by 90° between faces. Stent geometry repeats 
circumferentially, yet each face presents a different alignment of this repeating 
pattern. As such, while differences in track orientation between faces were present, 
they were ≤10% for all stents except the Coroflex Blue Neo.  
 
4.2.2 Coronary stent geometry influenced tracked particle density 
Controlling for stent length, the total number of particles tracked in Section 4.2.1 
varied between 32 per field of view (BiodivYsio OC and Penchant stents) and 95 per 
field of view (Matrix stent). Figures 4.12 – 4.16 show the distribution of moving 
particles, displaying track paths and the frequency of particles moving along each 
one as a percentage of the total. All coronary stents showed wide areas of zero or low 
frequency as particles tended to follow common streamlines and were funnelled or 
concentrated by the peak and valley structure. Similar patterns were observed on 
both faces of each stent and between models of identical geometry, with the 
exception of slightly higher particle concentration in the Pro Kinetic Energy stent 
compared to the Orsiro. 
The degree to which different stents funnelled particles is shown in Figure 4.17. 
Areas of zero frequency increased with stent length. Rather than an effect of the 
stents themselves, this was simply due to the number of tracked particles decreasing 
over the time taken to record longer stents. As such, the shortest example was 
identified (the Velocity stent, with 72 columns in the 100 µm grid) and in obtaining 
the data for Figure 4.17 the remaining stents were only considered up to that same 
point, equating both length and time under flow. 
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Figure 4.10 Particle track orientation and coronary stent geometry 
 
The orientation of tracked particle streamlines moving through coronary stents deployed 
within 2.5 mm diameter vessels was measured to quantify the impact of stent design on the 
direction of flow and, therefore, the direction of mechanical cues cells would be exposed to. 
The length of tracks at an angle greater than ±5° of the direction of flow (0°), as a percentage 
of the total length of tracks within each stent, is shown against stent geometry. There is no 
clear relationship between stent strut angle or strut thickness and the deviation of flow. 
Top: Track orientation and the mode angle of coronary stent struts relative to flow. 
Bottom: Track orientation and coronary stent strut thickness. 
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Figure 4.11 Differences in streamline orientation between coronary stent faces 
 
The orientation of tracked particle streamlines moving through coronary stents deployed 
within 2.5 mm diameter vessels was measured. The length of tracks at an angle greater than 
±5° of the direction of flow (0°) is shown as a percentage of the total length of tracks within 
each stent. Tracking was performed on two stent faces, A and B, with the stent rotated by 
90° in between the two. The difference in track orientation between faces was ≤10% for all 
stents bar the Coroflex Blue Neo, implying consistency in the effect of specific stent design 
which repeats circumferentially. 
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Figure 4.12 Tracked particle density heat maps in BiodivYsio OC and Chroma 
coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. The position of streamlines and the frequency of particles tracked moving along 
them was measured in relation to a 100 µm square grid and presented as a percentage of the 
total number of particles seen in each grid. 
Left: BiodivYsio OC stent. 
Right: Chroma stent. 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). The 
plane of focus is on the bottom of the vessel. 
0                                   85 % 
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Figure 4.13 Tracked particle density heat maps in Coroflex Blue and Coroflex 
Blue Neo coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. The position of streamlines and the frequency of particles tracked moving along 
them was measured in relation to a 100 µm square grid and presented as a percentage of the 
total number of particles seen in each grid. 
Left: Coroflex Blue stent. 
Right: Coroflex Blue Neo stent. 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). The 
plane of focus is on the bottom of the vessel. 
0                                    85 % 
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Figure 4.14 Tracked particle density heat maps in Matrix and Orsiro coronary 
stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. The position of streamlines and the frequency of particles tracked moving along 
them was measured in relation to a 100 µm square grid and presented as a percentage of the 
total number of particles seen in each grid. 
Left: Matrix stent. 
Right: Orsiro stent. 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). The 
plane of focus is on the bottom of the vessel. 
0                                   85 % 
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Figure 4.15 Tracked particle density heat maps in Penchant and Pro Kinetic 
Energy coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. The position of streamlines and the frequency of particles tracked moving along 
them was measured in relation to a 100 µm square grid and presented as a percentage of the 
total number of particles seen in each grid. 
Left: Penchant stent. 
Right: Pro Kinetic Energy stent. 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). The 
plane of focus is on the bottom of the vessel. 
0                                    85 % 
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Figure 4.16 Tracked particle density heat maps in Velocity and XTRM-Track 
coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. The position of streamlines and the frequency of particles tracked moving along 
them was measured in relation to a 100 µm square grid and presented as a percentage of the 
total number of particles seen in each grid. 
Left: Velocity stent. 
Right: XTRM-Track stent. 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). The 
plane of focus is on the bottom of the vessel. 
0                                   85 % 
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Figure 4.17 Streamline and particle density in coronary stents 
 
Particles were tracked moving through coronary stents deployed within 2.5 mm diameter 
vessels. The position of streamlines and the frequency of particles tracked moving along 
them was measured in relation to a 100 µm square grid, as a percentage of the total number 
of particles seen in each grid. 
Here, the concentration of particles within each grid square is presented as a percentage of 
the total number of squares. As there is variation in stent geometry, strut orientation and 
thickness, so too is there variation in particle distribution and concentration between 
different commercially available coronary stent designs. 
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4.2.3 Particle accumulation increased and varied in coronary stents 
Once flow was arrested following the acquisition of tracking data in Section 4.2.1 
accumulated particles were counted in 1 mm segments along the length of stents, and 
2 mm up and downstream of their leading and trailing edges. Controlling for length, 
the number of attached particles within stented models ranged from 6 per mm 
(comparable to empty control tubes, seen in Section 3.4.3) to more than six times that 
amount (Figure 4.18). However, accumulation per segment varied greatly along each 
stent. There were no clear trends for change in accumulation at stent leading edge, or 
as length progressed. 
The differences in accumulation between stents could not be proved to be an effect 
of differing geometry, as there was no similarity between stent models of identical 
design. In fact, there was great variation in the measured accumulation between 
repeats within the same model vessel, in terms of both absolute particle number and 
distribution along length. Models were rotated by 90° in between each experiment, 
but had rotational symmetry. Stent geometry did not appear to have an impact on 
specific sites of particle accumulation within each segment, as there was no 
correlation between particle and strut locations, with two exceptions – the Chroma 
and Matrix stents – in which particles almost exclusively settled immediately up or 
downstream of struts (Figure 4.19). 
 
4.3 Computational modelling 
Casts of vessels containing each coronary stent design were made and struts prised 
away from the wall. This successfully preserved fine detail, including areas of 
complex geometry and prolapsed struts (previously illustrated in Figure 3.24). 
Due to the wide range of stent lengths, µCT scan resolution varied between casts in 
order to balance image resolution and quality against time and field of view. Three 
coronary stents were modelled: the Coroflex Blue, Matrix, and Pro Kinetic Energy. 
These stents were selected as they were all of similar length. They were therefore 
scanned at similar resolutions (10 µm ±2 µm) and the same parameters as discussed 
in Section 3.5.6 could be applied. In addition, successful in vitro experiments were 
performed on each, allowing comparison to EC behaviour. 
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Figure 4.18 Particle accumulation in 2.5 mm diameter stented vessels 
 
After 20 minutes under flow the number of accumulated particles within coronary stents 
deployed in 2.5 mm diameter vessels was assessed. Particles were counted through each 
stent, and 2 mm up and downstream of its leading edge (LE) and trailing edge (TE). This 
was performed twice (red and blue lines) on two stent faces, with the stent rotated by 90° in 
between the two. There were no trends for change in at stent LE, or as length progressed. 
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Figure 4.19 Locations of particle accumulation within coronary stents 
 
After 20 minutes under flow, accumulated particles (green) within coronary stents deployed 
in 2.5 mm diameter vessels were imaged and counted within 1 mm segments (red lines). No 
pattern in the location or distribution of particles throughout each model was seen, with the 
exception of the Chroma and Matrix coronary stents shown here, in which accumulation was 
almost exclusively seen immediately up or downstream of struts. 
Top: Chroma stent. 
Bottom: Matrix stent. 
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4.3.1 Wall shear stress is heterogeneous within coronary stents 
A UDF simulating fully developed flow was applied in each model, with sufficient 
velocity to generate 1 Pa average wall shear stress in a 2.5 mm diameter vessel. The 
presence of coronary stents greatly altered the pattern of wall shear stress distribution 
and magnitude. Quantitative measures of the area-weighted average wall shear stress 
(AWA-WSS) were skewed by high shear forces on the luminal surface of prolapsed 
struts (Figure 4.20A). In this example, struts penetrating the lumen contributed to an 
AWA-WSS of 1.71 Pa in the Coroflex Blue, compared to the Pro Kinetic Energy 
(0.43 Pa) and Matrix (0.72 Pa). However, shear stress on the wall below these 
protruding struts was reduced to as low as 0.1 Pa (Figure 4.20B). 
Displaying vectors showed that stents had little influence on velocity magnitude, but 
altered the direction of flow up and over struts and therefore reduced the longitudinal 
component of velocity (and thus also reduced wall shear stress) (Figure 4.21). All 
coronary stents displayed regions of wall shear stress magnitude <0.5 Pa. These 
regions were focal to bridges and areas where struts from adjacent rings were in 
close proximity, hindering downstream recovery of longitudinal velocity 
(Figure 4.21C). Immediately downstream of valleys in circumferential strut rings, 
shear stress was reduced to as low as 0.1 Pa. 
 
Plotting shear stress along reference lines revealed the impact of stent struts due to 
this disturbed flow (Figure 4.22). Wall shear stress on their luminal surfaces was 
elevated even in the well apposed stent shown in this example. However, there were 
sharp decreases in shear stress immediately up and downstream of struts. In some 
instances, downstream wall shear stress could reach negative values, indicating flow 
reversal. Wall shear stress began to increase further downstream from struts as the 
longitudinal component of velocity began to recover. The degree of this recovery, 
and inter-strut shear stress magnitude, was gradually reduced by approximately 30% 
along stent length. Plotting a reference line over more complex geometry 
(Figure 4.22, blue line) showed that thinner bridge struts had little noticeable effect. 
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Figure 4.20 Wall shear stress within coronary stents 
 
PDMS casts of coronary stents deployed within 2.5 mm diameter vessels were made and 
µCT scans taken. In silico models were reconstructed from this data and used for CFD 
analysis to plot wall shear stress along the vessel. 
A: Coroflex Blue stent interior, showing elevated shear stress on prolapsed struts. 
B: Coroflex Blue stent wall, showing reduced shear stress downstream of struts. 
C: Pro Kinetic Energy stent wall, showing reduced shear stress downstream of struts. 
D: Matrix stent wall, showing reduced shear stress downstream of struts. 
Flow from left to right, 1 Pa average wall shear stress. Note: the maximum value of the scale 
bar is set to 3 Pa to better illustrate regions of low flow. 
A 
B 
C 
D 
0             1           2             3  Pa 
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Figure 4.21 Velocity vectors around coronary stent struts 
 
In silico models were reconstructed from coronary stent µCT data and used for CFD 
analysis. Vectors revealed that while stents had little effect on velocity magnitude they 
greatly impacted direction as flow moved up and over struts, leading to reduced wall shear 
stress in those regions. 
A: Matrix stent strut. 
B: Coroflex Blue stent strut. 
C: Coroflex Blue stent, showing reduced flow at the flow in a region of close proximity 
between adjacent strut rings. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 100 µm. 
 
A 
B 
C 
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Figure 4.22 Wall shear stress along reference lines within a Matrix coronary 
stent 
 
In silico models were reconstructed from coronary stent µCT data and used for CFD 
analysis. Plotting data along reference lines in the direction of flow revealed elevated wall 
shear stress on stent struts, greatly reduced shear stress immediately up and downstream of 
struts, and recovery of shear stress in inter-strut regions. 
A: Matrix stent, with two reference lines (red and blue). 
B: Wall geometry (top) and shear stress along the upper, red reference line. 
C: Wall geometry (top) and shear stress along the lower, blue reference line. 
Flow from left to right, 1 Pa average wall shear stress. 
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4.3.2 Wall shear stress variation reduced with increased fluid viscosity 
Simulating the flow of a fluid with viscosity and density equal to that of blood 
resulted in an AWA-WSS decrease of 10% (to 0.79 Pa) within the Matrix stent, due 
to reduced wall shear stress on the first three struts (Figure 4.23, top). 
Wall shear stress magnitude and distribution in between the first four struts were 
similar to the low viscosity model. However, as longitudinal distance increased this 
pattern remained constant and inter-strut shear stress was not continuously reduced 
as per the low viscosity model (Figure 4.23, bottom). 
 
4.3.3 Wall shear stress increased with reduced µCT scan resolution 
A second µCT scan of the Coroflex Blue cast was taken at 17.47 µm, almost half the 
resolution used to create the model in Section 4.4.1 (9.92 µm), and the same 
conditions were simulated. AWA-WSS decreased by 40% to 1.01 Pa, primarily due 
to reduced shear stress on the luminal surface of struts. The overall shape of wall 
shear stress distribution remained broadly similar, and low shear stress regions were 
again present adjacent to struts, but the width of these regions was reduced. As such, 
the area of wall exposed to <0.5 Pa was greatly reduced (Figure 4.24). 
 
 
 
 
 
 
 
 
 
 
 
166 
 
 
 
 
 
 
Figure 4.23 Wall shear stress within a Matrix coronary stent modelled with 
blood-equivalent viscosity 
 
Wall shear stress resulting from the flow of a Newtonian liquid with the equivalent viscosity 
of blood (3.5 mPa.s) was plotted within an in silico model of a Matrix coronary stent.  
Top: Wall shear stress magnitude along the length of the stent. Note: the maximum value of 
the scale bar is set to 3 Pa to better illustrate regions of low flow. 
Bottom: Wall shear stress plotted along a reference line (black), as per Figure 4.22, shows 
that shear stress in the higher viscosity model (green line) is maintained in inter-strut regions 
in comparison to the standard viscosity model shown in the previous figure (red line). 
Flow from left to right, 1 Pa average wall shear stress. 
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Figure 4.24 Wall shear stress within a Coroflex Blue coronary stent model of 
reduced resolution 
 
A PDMS cast of a Coroflex Blue coronary stent deployed within a 2.5 mm diameter vessel 
was scanned via µCT at 50% of the resolution used in Figure 4.20. An in silico model was 
reconstructed from this data and used for CFD analysis to plot wall shear stress along the 
vessel. The reduced resolution model showed similar distribution, but reduced average shear 
stress magnitude, in comparison to the full-resolution model. 
Flow from left to right, 1 Pa average wall shear stress. Note: the maximum value of the scale 
bar is set to 3 Pa to better illustrate regions of low flow. 
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4.4 Cell migration 
Cell migration studies were performed on coronary stents, connected to either the 
peristaltic pump or ibidi system, with flow rates set to induce an average wall shear 
stress of 1 Pa. Cell migration studies were performed for each of the available stent 
designs described in Section 4.1, with the exception of the Penchant and the Orsiro 
(their omission is discussed further in Section 4.5). 
 
4.4.1 HUVEC migration was reduced in coronary stents 
The minimum threshold of 24 hours under flow was met for all stent designs other 
than the Coroflex Blue Neo. However, due to the limited number of available stents 
and experiment success rates, the threshold was met by just one sample per design, 
with the exception of the Pro Kinetic Energy (n = 3). 
In addition, in four of these stents (BiodivYsio OC, Coroflex Blue, Velocity, XTRM-
Track) and one of the Pro Kinetic Energy samples, the cell monolayer did not reach 
the stent leading edge. The migration distance and rate of monolayers within the 
empty vessel upstream of each stent was measured and found to be comparable to 
empty control models, whereas leader cell migration was reduced (Figure 4.25). 
In the Chroma, Matrix and remaining Pro Kinetic Energy stents, the monolayer was 
seen migrating in the direction of flow but was arrested at the stent leading edge 
(Figure 4.26). In each instance, a small number of cells migrated downstream of this 
leading strut, with greater cell numbers and maximum migration distance beyond the 
first strut observed within the Matrix stent. Final migration distance and rate was 
dependent on the proximity of the cells’ initial position to the stent (Figure 4.27). 
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Figure 4.25 Cell migration distances and rates in empty regions of stented 2.5 
mm diameter vessels 
 
In several experiments HUVEC, seeded within 2.5 mm diameter model vessels with 
deployed stents, survived the minimum 24 hours under 1 Pa flow but, due to poor stent 
placement, were unable to reach the first struts. Migration within the empty section of the 
vessel was measured and compared to that of an empty 2.5 mm diameter control vessel. 
Unlike the repeated empty control examples, there was variation in migration distance and 
rates, and the participation of cell monolayers or individual leader cells.  
Control: mean with SD (n=3). All coronary stents: (n=1). 
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Figure 4.26 Cell migration in 2.5 mm diameter stented vessels 
 
The migration of HUVEC monolayers (green line) and leader cells (green dots) beyond an 
initial seeding point (red line) was observed in the direction of flow within 24 hours. 
Monolayer migration was arrested upon meeting the leading edge of the stent. Small 
numbers of leader cells crossed the first strut, but further migration was reduced. 
A: Pro Kinetic Energy stent (n=2, representative image from one experiment shown here) 
B: Matrix stent (n=1) 
C: Chroma stent (n=1) 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
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Figure 4.27 Cell migration distance and rate in 2.5 mm diameter stented vessels 
 
The distance and rate of HUVEC migration within stented 2.5 mm diameter vessels under 1 
Pa flow was measured. Cells monolayers began upstream of deployed coronary stents and 
met their leading edges within 24 hours, at which point migration was arrested (monolayer 
migration distance is therefore a measure of initial distance between the monolayer and 
stent). The migration of individual leader cells over the first stent struts can be inferred by 
their increased distance. Within the free space between initial cell positions and stent leading 
edge, monolayer migration was comparable to that in empty control vessels. 
Chroma and Matrix: (n=1). Pro Kinetic Energy: (n=2, plotted here as separate bars). 
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4.4.2 EC coverage was enhanced in the presence of a ROCK inhibitor 
The ibidi pump system was used to study the Coroflex Blue stent alone, as this was 
the only available design with the correct nominal diameter for deployment within 
the 1.5 mm models. As per the tests with empty vessels (Section 3.3.2), experiments 
were performed using standard EC growth medium and medium supplemented with 
2 µM Y27632 as a ROCK inhibitor. For both conditions the minimum threshold of 
24 hours under flow was met for n = 3, with experiments lasting a total of 48 hours. 
Due to difficulties in seeding HUVEC and deploying stents in smaller vessels, well 
defined cell layer boundaries ahead of stent leading edges could not be attained in 
1.5 mm diameter vessels. This meant that migration distance could not be assessed 
by measuring the changing position of a monolayer or leader cells against the empty 
wall, as described in Section 2.2.6.  Therefore down-stent cell migration was 
assessed by counting the number of cells present in stent sections as time progressed, 
and comparing cell numbers to those found at t = 0 (Figures 4.28 and 4.29). Each 
inter-strut region was considered separately and an area upstream of the first strut 
was included as a control. 
A small change in cell coverage (0.9%) was seen in all regions after 24 hours of 
standard EC medium flow. After 48 hours, this rate remained the same upstream of 
the first strut and downstream of the second strut, but increased to 1.4% downstream 
of the first strut. 
The presence of a ROCK inhibitor significantly increased endothelialisation 
downstream of the first strut after 24 hours and downstream of both the first and 
second struts after 48 hours. Furthermore, a very small number of cells was seen 
downstream of the third strut, again increasing over time (not visible in Figure 4.28). 
In addition, areas where struts on adjacent rings were in close proximity, seen to 
remain bare when standard EC growth medium was used, were gradually 
endothelialised in the presence of a ROCK inhibitor (Figure 4.30). 
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Figure 4.28 Cell migration in 1.5 mm diameter stented vessels 
 
Coronary stents were deployed over HUVEC (green dots) seeded within 1.5 mm diameter 
model vessels. HUVEC were identified and counted within the stent over time, in three 
distinct regions: upstream of the stent (between the red line and the first struts), between the 
first and second struts, and between the second and third struts. 
Left: Coroflex Blue stent, with standard EC growth medium. 
Right: Coroflex Blue stent, with standard EC medium supplemented with + 2µM Y27632 
ROCK inhibitor. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
(n=3, representative images from one experiment shown here). 
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Figure 4.29 Cell numbers in distinct regions of coronary stent geometry 
 
The number of HUVEC present in distinct regions of coronary stent geometry was counted 
over time under 1 Pa flow. At each time point the increase in the number of cells within each 
region was calculated, relative to the number present at t=0. 
Top: After 24 hours cell numbers in all regions increased by approximately 0.9% when 
HUVEC were in standard EC growth medium, while the presence of a ROCK inhibitor 
significantly increased endothelialisation downstream of the first strut. 
Bottom: After 48 hours cell numbers downstream of the first strut increased further in 
standard EC growth medium, while the ROCK inhibitor increased endothelialisation 
downstream of both the first and second struts. 
Mean with SD (n=3), differences between means analysed via two-way ANOVA with Sidak 
post-hoc test. 
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Figure 4.30 Cell migration local to stent struts 
 
Coronary stents were deployed over HUVEC seeded within 1.5 mm diameter model vessels. 
Post-deployment, denuded areas of vessel wall which were local to stent geometry remained 
bare when HUVEC were in standard EC growth medium (left). Equivalent areas were 
gradually endothelialised when HUVEC were in the presence of a ROCK inhibitor (right, 
yellow line indicates boundary of cell layer).  
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 100 µm. 
(n=3, representative images from one experiment shown here). 
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4.5 Discussion 
This chapter investigated the effect of coronary stent geometry on EC migration, 
local fluid flow and wall shear stress. Coronary stents of ten different designs, 
detailed in Section 4.1, were deployed in in vitro model vessels. All stents tested 
were of the ‘slotted tube’ variety, but the range of clinically available geometries was 
well represented [8][206][207]. Multiple examples of stents from the same 
manufacturer allowed comparisons between stents of identical geometry and between 
different iterations of the same general design. The length of available stents could 
not be controlled, which, for experiments with HUVEC, was not important as the 
shortest stents (8 mm) were longer than the greatest cell migration distance seen in 
previous studies (2.5 mm, over 96 hours [127]). However, in particle tracking and 
computational studies, length was expected to have an effect on flow and was 
controlled for as much as possible (Sections 4.2 and 4.3). 
 
The extent to which the presence of coronary stents disturbs local fluid dynamics was 
revealed by tracking the motion of 10 µm particles through their structure. As shown 
in Figures 4.3 – 4.7, flow was clearly influenced by stent struts and differences in 
flow direction between stent designs were noted. The degree to which streamlines 
followed stent struts, were separated or funnelled by peaks and valleys in the stent 
ring structure (and the degree to which they remained concentrated or re-distributed 
once beyond each ring), and avoided or became trapped in areas of complex 
geometry, varied between stents of different design. The extent to which flow was 
disturbed was quantified as the percentage of streamlines at an angle greater than ±5° 
to flow. However, no relationship could be found between this and either stent strut 
size or orientation (Figure 4.10). It was also noted that the BiodivYsio OC and 
Penchant stents (with identical geometry), and Coroflex Blue and Coroflex Blue Neo 
stents (with almost identical geometry), produced very different results (Figure 4.9). 
41% of streamlines within the BiodivYsio OC stent were outside ±5° to flow, 
compared to 28% in the Penchant stent. 39% of streamlines within the Coroflex Blue 
stent were outside ±5° to flow, compared to 56% in the Coroflex Blue Neo. This 
latter stent had the thinnest struts and therefore might have been expected to have the 
smallest impact on flow direction. 
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These results could be due to the fact that, when measuring their orientation, 
streamlines were not weighted for the frequency of particles travelling along them. 
For example, a stent may have a definite, noticeable effect on flow with a hundred 
particles following a single track at 45° to flow direction. If just one additional 
particle is seen to follow a different path (e.g. travelling with flow at 0°), this second 
track carries the same weight as the first. In this example, despite >99% of particles 
travelling at 45°, the percentage of streamlines at an angle greater than ±5° to flow 
would be just 50%. Therefore, while stents of identical geometry may be expected to 
produce identical particle tracking data, and there may indeed be a relationship 
between track orientation and strut size or orientation, this information could be lost 
in the noise created by every individual particle travelling on an independent path. 
The sensitivity of this approach could be improved with greater sample sizes. 
Accepting the limited sample size in this study, the available data could be improved 
by isolating individual paths, measuring the orientation of each separately and taking 
particle frequency into account when recombining the results. However, with a total 
of 5,300 tracks between the ten stent designs, this process would need to be 
automated, which proves difficult when taking account of streamlines which merge, 
overlap or cross. 
 
The use of heat maps to display particle density goes some way to rectifying the 
issue described above (Section 4.2.2). Although orientation data was not preserved, 
the location of streamlines within the stents were noted and particle frequency taken 
into account to illustrate the density of particle flow through specific regions of 
100 µm square grids. Here, there was good agreement in particle density between 
different faces of the same deployed stent and between different stents of similar or 
identical geometry. The impact of stent geometry, and variation between dissimilar 
designs, is displayed in Figures 4.12 – 4.16. The concentration of particles within 
each square of the grid, as a percentage of the total grid area, is shown in Figure 4.17. 
All coronary stents concentrated at least 40% of particles (the top concentration band 
highlighted in Figure 4.17) within 100 µm square sections at some locations, and the 
maximum particle concentration was as high as 84% in the Matrix stent. However, 
although this latter value was consistent throughout the length of the Matrix stent, it 
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still only represented a small percentage of the total area and this high concentration 
is thus invisible in the data. Increased streamline and particle density is not clearly 
shown in Figure 4.17, as concentration naturally occurred within a small area. It was 
therefore difficult to demonstrate the information illustrated in heat maps 
quantitatively. 
 
Following particle tracking, any FluoSpheres which may have attached to stents were 
counted to identify potential areas of accumulation (Section 4.2.3). These data were 
very variable, with large variation in accumulation between stents of identical 
geometry and between faces of the same deployed stent (Figure 4.18). Consensus 
may have emerged with the use of a higher sample size or, alternatively, by 
increasing the time duration the stents were under flow conditions (although image 
clarity could quickly be lost with increased accumulation of particles within the 
model vessel).  
Particle accumulation at random points within inter-strut regions, which were 
expected to be areas of relatively undisturbed flow, was thought to be due to the 
applied low flow velocity, allowing particles to settle. Alternatively, there was 
perhaps a propensity for the polystyrene particles to adhere to PDMS. This was 
compared to currently unpublished in silico results from Adrien Lefieux (Emory 
University, USA, personal communication). In his work the high-end processing 
power of a supercomputer, which had previously been used to study 
haemodynamics [208], was employed to simulate a large number of particles flowing 
through high-resolution models of stented vessels. In agreement with the data here, 
results from those simulations also showed the accumulation of particles in 
seemingly random areas of relatively undisturbed flow. This was considered to be an 
artefact of the conditions applied to the model, with particles approaching the wall, 
contacting the no-slip boundary and having their velocity reduced to zero. To the 
author’s knowledge, while particle tracking velocimetry has previously been 
performed on stents [94][204], no measure of the subsequent accumulation of 
particles of this size has been taken, with which to compare these in vitro and in 
silico findings and judge their accuracy. 
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The effect of stent geometry on both particle flow and accumulation has particular 
relevance to the regrowth and maintenance of a healthy endothelium, and the 
prevention of thrombus formation [43]. Blood is a particulate suspension containing 
formed elements (described in Section 1.4.2). As such, it could be considered that 
uniform dispersal of these elements would be beneficial. Well distributed EPC over 
the entirety of a stent, in addition to nutrient and oxygen delivery over the local 
endothelium via mass transport, could improve vessel reendothelialisation [55]. 
Good EC distribution could also prevent any single area of the stent becoming a 
focal point for cell or plaque accumulation, which would in turn prevent thrombus 
formation. In addition, particle flow and accumulation is of significance to recent 
technological developments in the use of nano- and micro-particles as drug carriers, 
for targeted delivery [209]. 
 
Cell migration studies were performed on coronary stents, but success rates were 
low. Although clearly defined cell seeding boundaries could be obtained using the 
methods described in Section 2.2.4, and stents could be deployed with relative 
accuracy, the short duration of experiments allowed only models with initial cell 
positions in very close proximity to stents to provide useful data (Figure 4.26). 
If experiment duration was able to be extended, poor stent placement would not be 
an issue. Assays with distal initial HUVEC location would be of interest, as they 
would allow a direct comparison between migration rates within both segments of 
empty vessel and stent structure, in the same experiment. However, this was not 
possible in the current model due to the constraints outlined in Section 3.6. 
Cell migration studies were attempted on all of the available coronary stent designs, 
with the exception of the Penchant and Orsiro. However, these stents had identical 
geometry to the BiodivYsio OC and Pro Kinetic Energy respectively, which were 
tested. Furthermore, the Orsiro was a DES (the only example in this study). Despite 
exceeding the stated expiration date, it was decided that the sirolimus coating would 
render any EC migration data incomparable to the other BMS. 
While not DES, the BiodivYsio OC and Pro Kinetic Energy stents were coated (see 
Table 4.1), but were deemed usable to avoid a further reduction in sample size. 
Unfortunately, poor stent placement prevented data being obtained from the 
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BiodivYsio OC stent. Two of the five successful cell migration studies using the 
peristaltic pump were obtained from Pro Kinetic Energy stents, coated with silicon 
carbide. Silicon carbide is used to passivate stents and improve their 
haemocompatibility, rather than to exert an active influence on EC like DES 
(Section 1.3.4) [70]. Migration distance within the Pro Kinetic Energy stents was half 
that seen within the other two successful models: this could be deemed to be 
confirmation that the silicon carbide had no positive effect, or alternatively, that the 
(again, expired) coating was actually detrimental to EC. However, cell migration 
distance and rate (Figure 4.27) did not take into account the initial location of cells in 
relation to the stent (Figure 4.26). Cells within Pro Kinetic Energy stented vessels 
had less distance to travel before they were arrested by the first stent struts, and the 
same effect would presumably be seen with cells beginning experiments at the same 
proximity to uncoated BMS. 
In each of the examples shown in Figure 4.26, migration of the HUVEC monolayer 
stopped at the stent and cells that passed the first strut were low in number and 
remained close to the structure. Stent struts induce areas of recirculation (identified 
in Figure 4.8) and EC are exposed to bidirectional mechanical cues which hinders 
effective migration. This behaviour is similar to that shown in the findings of Hsiao 
et al [103], in which bulk HUVEC migration was arrested by a 100 µm ridge and 
cells that crossed this obstacle remained immediately downstream of it. This 
similarity to data obtained from a recognized protocol which used established, 
commercially available equipment (as well as to cell migration data from other 
existing parallel plate studies), could indicate the validity of the novel model and 
protocol in use in this work. Here, however, by further developing a model in which 
data is obtained from clinical-grade stents, in vessels of realistic size and geometry, 
physiological relevance could be increased, as could the translational potential of 
results and the confidence with which they could be compared to clinical data and in 
vivo study. 
 
In 1.5 mm diameter vessels HUVEC migration was assessed by counting cells within 
separate stent sections as time progressed, the assumption being that cells migrating 
in the direction of flow would increase the total number in that direction (Figure 
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4.28). Increased cell numbers were indeed seen. In standard EC growth medium the 
rate of increase remained constant over time, with the exception of an enhanced rate 
in the first inter-strut region after 48 hours (Figure 4.29). The presence of a ROCK 
inhibitor did not affect cell numbers upstream of the stent, but greatly increased the 
rate of change in cell number in the inter-strut regions. 
It may be reasoned that, upstream of the stent, cell migration was high and cell 
confluence was reached quickly, prior to the first time point within the experiment. 
This could explain why the rate of increase in cell number within this region 
remained both low and constant over time. Migration was high because cells in this 
region were exposed to unidirectional mechanical cues from undisturbed flow, as per 
empty control tubes (Section 3.3). Conversely, migration was hindered within the 
inter-strut regions due to the presence of bidirectional mechanical cues and reduced 
wall shear stress [112][113]. Therefore, while a similar level of confluence was 
eventually reached in the first inter-strut region, the process took longer and the 
corresponding increase in cell number was not seen until the third time point. The 
influence of bidirectional flow, via the mechanism outlined in Section 1.4.4 [103], 
was shown by the large impact of the ROCK inhibitor on cell numbers within the in-
stent regions once induced mechanical cues were silenced. This is further supported 
by the fact that the ROCK inhibitor had an even more pronounced effect in the 
second inter-strut region where, it may be assumed, flow disturbance was greater 
still, and had no noticeable effect in undisturbed flow upstream of the stent. 
 
Simulating fluid flow through stents, using in silico models created from µCT data 
provided data on induced flow disturbances and altered wall shear stress (Section 
4.3) with which to compare EC migration. In the Matrix stent, a particularly well-
apposed example, flow was disturbed immediately up and downstream of struts 
(Figures 4.20 – 4.22). These areas were subject to low longitudinal velocity and 
reversed flow, and therefore low and bidirectional wall shear stress. In addition, these 
areas corresponded to the locations at which HUVEC monolayer migration was 
arrested (upstream) and at which HUVEC leader cell migration was reduced 
(downstream) (Figures 4.26 and 4.27). The combined CFD/cell migration data 
compares well to previous in vitro and in silico studies of simple stent geometries 
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[103], as well as in-plane particle tracking [94] and CFD simulations of both 
idealised models and in vitro model- or patient-specific geometries [162][112].  
CFD analysis revealed regions of low wall shear stress further downstream of stent 
struts. In these inter-strut areas, flow began to recover and shear stress increased to 
some extent, but the presence of additional downstream struts halted this process. 
Thus, the vessel wall was subjected to wide areas of <0.5 Pa wall shear stress, which 
enlarged with increased downstream distance. Unfortunately, HUVEC migration 
studies in 2.5 mm diameter vessels did not proceed long enough to see cells approach 
these regions. However, cell counts in 1.5 mm diameter vessels illustrated the 
detrimental effect of these local mechanical conditions (Figures 4.28 and 4.29). In 
addition, HUVEC were only observed to move and proliferate in areas of particularly 
low shear stress highlighted by CFD analysis, such as areas where adjacent struts 
were in close proximity, when in the presence of a ROCK inhibitor (Figure 4.30). 
This once again implied that the migration of EC in standard growth medium was 
hindered by bidirectional mechanical cues from disturbed flow. Due to this induced 
EC dysfunction, these areas could not be considered conducive to rapid 
endothelialisation [89][163]. 
 
Computational simulations were also performed with a Newtonian fluid of the same 
viscosity of blood. The results showed a reduction in the extent of both flow 
disturbance and diminishing shear stress along stent length, compared to those 
obtained using EC growth medium equivalent fluid properties (Figure 4.23). 
However, it cannot be concluded that HUVEC in vivo are in a more favourable 
mechanical environment to those in vitro. Here, blood flow was simulated using the 
same steady conditions applied in vitro whereas, in reality, blood flow is pulsatile 
and unsteady [55]. In addition, arteries stretch in response to this pulsatile flow and 
the coronary arteries are distorted when the surface of the heart moves during the 
cardiac cycle [6]. In vivo haemodynamics would therefore be much more complex. 
Furthermore, as discussed in Section 1.4.2, blood is a non-Newtonian fluid and is 
more often simulated using the Carreau model as opposed to the constant viscosity 
model used here. The CFD simulations of higher-viscosity fluid are therefore 
perhaps best placed to illustrate the flow of the thickened EC growth medium 
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described in Section 2.2.2.2 and to demonstrate how local fluid dynamics would 
change if more physiological parameters (e.g. velocity, Reynolds number, etc.) were 
accounted for in addition to wall shear stress. 
 
As CFD analysis revealed the effect of stent struts on local fluid dynamics and wall 
shear stress, it also demonstrated the differences in fluid dynamics across dissimilar 
stent geometry (Figure 4.20). Wall shear stress magnitude, distribution and the extent 
of its reduction over stent length, were seen to vary with stent structure. The 
influence of design parameters such as strut thickness and spacing have been shown 
in parametric studies of idealised models [111][112][113]. Any conclusions drawn 
from models based on in vitro vessels must not only take into account general stent 
structure, but also the degree to which each strut is apposed or prolapsed into the 
lumen. This was shown to have a great impact on AWA-WSS (Figure 4.20) and 
prolapsed struts induced more complex flow than those which were well embedded. 
Once again, a greater number of samples would aid in investigating the impact of 
small changes in strut prolapse and apposition between individual deployments. 
Simulations using the lower resolution Coroflex Blue model (Figure 4.24) revealed a 
reduction in areas of low wall shear stress in comparison to the standard resolution 
model (Figure 4.20). Reducing µCT resolution enabled a crude parametric study, as 
losing image quality effectively resulted in a model with thinner struts, but otherwise 
identical strut position and orientation. An increase in shear stress heterogeneity, 
toward baseline levels of 1 Pa, was seen as strut thickness and therefore the overall 
impact of stent structure was diminished. 
 
Finally, while it has been shown here, and in the relevant literature, that stents have 
an impact on local haemodynamics and EC behaviour, a return to physiological flow 
conditions is not as straightforward as simply reducing the number, or size, of stent 
struts. For example, Biocompatibles Ltd. produces the BiodivYsio AS stent (‘Added 
Support’, as opposed to the OC ‘Open Cell’ studied here) with increased strut 
density, as an alternative model. This is a reminder that coronary stents are used to 
widen and scaffold muscular arteries and that their ability to do this must take 
precedence, however large their impact on haemodynamics may be. 
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However, local haemodynamics plays an important role in the reendothelialisation 
and healing of stented vessels and, where possible (if, for example, specific stent 
features are designed with copyright or a company’s signature theme in mind, rather 
than function), should be considered a key factor in stent design. The development of 
the novel model and protocol described in this work, its validation in comparison to 
data from established, yet less physiologically relevant parallel plate and idealised 
computational models, and its ability to apply various techniques to study and 
compare a wide range of coronary stent designs contributes to that objective. 
Increasing the reliability of experiments, the resolution of resultant data and, through 
increased physiological relevance, its realism in comparison to in vivo data, will aid 
in the exploration of the impact of modified stent design on reendothelialisation.  
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Chapter Five 
5 In Vitro and In Silico Study of Flow Diverter Stent 
Haemodynamics and Cell Migration 
 
The regrowth of a healthy endothelial layer is hindered by EC dysfunction, caused by 
the presence of cardiovascular stents and their effect on local wall shear stress. 
Chapters 2 and 3 considered the creation of an experimental platform through which 
the biomechanical conditions of stented vessels could be studied. Chapter 4 
considered the application of that platform to a range of clinical-grade coronary 
stents, highlighting the effect of stent-induced flow disturbance on wall shear stress 
and EC behaviour. This chapter concerns the application of the platform to clinical-
grade flow diverter stents, with greatly dissimilar geometry and function to that of 
coronary stents. 
 
5.1 Flow diverter stent deployment 
5.1.1 Flow diverter stent geometry was relatively uniform 
Two different flow diverter stent designs, the Leo and Silk, were supplied by Dr. Ana 
Paula Narata (INSERM U930, France). These were deployed within in vitro model 
vessels of 2 mm diameter and are detailed in Table 5.1. Both stents were woven from 
thin wires of circular cross-section. Thick struts, created by coiling one wire around 
another, supported a mesh of thinner struts. Meshes were formed from regularly 
aligned struts (Figure 5.1) and the main differences between the two stents pertained 
to the density of these meshes and the associated MSA. While only two designs were 
tested, they are representative of the majority of flow diverter stents used in clinical 
practice [24].  
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Table 5.1 Properties of flow diverter stents 
 
Only flow diverter stents of 2 mm nominal diameter and 10 mm length were deployed within 
2 mm model vessels. 
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Figure 5.1 Flow diverter stent strut orientation 
 
The orientation of flow diverter stent struts was measured in relation to the direction of 
applied flow (0°), as illustrated in Figure 2.3. The length of struts at each angle (to the 
nearest 10°) is shown here as a percentage of the total strut length. Each chart represents an 
average measurement taken from two faces of each stent (rotating the stent 90° between the 
two) and one repeating unit of stent geometry. Flow diverter stents show little variation, with 
regular meshes of struts at 30 - 50°. 
 
 
 
 
 
Leo Silk 
90° 
60° 
30° 
0° 
90° 
60° 
30° 
0° 
0               20                40              60 0               20                40              60 
Percentage of strut length Percentage of strut length 
188 
 
5.1.2 Deployment showed variation in flow diverter stent geometry 
Variability in stent geometry between deployments of the Leo stent was reduced in 
comparison to coronary stents (described in Section 4.1.2). In contrast, variability in 
stent geometry between deployments of the Silk stent was larger in comparison to 
Leo and coronary stents. The ideal, regular mesh of the Silk stent was affected by 
three factors, illustrated in Figure 5.2: 
1. Silk stent struts, the thinnest seen in any of the flow diverter or coronary stent 
struts, were more susceptible to slight distortion. 
2. At either end of the stent, the interwoven struts were freed and remained 
unlinked. This resulted in irregular, non-uniform distribution and reduced 
radial expansion force which meant that this region was particularly prone to 
prolapse and under-expansion. 
3. The self-expansion of Silk stents would often halt as soon as the first, thicker 
struts came into contact with the wall. This could then result in a gap (~100 
µm) between the wall and regions of thinner interwoven struts. 
 
5.2 Flow diverter stent geometry had a reduced impact on visible 
flow 
5.2.1 Influence of flow diverter geometry on streamline orientation 
Figure 5.3 shows tracked particle streamlines within representative areas of the flow 
diverter stents (streamlines through the full stents are provided in the Appendix). 
Once again, there was good agreement between the two sequences in each field of 
view and clear streamline patterns followed from one field of view to the next. 
30% of the total number of tracks deviated from a path within ±5° of flow direction 
in the Silk stent (the joint lowest value of all stent types, equal to the Penchant 
coronary stent) and 40% in the Leo stent (exactly mid-range). The higher value 
obtained from the Leo could be seen to be due to a number of particles following its 
relatively thick strut. 
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Figure 5.2 Structure of deployed Silk flow diverter stent 
 
A Silk flow diverter stent deployed within a 2 mm diameter vessel was photographed under a 
brightfield stereo microscope. The stent consisted of thin (30 µm) braided wires and four 
thicker (70 µm) struts. 
Top: Loose struts at either end of the stent were disordered and prone to prolapse into the 
lumen 
Bottom: The braided design and relatively weak self-expansion left gaps between the vessel 
wall (green line) and struts (red line). 
Scale bar: 0.5 mm. 
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Figure 5.3 Tracked particle streamlines in Leo and Silk flow diverter stents 
 
Particles were tracked moving through each flow diverter stent deployed within 2 mm 
diameter vessels. Tracking was performed for two 30-second long sequences (red and blue 
tracks) on two stent faces, with the stent rotated by 90° between the two faces. 
Top: Leo stent. 
Bottom: Silk stent. 
Flow from left to right, Re = 43 (equivalent to blood flow with 1 Pa wall shear stress). 
Representative images are mid-stent length and the plane of focus on the bottom of the 
vessel. 
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The stents had clear strut orientations of ±50° (Silk) and ±40° (Leo). Plotting this 
additional information on Figure 4.10 further reduced the appearance of any trend. 
As per Section 4.2.1, the difference in track orientation between different faces of 
each stent was ≤10% (Figure 5.4). 
 
5.2.2 Influence of flow diverter geometry on tracked particle density 
A total of 212 and 195 particles were tracked moving through the Silk and Leo 
stents, respectively. These values were 40 – 80% lower than the range of tracked 
particle numbers seen within coronary stents, when controlling for length. Figure 5.5 
shows the distribution of moving particles, displaying track path and the frequency of 
particles moving along each one, as a percentage of the total number of particles. As 
for the coronary stents, both flow diverter stents contained large areas of low particle 
flow. However, this was due to low overall particle numbers as there was little 
funnelling effect seen. Variation in the degree to which stents funnelled particles is 
shown in Figure 5.6, based on the first 72 columns of each grid as per Section 4.2.2. 
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Figure 5.4 Differences in streamline orientation between flow diverter stent 
faces 
 
The orientation of tracked particle streamlines moving through flow diverter stents deployed 
within 2 mm diameter vessels was measured. The length of tracks at an angle greater than 
±5° of the direction of flow (0°) is shown as a percentage of the total length of tracks within 
each stent. Tracking was performed on two stent faces, A and B, with the stent rotated by 
90° in between the two. The difference in track orientation between these faces is shown 
here. The difference in track orientation between faces was ≤10% in each stent, implying 
consistency in the effect of the repeating mesh stent strut design. 
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Figure 5.5 Tracked particle density heat maps in Leo and Silk flow diverter 
stents 
 
Particles were tracked moving through each flow diverter stent deployed within 2 mm 
diameter vessels. The position of streamlines and the frequency of particles tracked moving 
along them was measured in relation to a 100 µm square grid and presented as a percentage 
of the total number of particles seen in each grid. 
Left: Leo stent. 
Right: Silk stent. 
Flow from bottom to top, Re = 43 (equivalent to blood flow with 1 Pa wall shear stress). The 
plane of focus is on the bottom of the vessel. 
0                                        85 % 
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Figure 5.6 Streamline and particle density in flow diverter stents 
 
Particles were tracked moving through flow diverter stents deployed within 2 mm diameter 
vessels. The position of streamlines and the frequency of particles tracked moving along 
them was measured in relation to a 100 µm square grid, as a percentage of the total number 
of particles seen in each grid. 
Here, the concentration of particles within each grid square is presented as a percentage of 
the total number of squares. Particles were relatively well distributed throughout flow 
diverter stents with the large area of 0% density due to low overall particle numbers. 
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5.2.3 Particle accumulation increased and varied in flow diverter stents 
As per Section 4.2.3, accumulated particles were counted in relation to their position 
along the length of stents and 2 mm up and downstream of their leading and trailing 
edges (Figure 5.7). As flow diverter stents were only deployed in 2 mm diameter 
models accumulation was counted twice: once after 20 minutes to compare against 
coronary stents after the same time under flow, and again after the same total volume 
of particle suspension. 
As expected, particle numbers increased with time. However, at the second time 
point, after equal flow volume, the number of particles in the Leo stent remained 
50% lower than an empty 2 mm vessel, controlling for length. Numbers within the 
Silk stent were double that of an empty control and comparable to coronary stents. 
Particle attachment within the Leo stent showed no bias toward stent geometry and 
the Silk stent’s dense mesh rendered any assessment of attachment relative to strut 
location impractical. 
For both stents, linear regression analysis suggested a gradual reduction in particle 
accumulation along stent length (R
2
 = 0.5 - 0.8, in comparison to <0.1 in the majority 
of coronary stents). The highest number of particles at a given location in any flow 
diverter or coronary stent was seen in the 2 mm of empty vessel up and downstream 
of the Silk stent (Figure 5.8). Comparing these sections to their immediate in-stent 
neighbours also produced some of the sharpest reductions in particle number 
between adjacent regions. 
 
5.3 Computational modelling 
Casts of vessels containing Silk stents were made before struts were pulled out 
through the lumen. This preserved fine details, including areas of interwoven and 
coiled struts. The cast could be scanned at high resolution (3.48 µm) due to its small 
size. This high resolution resulted in a complex, computationally expensive model. 
As such, only half of the in silico Silk stent model was meshed (Figure 5.9) and a 
plane of symmetry applied at the new boundary. 
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Figure 5.7 Particle accumulation in 2 mm diameter stented vessels 
 
The number of accumulated particles within flow diverter stents deployed in 2 mm diameter 
vessels was assessed after 20 minutes under flow (the same amount of time as used in 
coronary stent models), and after 40 minutes under flow (the same total particle suspension 
volume as coronary stent models). Particles were counted in 1 mm segments through each 
stent, and 2 mm up and downstream of the stent leading edge (LE) and trailing edge (TE). 
This was performed twice (red and blue tracks) on two stent faces, with the stent rotated by 
90° in between the two. Linear regression analysis suggests a gradual reduction in particle 
accumulation along stent length (R
2
 = 0.5 – 0.8, compared to <0.1 in coronary stents). 
0 
20 
40 
60 
LE TE 
N
o
. 
o
f 
p
ar
ti
cl
es
 
0 
20 
40 
60 
LE TE 
N
o
. 
o
f 
p
ar
ti
cl
es
 
0 
20 
40 
60 
LE TE 
N
o
. 
o
f 
p
ar
ti
cl
es
 
0 
20 
40 
60 
LE TE 
N
o
. 
o
f 
p
ar
ti
cl
es
 
0 
20 
40 
60 
0 mm 10 mm 
N
o
. 
o
f 
p
ar
ti
cl
es
 
0 
20 
40 
60 
0 mm 10 mm 
N
o
. 
o
f 
p
ar
ti
cl
es
 
Leo (equal time) Leo (equal vol.) 
Silk (equal time) Silk (equal vol.) 
2 mm control        
(equal time) 
2 mm control         
(equal vol.) 
197 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Location of particle accumulation within the Silk flow diverter stent 
 
After 40 minutes under flow, accumulated particles (green) within flow diverter stents 
deployed in 2 mm diameter vessels were imaged and counted within 1 mm segments (red 
lines). Particle accumulation in the Silk stent was enhanced immediately up and downstream 
of the structure. 
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Figure 5.9 In silico model of a Silk flow diverter stent 
 
In silico model of vessel wall and stent struts reconstructed from a 3.48 µm resolution µCT 
scan of a Silk flow diverter stent cast. Due to the destructive nature of strut removal prior to 
the scanning of the cast, only a short segment of the stented vessel’s length contained viable 
geometry. In addition, due to the high resolution of the scan image, flow through only one 
half of the stented vessel was simulated in CFD analysis to reduce computational expense, 
and a plane of symmetry applied. 
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5.3.1 Wall shear stress was reduced within flow diverter stents 
A UDF simulating fully developed flow was applied, with sufficient velocity to 
generate 1 Pa average wall shear stress in a 2 mm diameter vessel. Maximum shear 
stress was 28.14 PA (at a single unrepresentative point). The AWA-WSS within the 
Silk stent was 1.34 Pa, higher than the majority of coronary stents. However, as for 
coronary stents, prolapsed struts were exposed to higher wall shear stress which 
moved this average upwards. With a far greater number of struts, all of which lay 
within the lumen adjacent to the wall, this increase was pronounced in the Silk stent 
(Figure 5.10A). 
Disregarding the stent struts and considering the wall only, wall shear stress 
decreased towards the centre of model, as flow moved into the mesh. This region 
was exposed to no more than 0.5 Pa (Figure 5.10B), with areas of <0.1 Pa local to 
stent struts. Velocity vectors revealed extremely low flow at the wall (Figure 5.11). 
Wall shear stress recovery between struts was lower than that seen in coronary stents 
due to the high density of the mesh reducing the inter-strut distance.  
Simulating the flow of a fluid with viscosity and density equal to that of blood 
resulted in an AWA-WSS of 0.85 Pa within the model. Shear stress at the wall was 
reduced (>1 Pa), as was the longitudinal distance over which shear stress dropped to 
this level (Figure 5.12). 
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Figure 5.10 Wall shear stress within a Silk flow diverter stent 
 
PDMS casts of flow diverter stents deployed within 2 mm diameter vessels were made and 
µCT scans taken. In silico models were reconstructed from this data and used for CFD 
analysis to plot wall shear stress along the vessel. 
A: Silk stent interior, showing elevated wall shear stress on prolapsed struts. 
B: Silk stent wall, showing reduced wall shear stress downstream of thick struts and 
underneath the thin strut mesh. 
Flow from left to right, 1 Pa average wall shear stress. Note: the maximum value of the scale 
bar is set to 3 Pa to better illustrate regions of low flow. 
 
 
 
0             1           2             3  Pa 
A 
B 
201 
 
 
 
 
 
 
 
 
Figure 5.11 Velocity vectors around Silk flow diverter stent struts 
 
In silico models were reconstructed from flow diverter stent µCT data and used for CFD 
analysis.  
A: Longitudinal view. Vectors revealed greatly reduced velocity magnitude at the vessel 
wall local to Silk stent struts, and little recovery between struts due to the high density of the 
mesh. 
Flow from left to right, 1 Pa average wall shear stress. 
B: Cross-section. Gaps were present between Silk stent struts and the vessel wall even when 
fully deployed, due to the interweaving braided struts, which further reduced velocity and 
flow recovery at the wall. 
Scale bar: 100 µm. 
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Figure 5.12 Wall shear stress within a Silk flow diverter stent modelled with 
blood-equivalent viscosity 
 
Wall shear stress resulting from the flow of a Newtonian liquid with the equivalent viscosity 
of blood (3.5 mPa.s) was plotted within an in silico model of a Silk flow diverter stent. Shear 
stress in the higher viscosity model was reduced in comparison to the standard viscosity 
model as per Figure 5.14. 
Flow from left to right, 1 Pa average wall shear stress. Note: the maximum value of the scale 
bar is set to 3 Pa to better illustrate regions of low flow. 
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5.4 Cell migration was arrested in flow diverter stents 
Cell migration studies were performed on flow diverter stents, connected to the 
peristaltic pump system with flow rates set to induce an average wall shear stress of 1 
Pa. The threshold of 24 hours under flow was achieved for both Leo (n = 2) and Silk 
stents (n = 3), with one Silk stent experiment progressing to the maximum 72 hours. 
In flow diverter stents, the initial position of HUVEC from which migration was to 
be measured was within the boundary of the deployed stent (this change in the 
protocol is discussed in Section 5.5). No HUVEC migration beyond this point was 
seen in any experiment, for either stent design (Figures 5.13 and 5.14). This applied 
to both monolayer migration and the migration of individual leader cells. HUVEC 
were only ever seen upstream of the initial seeding point and all inter-strut regions 
downstream of this point contained debris only (Figure 5.15). 
Flow diverter stent deployment created wounds in the HUVEC monolayer upstream 
of the stent. These wounds were observed to close within the first 24 hours of 
experiments, with their boundaries moving in the direction of flow (Figure 5.16). 
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Figure 5.13 Cell migration study in the Leo flow diverter stent 
 
In Leo flow diverter stents, no migration of HUVEC monolayers (green line) was seen 
beyond an initial seeding point (red line) after 24 hours under flow. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
(n=2, representative images from one experiment shown here). 
0 h 
24 h 
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Figure 5.14 Cell migration study in the Silk flow diverter stent 
 
In Silk flow diverter stents, no migration of HUVEC monolayers (green line) was seen 
beyond an initial seeding point (red line) after 72 hours under flow. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
(n=3, representative images from one experiment shown here). 
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Figure 5.15 Cells within Silk flow diverter stent structure 
 
No cell migration was observed beyond initial seeding points within flow diverter stent 
structure.  
A: Silk stent after 48 hours under flow. Attached HUVEC could be seen in the inter-strut 
regions upstream of the seeding point (red box), but only debris was present downstream 
(green box). 
B: Magnified inter-strut region upstream of the initial seeding point (left), containing 
attached HUVEC (yellow, right). 
C: Magnified inter-strut region downstream of the initial seeding point (left), containing no 
HUVEC. Only cell debris (yellow lines, right) could be seen accumulating around struts. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
Identical results seen in all flow diverter stents: (n=5, representative images from one 
experiment shown here). 
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Figure 5.16 Cell monolayer wound closure upstream of flow diverter stents 
 
No cell migration was observed beyond initial seeding points within flow diverter stent 
structure. However, upstream of the stents, HUVEC were seen to close wounds created 
where stent introducer sheaths scraped the monolayer, with the wound boundaries (yellow 
lines) moving in the direction of flow. 
Flow from left to right, 1 Pa average wall shear stress. 
Scale bar: 0.5 mm. 
Leo: (n=2), Silk: (n=3, representative images from one experiment shown here). 
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5.5 Discussion 
This chapter investigated the effect of flow diverter stent geometry on EC migration, 
local fluid flow and wall shear stress. Flow diverter stents of two different designs, 
detailed in Section 5.1, were deployed in in vitro model vessels. As described in 
Section 3.6, the result represented stent deployment in vivo, although particular care 
was required to minimise the gap between stent struts and the vessel wall (discussed 
further within this section). Although only two designs were available, they 
represented the range of clinically available flow diverter stent geometries [24]. Flow 
diverter stents typically consist of braided strut meshes of varying density and the 
stents tested here were at the fine (Silk) and coarser (Leo) ends of the scale. Flow 
diverter stent lengths were identical and so results which may otherwise have been 
affected by this parameter could be directly compared. When required, length was 
controlled for when making comparisons to coronary stents. 
 
The extent to which the presence of flow diverter stents disturbs local fluid dynamics 
was revealed by tracking the motion of 10 µm particles through the stents’ structure. 
In coronary stents, these studies showed obvious disruption created by struts, 
including zones of recirculation which corresponded to regions where EC migration 
was arrested or slowed. These results were in agreement with parallel plate and other 
particle tracking studies [94][103] which, taken together, implies a link between 
disturbed flow and cell dysfunction. However, despite the complete lack of HUVEC 
migration in flow diverter stents, a much smaller effect on particle tracking was 
observed (Figure 5.3). 
An average of 20 particles were tracked per field of view in each flow diverter stent. 
This is less than 50% of the number within coronary stents (an average of 52 per 
field of view) and this disparity worsens when controlling for length. In flow diverter 
stents, values of tracked streamline orientation were similar to those seen within the 
majority of coronary stents. 30% of streamlines within the Silk stent and 41% of 
those within the Leo stent were at an angle >±5° to flow (Figure 5.4). Mapping the 
density of streamlines, taking into account both the location and the frequency of 
particles moving along them, revealed a more uniform distribution of flowing 
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particles, although small areas of concentration could be seen (Figure 5.5). The 
overall effect was similar to that seen in many of the coronary stents. 
Section 4.5 discussed the ability of individual particles to skew tracking data. In flow 
diverter stents, this effect was even more pronounced due to the much lower number 
of particles seen overall: the orientation of one streamline, or the addition of a single 
extra particle to a 100 µm grid square, could alter results by 10%. In coronary stents, 
high density represented the concentration of tens of particles, whereas, in flow 
diverter stents, it could result from just two or three particles moving along separate 
streamlines that briefly crossed. Comparing quantitative data from flow diverter 
stents with that from coronary stents (Figures 4.17 and 5.6) is problematic as it is 
difficult to distinguish between large areas of low density which were a by-product 
of high concentration, and those which were simply due to low particle numbers. At 
face value, particle tracking data from flow diverter stents looks comparable to that 
from many coronary stents. However, when the above is taken into account the 
former appear more like empty control tubes (albeit with far fewer tracked particles). 
These results may be due to the stents diverting flow away from the wall, as they are 
designed to do in vivo and are observed to do in separate in vitro and in silico models 
[27][28][210]. As detailed in Section 2.3, the bottommost stent struts are brought into 
focus prior to image acquisition and only particles within focal range are tracked. 
Thus, if flow diverter stents are diverting and concentrating the bulk of the particles 
toward the centre of the vessel, only a small number of particles will remain in the 
suspension’s fluid phase local to the wall where data is gathered.     
 
In comparison to empty control models, the accumulation of particles over time was 
greatly reduced in the Leo stent, again possibly due to the diversion of flow away 
from the wall. In contrast, accumulation was increased in the Silk stent (Figure 5.7) 
and equivalent to that within the majority of coronary stents after equal time, despite 
half the number of particles flowing through the smaller 2 mm diameter model. This 
could be due to the loose, disordered end struts, where peaks in accumulation were 
seen. It has been suggested that the used of braided stents with untrimmed edges 
should be minimised in clinical practice, as any tendency for these areas to be focal 
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points of cell or plaque accumulation could increase (or potentially be responsible 
for) the heightened risk of thrombus formation within flow diverter stents [113]. 
 
Cell migration studies were performed on flow diverter stents deployed within 2 mm 
diameter models and connected to the peristaltic pump system. As per coronary stent 
models, success rates were low. However, samples sizes of n=3 (Silk) and n=2 (Leo) 
met the minimum experiment threshold of 24 hours. In addition, a Silk stent sample 
met the maximum experiment duration of 72 hours. As mentioned in Section 3.6, in 
order to model a sufficiently denuded endothelium, flow diverter stents were 
deployed within model vessels in which there was a clear boundary between an 
attached HUVEC monolayer and bare vessel wall. While coronary stents were 
deployed with their leading edge as close to this boundary as possible, flow diverter 
stents were deployed with the boundary midway along their length. This alteration to 
the protocol as described in Section 2.2.4 was altered after initial experiments 
revealed the disordered geometry of loose, prolapsed struts at the ends of interwoven 
meshes (particularly within the Silk stent, illustrated in Figure 5.2). The random 
nature of this structure impaired the ability to compare between repeat experiments 
of the same design, as the difference in geometry between deployments was even 
more pronounced than that seen between coronary stents. Additionally, these regions 
were prone to debris collection which hindered the identification and imaging of 
HUVEC. The decision was made to begin cell migration assays from a point within 
the stent, of more ordered, regular strut geometry, to aid comparison between 
models. This was considered a valid approach as, unlike coronary stents which are 
deployed in sections of diseased artery, flow diverter stents are deployed within 
arteries that (other than the aneurysm neck) are relatively endothelialised [29]. 
Combined with the gentle expansion of flow diverter stents, it can therefore be 
reasonably assumed that EC will be present within the stent following deployment. 
However, as EC migration is still required to properly endothelialise stent struts and 
reduce the risk of thrombus formation [34][62], studying flow diverter stents in the 
manner described here remains relevant. Applying the protocol described in 
Section 2.2 to flow diverter stents also provided an interesting contrast to the results 
obtained in experiments using dissimilar coronary stent geometry. 
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In each of the cell migration experiments performed, no movement of the HUVEC 
monolayer or individual leader cells was seen, at any time point up to and including 
72 hours (Figures 5.13 and 5.14). In comparison, in each successful experiment with 
empty control vessels (Section 3.3.2) and deployed coronary stents (Section 4.4.1) 
migration of a monolayer and/or individual leader cells of some extent was observed. 
This included individual leader cells within coronary stent structure (Figure 4.26). 
Identifying HUVEC was more difficult between the denser struts of flow diverters in 
comparison to the open inter-strut regions of coronary stents. The use of a 
fluorescent dye and portable light system was trialled (Section 3.3.3) but individual 
cells were dim and locating anything other than the bulk monolayer was not possible 
(Figure 3.12). With practice, brightfield microscopy under higher magnification was 
used to confirm the lack of migration, by locating individual cells upstream of the 
initial seeding point and discerning them from gradually accumulating debris 
downstream (Figure 5.15). 
The lack of cell migration could be due to flow diverter stent structure, as opposed to 
issues with overall cell viability or the PDMS model, as normal cell behaviour was 
observed upstream of both the Silk and Leo stents. It was noted that the stent 
introducer sheath used during the deployment of flow diverter stents was wider than 
the catheter guide wires used to insert coronary stents. Thus, the tip of the sheath 
tended to scrape the model vessel wall on insertion. This created wounds in the 
HUVEC monolayer upstream of the stent (the monolayer local to the initial seed 
point, underneath the body of the sheath, remained intact as was confirmed prior to 
each experiment). Reassuringly, these wounds were observed to close within the first 
24 hours of experiments (Figure 5.16). Confluent monolayers were maintained for 
the remaining duration of the experiments, so it is unlikely that the lack of HUVEC 
migration was due to detrimental cell health or viability. 
 
Simulating fluid flow through an in silico model of a Silk stent created from µCT 
data allowed wall shear stress to be analysed and compared to the results of cell 
migration studies from Section 5.4. This aspect of local mechanical conditions could 
not be revealed by in vitro particle tracking data. The Silk stent showed a high 
AWA-WSS of 1.34 Pa. As in coronary stent models, this was skewed by high shear 
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stress on the luminal surface of stent struts (Figure 5.10A). This may have had an 
even greater effect in the Silk model, as the dense mesh of more prolapsed struts had 
a larger contribution to the model’s total area. Therefore, the AWA-WSS was not a 
useful indication of the conditions found on the wall of the vessel only. 
Considering the wall alone, a pattern similar to that seen within coronary stents was 
identified (Figure 5.10B). Areas of greatly reduced wall shear stress (<0.1 Pa) were 
found immediately up and downstream of struts. However, the dense mesh in flow 
diverter stents increased the number of such areas along the vessel length, in 
comparison to thicker, but more spaced coronary stent struts. Wall shear stress 
magnitude began to recover in between struts but could reach no more than 0.5 Pa, 
50% of the applied 1 Pa. This was again due to the dense mesh reducing the distance 
between struts within which flow recovery could take place. The overall effect was a 
wider area of reduced wall shear stress and a more homogeneous distribution 
compared to that found within coronary stents. 
Wall shear stress in coronary stents was reduced when fluid moved up and over 
struts and the horizontal component of flow velocity decreased (Section 4.3.1). This 
phenomenon was more pronounced in the Silk stent due to the presence of a gap 
between the struts and wall (Figure 5.11). Large gaps were often seen after in vitro 
flow diverter deployment (Section 5.1.2) and this may be a trait of the in vitro model. 
More compliant cerebral artery tissue [21], or the remodelling of stented vessels, 
might eliminate any substantial gap between strut and wall in vivo. Yet, weak 
expansion of the Silk stent in clinical application has been reported [31][32]. To 
avoid this issue in this project, only well-expanded stents were used for in vitro 
experiments, subsequent scanning and in silico modelling. However, even in optimal 
examples small gaps between struts and vessel wall were unavoidable due to the 
woven structure of the stents. Each strut in contact with the wall had another strut 
moving over it, which was kept apart from the wall by a distance equal to the 
diameter of the lower strut. This pattern was repeated throughout the entire stent and 
the problem was amplified where numerous thin struts met and crossed over the four 
thicker struts. Thus, the recovery of undisturbed flow (and therefore wall shear 
stress) in the already small inter-strut regions was further hindered by the increased 
distance to the wall (Figure 5.11). 
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The ever present gap between flow diverter stent struts and vessel wall also meant 
that plotting along reference lines, to obtain specific values of wall shear stress 
magnitude and to visualise how shear stress altered with stent geometry along vessel 
length (as per Figure 4.22), was not possible for the Silk stent model. This method 
returned shear stress data from every boundary along the reference line. At any given 
location along the line within well-apposed coronary stents, this resulted in one data 
point (from the wall/fluid or stent/fluid boundary). In flow diverter stents, the 
interweaving of struts and the gap between them and vessel wall increased the 
number of potential boundaries at any given location (e.g. wall/fluid, bottom of lower 
strut/fluid, top of lower strut/fluid, bottom of upper strut/fluid, etc.). Wall shear stress 
data from the wall/fluid boundary only could not be isolated. 
 
In coronary stents, migration studies revealed reduced cell movement and 
computational analysis revealed a low wall shear stress environment and disturbed 
flow. This agrees well with the bulk of literature which finds EC behaviour, 
including migration, is dysfunctional in regions of low shear stress [89][163]. 
Although wall shear stress was reduced further in the Silk flow diverter stent in terms 
of the amount of wall area exposed to <0.5 Pa, the absolute lowest magnitudes of 
shear stress found local to struts, and the amount of wall exposed to those minimum 
levels, was not dissimilar to coronary stents. However, rather than reduced cell 
movement, in vitro studies of flow diverter stents showed a complete lack of cell 
migration (Figures 5.13 and 5.14). It would be difficult to conclude, therefore, that 
the differences seen between these simulations could have such a profound effect on 
EC. 
Previous studies have seen cell migration at both 0.2 and 0.3 Pa wall shear stress 
[95][127]. It could be reasoned that, as per these studies, HUVEC within flow 
diverter stents were in motion, but net downstream migration was zero due to low 
persistence caused by bidirectional mechanical cues (as described in Section 1.4.4). 
The use of a ROCK inhibitor with flow diverter stents would have been of interest, to 
observe whether cell movement of any magnitude occurred once these cues were 
silenced [103]. However, ROCK inhibition experiments were carried out using the 
ibidi pump system, requiring 1.5 mm diameter models. The 2 mm diameter flow 
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diverter stents required deployment within vessels of identical size to avoid acute 
under expansion. Therefore, the introducer sheaths of the available flow diverter 
stents were unfortunately too tight a fit for 1.5 mm diameter models. 
 
It may also be possible that the lack of cell migration in flow diverter stents is due to 
a factor, or factors, other than wall shear stress (mass transport volume at the vessel 
wall, perhaps, or particle residence time) which does not have the same influence or 
effect in coronary stents. By focusing primarily on variation in wall shear stress 
magnitude or direction, the bulk of literature rarely considers such factors and, by 
using mock coronary stent geometry (or simple, empty parallel plate models), cannot 
recreate them. This, therefore, illustrates the advantage of the novel model and 
protocol described in this work, in enabling not only the assessment and direct 
comparison of clinical-grade stent geometry, but of stents of greatly differing design, 
type and purpose. Furthermore, in applying a more physiologically relevant flow and 
allowing haemodynamic variation to be generated by stent geometry (rather than the 
use of separate, distinct flow rates), additional geometry-induced haemodynamic 
factors and effects may reveal themselves. 
However, a more straightforward answer to the discrepancy between the results of 
cell migration studies and computational analysis may lie in the way the Silk stent 
was cast and modelled in silico in this study. As mentioned in Section 3.5.4 an 
accurate, undamaged cast could only be created by pulling stent struts out of the 
lumen. This required the removal of both ends of the stent and resulted in a cast 
representing only the middle third of the Silk stent structure. Furthermore, the 
complexity of the in silico model created from high resolution µCT data imposed the 
aforementioned requirement of only simulating flow through half of the model 
(Section 5.3 and Figure 5.9). Therefore, simulation results were firstly not 
representative of the entire stent, and secondly may have been unique to the 
geometry of the specific half of the stent being modelled. 
Simulation results were not representative of the entire Silk stent as the cast and in 
silico model did not capture the struts at the leading edge. This was not the region of 
interest, as HUVEC were seeded midway along the stent. Yet the prolapsed, 
disordered struts at the front of the stent must surely impact downstream flow, an 
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effect that could not be considered in the in silico model. Nor did the model consider 
the detrimental effect of the presence of sequential, more regular struts upstream (as 
shown in coronary stent data, Figure 4.22), as the struts captured in the in silico 
model were essentially considered as the stent’s leading edge. 
Simulation results may have been unique to the geometry of the specific half of the 
stent being modelled as, due to the Silk stent’s criss-cross pattern, each half 
contained a different alignment of thicker struts. These struts were in contact with the 
vessel wall and the degree to which differing alignment diverted or funnelled flow 
would have an effect on the shear stress of the vessel wall behind them. This effect is 
illustrated in Figure 5.17, and can be seen in the distribution of wall shear stress in 
Figure 5.10B. Although the flow between struts and wall was greatly reduced, it may 
still have been overestimated where the gap was open to the oncoming fluid. The 
result of this overestimated flow, within the reduced volume of the strut-wall gap, 
would be elevated wall shear stress. 
Taking these factors into account, it could be proposed that the mechanical 
environment within the Silk stent is actually much worse, in terms of induced EC 
dysfunction, than the CFD simulations suggest. Local wall shear stress may have 
been greatly overestimated and, as such, the true environment within the stent in 
vitro could be severe enough to completely arrest HUVEC migration. 
As per the conclusions drawn in Section 4.5, the ability of the stent to perform its 
primary function is paramount, but vessel healing could be improved by taking 
haemodynamics into account during the design phase where possible. When 
considering flow diverter stents however, their specific task is to exert a direct effect 
on blood flow and local haemodynamics is already a crucial design consideration. 
The stents considered in this chapter must prevent, or reduce, blood flow within 
cerebral aneurysms and, in doing so, cannot discriminate between diverting flow 
away from the neck and away from the otherwise unaffected vessel wall. Therefore, 
all of the above, including the lack of HUVEC migration, the low numbers of tracked 
particles, the reduced effect on the motion of those particles, and reduced wall shear 
stress, may be regarded simply as a consequence of flow diverter stents doing the job 
they were designed for, and diverting flow. 
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Figure 5.17 The impact of stent structure selection on CFD simulations 
 
The entire length of Silk flow diverter stents could not be captured in PDMS casting. In 
addition, due to the size and complexity of the model, computational simulations of Silk 
flow diverter stents were performed on half of the model only (with a plane of symmetry 
applied). The geometry of the specific section selected for modelling could impact the final 
results, depending on the position of thicker struts which were in contact with the wall. 
A: Representative geometry of a full flow diverter stent. 
B: Wall shear stress data from CFD simulations could be affected by the position of thick 
struts in the smaller regions selected for modelling. Oncoming flow (arrows) could be 
diverted away from the wall (left), or the wall could be open to this flow (right). 
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B 
217 
 
Nonetheless, even if flow diverter stent haemodynamics cannot be modified, it (and 
its effect on cell migration) must at least be properly understood. The development of 
the novel model and protocol described in this work, and its ability to apply various 
techniques to study and compare stents not only of varying design but different type 
and function, can again contribute to that objective. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
218 
 
   
219 
 
Chapter Six 
6 Discussion 
 
This project aimed to create an experimental platform, consisting of a novel model 
vessel and a unique combination of in vitro and in silico techniques, to study the 
impact of stent geometry on local wall shear stress and endothelial cell migration. 
Vessels of circular cross-section and typical artery diameter were fabricated, 
allowing the application of more physiologically relevant flow conditions than 
microfluidic parallel plate studies. The physical properties of PDMS enabled the 
deployment of coronary and flow diverter stents, in addition to the attachment and 
real-time monitoring of EC. An advantage of in vitro modelling was highlighted by 
the ability to provide an initial cell-free area in which to monitor migration. As 
discussed in Section 1.6.1, in vivo studies require some effort to induce vascular 
disease [121][122]. Porcine and small mammal arteries are therefore in good health 
and even intentionally forceful stent deployment cannot create cell-free zones in 
which to assess reendothelialisation [103]. 
 
The simple, rapid manufacture of model vessels and flow system set-up allowed a 
number of different cardiovascular stent designs to be studied. EC migration in 
coronary stents was reduced, particularly at areas of low or oscillatory wall shear 
stress, which compared favourably to the results of previous studies [103][114]. No 
EC migration was observed in flow diverter stents. CFD analysis showed decreased 
wall shear stress in these models and it has already been discussed that the true in 
vitro environment may be even more hostile to EC function (Section 5.5). However, 
endothelialisation of flow diverter stents is seen clinically, suggesting fundamental 
differences between in vivo conditions and the in vitro model. One of the most 
notable differences is the duration of interest. Endothelialisation in vivo, whether by 
healthy, local EC migration or EPC accumulation, can take months [29][211]. It may 
therefore not be unusual to see no visible movement of cells in an experiment of only 
3 days. An additional difference is that flow diverters were deployed in a model 
which was primarily designed to represent coronary arteries which included, as 
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mentioned above, denuded areas. As illustrated in Section 3.3.1, stent deployment 
over an EC layer in vitro did not injure the cells and, in vivo, islands of EC remain 
following flow diverter stent implantation [62]. Local cells at stent deployment sites 
could potentially endothelialise struts with little net migration required. 
If, however, the results of these in vitro migration studies were taken as accurate and 
relevant, they could be considered important in the context of clinical treatment. As 
the devices are a more recent development, the post-operative protocols for flow 
diverter stents essentially borrow from those developed for coronary stents (indeed, 
the first flow diversion procedures were performed using coronary stents [23]), 
which include the use of medication to inhibit VSMC [24]. In coronary stents the 
collateral inhibition of EC is deemed to be acceptable given the high risk of ISR. In 
contrast, flow diverter stent deployment does not cause injury to the vessel wall, 
VSMC are not exposed and, as such, ISR is of less concern. The high metal content 
of flow diverter stents means that thrombosis poses the greater risk [24], and stent 
strut endothelialisation is vital. The potential issue, therefore, is that an effort to 
reduce a negligible ISR risk (such as the use of anti-proliferative treatment, in a 
similar manner to coronary stent treatment strategies) could actually increase the 
heightened risk of thrombosis by further hindering the migration of EC, which are 
already inhibited by local haemodynamic forces (or a lack thereof). 
 
Particle tracking revealed stark differences regarding the various tested stents’ effect 
on flow. However, there was no significant link between these differences and the 
aspects of stent design studied here, and there were noticeable disparities between 
stents of identical geometry. Furthermore, the limited cell migration data did not 
allow a comparison between EC migration and specific stent design. This method did 
show that stent geometry affects local flow patterns and that EC are affected by 
disturbed flow and modified shear stress. However, beyond gross structural 
differences (i.e. those between coronary and flow diverter stents) the model may not 
be sensitive enough to identify the contribution or action of small scale design 
features (i.e. those between different models of the same stent type). 
This situation may be optimised by the continued development and improvement of 
the in vitro model. Any increase in experiment success rate would be valuable and 
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could reduce any noise seen in results which may be obscuring trends or 
relationships. One particular drawback of this study is the low sample size, as the 
limited pool of available stents was further reduced by the small number of EC 
migration experiments that reached the 24 hour time point. The solution may be as 
simple as altering the system: a greater success rate was achieved with the ibidi 
system, which was self-contained and compact enough to sit within laminar flow 
hoods and CO2 incubators. A peristaltic pump was required for larger diameter 
vessels, but set-up was more complex and tubing was prone to wear. In addition, the 
peristaltic pump could not be placed in an incubator and the thick tubing prevented 
CO2 incubator doors from closing. 2 and 2.5 mm diameter models were therefore 
only able to fit within modified egg incubators. These smaller egg incubators did not 
supply CO2, and as such the optimum pH of EC growth medium could not be 
maintained. This was not thought to be an issue given the short duration of 
experiments and the fact that those which were successful, although less frequent, 
performed as well as models attached to the ibidi system. A buffer could have been 
added to peristaltic pump reservoirs to preserve pH, but this was not carried out as 
these compounds can have their own effects on cell growth and metabolism [157]. 
The need for a fibronectin coating for EC attachment meant that each in vitro model 
was single-use, as discussed in Section 3.6. If this could have been avoided then 
repeat experiments would have increased sample sizes, however in all other respects 
PDMS was the most suitable material available for in vitro modelling. 
 
In studying the effects of stent geometry on haemodynamics and EC migration, an in 
vitro model of increased sensitivity may have its own disadvantages. Many of the 
small scale design features considered in the tested stents (strut thickness for 
example) differed by a few tens of microns. Any model sensitive enough to resolve 
the differential effects of these changes would also detect features specific to realistic 
stent deployment (malapposed struts, varying penetration or prolapse, etc.), which 
cannot be controlled. In addition, stents contain complex geometry. It may prove 
difficult to identify which design parameters cause certain effects, to take into 
account effects which are compounded as flow moves downstream through stents, 
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and to appreciate the knock-on consequences of altering parameters on other aspects 
of the structure. 
This highlights an advantage of parametric study with simpler models. One option to 
better understand the effects of specific stent design features could be to combine the 
mock stent geometry used in parallel plate studies with the in vitro system used here. 
The shape, thickness, orientation and density of ridges, representing stent struts, 
could be controlled at the fabrication stage, while EC within the model would still be 
exposed to more physiologically relevant flow in a full-sized vessel of circular cross-
section. Alternatively, there is also plenty of scope for added realism as in vitro 
models are far from perfect representations of in vivo conditions. Noted drawbacks 
include the obvious lack of circulating blood, as well as circulating cells, platelets 
and leukocytes. Furthermore, current models do not replicate additional components 
such as VSMC, extracellular matrix, and vessel media and adventitia [107][131]. 
A combination of different PDMS mixing ratios or additional material could be used 
to model the various layers of the vessel wall, or areas of plaque and stenosis. The 
geometry of model vessels could also be made more realistic by removing material to 
create aneurysm sacs, or by modelling branch points or curvature [204]. Patient 
specific geometry, obtained from clinical scans, has been modelled in silico [172]. 
These computational models could be used to create physical moulds, via 3D 
printing, for the fabrication of patient specific in vitro vessels. 
The realism of experimental conditions could be improved with the application of 
physiological flow rates (requiring the use of thickening agents, as discussed in 
Chapter 3) and pulsatile flow. Again, in vivo cardiac rhythm has already been 
measured and applied to in silico models [103] and the same could be done in vitro 
with programmable pump and control systems. The cellular environment could be 
better represented by seeding HCAEC and the isolation of VSMC could allow co-
culture within model vessels [99]. An EC suspension could be circulated through the 
model to simulate endothelialisation by EPC accumulation, although given the 
success rates of standard cell attachment this may not prove viable.  
CFD analysis proved to be a useful complementary tool and µCT scanning of PDMS 
casts was an efficient means of replicating the geometry of stented vessels in silico. 
The technique may yet be optimised. The impact of scan power and, more 
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importantly, resolution on the accuracy of the final in silico model should be more 
carefully studied, as should the effect of reconstruction and meshing parameters. The 
creation of stepwise geometry should be reduced as stagnation points are created 
where flow meets blunt faces [208], and the threshold beyond which increased 
resolution does not improve the model should be discovered. 
As per the in vitro system, improvements can be made to the CFD protocol. The 
added benefit of in silico modelling is that the original information is not lost and 
many of these improvements can be made retroactively. The application of a UDF at 
the centre of the model inlet to create fully-developed flow allowed the use of 
smaller, less computationally expensive meshes. However, as stent deployment often 
distorted vessels their inlets were rarely of perfect circular cross-section. Velocity 
(and therefore wall shear stress) could be unrealistically high where the parabolic 
profile applied by the UDF crossed the wall, or zero where it fell short. These issues 
were limited to the initial upstream segments of in silico models and viscous effects 
would rapidly normalise the flow, but it was still necessary to extend the models 
somewhat (increasing their complexity and computational expense) to ensure the 
disturbances were kept away from stent geometry. 
Steady Newtonian flow was used in this project but realistic pulsatile flow of non-
Newtonian fluid could be simulated, allowing time-dependent metrics such as 
TAWSS and OSI to be obtained. Simulations by Balossino et al (2008), which were 
discussed in Section 1.6.5, showed wall shear stress increasing with stent strut 
thickness [167]. These results are in stark contrast to the rest of the literature, and are 
presumed to be due to the combined use of both realistic pulsatile flow and realistic 
deformed vessel geometry. It is clear that flowing blood creates a different 
haemodynamic environment than that which EC are exposed to in cell culture 
medium, as illustrated in Section 4.3.2. However, Balossino’s results suggest that it 
may also create a completely different relationship between stent structure and wall 
shear stress than that which is found in vitro. Perhaps then, a dual approach is best. 
Complex, realistic in silico geometry and flow could reveal the impact of stent 
design on wall shear stress magnitude, direction and time variation, while simple, 
idealised in vitro and in silico models could explore how EC are likely to respond 
under those conditions. 
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A full understanding of the link between stent structure, wall shear stress, and EC 
behaviour, obtained with reliable, fully developed in vitro and in silico models, could 
be used to optimise existing stent designs, or predict the effect of novel designs on 
endothelialisation. The same techniques could be used to trial novel devices such as 
the ‘Instent’ sensor which can inform post-operative treatment by analysing stent 
coverage in vivo [212], and may also be applied to the study of other related subjects: 
monitoring the breakdown of bioabsorbable stents [72][213], assessing DES drug 
release and its influence on EC [67][214], modelling nanoparticle accumulation 
[209] and biofouling [215], and assessing pro-EC stent coatings [8][54]. 
By allowing the assessment of clinical-grade stents of varying design, type and 
purpose, and enabling the application of mechanical conditions of increased 
physiological relevance, the novel platform developed here could be seen as a test 
bed for techniques which, like many others, could play a role in characterising the 
complex biomechanics and biochemistry of stented arteries. Furthermore, as the 
relevant fabrication, experimental, or simulation protocols could modified without 
compromising separate procedures or overall workflow, any or all of the 
developments and improvements detailed previously could be applied to the in vitro 
and in silico models, in any combination. Indeed, of late, the work of Antoine et al 
has demonstrated the use of both co-culture (EC and VSMC) and a 3D engineered 
tissue (an SMC-embedded hydrogel) within a stented in vitro vessel [160], 
techniques which could be readily applied here. 
In the future, as our knowledge and the capability of our clinical, computational and 
manufacturing tools increases, there may be a point at which patient recovery is 
hastened by the use of personalised tailor-made stents. The same scan data used to 
diagnose cardiovascular disease could be used as the basis of a virtual model, in 
which a variety of stent designs are trialled and refined to create the most pro-EC 
haemodynamic environment. Surgeons could be offered the most suitable off-the-
shelf stent, or individual devices could be rapidly manufactured for each patient as 
they await surgery. Until such a time, as millions of people receive stents each year, 
any small improvement in their impact on vascular repair could reduce mortality and 
improve quality of life. 
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Appendix 
 
Particle Tracks: 
                          
Tracked particle streamlines through BiodivYsio OC coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Chroma coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Coroflex Blue coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Coroflex Blue Neo coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Matrix coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Orsiro coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Penchant coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Pro Kinetic Energy coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Velocity coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through XTRM-Track coronary stent 
Flow from bottom to top, Re = 68 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Leo flow diverter stent 
Flow from bottom to top, Re = 43 (equivalent to blood flow with 1 Pa wall shear stress). 
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Tracked particle streamlines through Silk flow diverter stent 
Flow from bottom to top, Re = 43 (equivalent to blood flow with 1 Pa wall shear stress). 
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